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Abstract
The purpose of this study was to investigate the effects of reduced Connexin43 function
on the developing skull phenotype, osteoblast and chondrocyte proliferation and
differentiation, and to determine if a correlation exists between cell processes and gross
morphology. Using the Cx43I130T/+ mouse model, skull shape was analyzed using
geometric morphometrics and cell proliferation and differentiation were assessed using
immunohistochemistry at late embryonic and early post-natal stages. The largest shape
changes between Cx43

I130T/+

and wildtype mice were observed in the cranial base and

facial skeleton. Changes in facial morphology correspond to reduced osteoblast
differentiation. However, no changes in chondrocyte proliferation or differentiation
within the cranial base were detected in mutant mice, and thus, alterations to these
chondrocyte processes do not explain the profound phenotypic changes observed in the
cranial base. This study provides a detailed account of the cellular and phenotypic effects
of the Cx43I130T/+ mutation within the skull.
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Chapter 1
1 Introduction
1.1
1.1.1

Mammalian Skull Development
Developmental Complexity

Skull development is a very complex process, which requires the coordination of multiple
bones that are derived from distinct embryological origins and ossify via different
ossification modes. The skull must also house and protect the brain, and provide a base
on which sensory and feeding organs reside (Chai & Maxson, 2006). Despite this
diversity in development and function, the skull must develop in a highly integrated
fashion. Thus, through developmental and functional integration, alterations in one region
of the skull can influence other regions (Vora, 2017). This developmental complexity
may explain why approximately three fourths of all congenital disorders involve
alterations to the craniofacial skeleton (Chai & Maxson, 2006). Some of these more
common defects include orofacial clefts, craniosynostosis, and microcephaly. The
etiology of these conditions can be difficult to determine, though many arise through
genetic alterations (single-gene disorders, chromosomal or epigenetic mutations) and inutero exposure to teratogens (Saal, 2016). Ultimately, these genetic and environmental
factors act on cellular processes to determine the gross phenotypic outcome (Atchley &
Hall, 1991). The specific skeletal tissues and cell types affected by genetic and
environmental insults are determined by developmental factors such as timing,
embryological origin and mode of ossification. Thus, not all skeletal elements of the
skull are similarly affected by the same environmental or genetic perturbation.
Understanding the relationship between cellular processes and phenotypic outcomes in
the skull will provide insight on the etiology of many craniofacial anomalies.

1.1.2

Intramembranous and Endochondral Ossification

The migration of undifferentiated mesenchymal cells to locations of bone growth, marks
the beginning of skeletogenesis early in embryonic development (Hall & Miyake, 1992;
Berendsen & Olsen, 2015). At the site of growth, mesenchymal condensations form and
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bone tissue subsequently develops via two distinct developmental processes:
intramembranous and endochondral ossification.
Intramembranous ossification occurs in the medial part of the clavicle, membranous
bones of the neurocranium (including the cranial vault) and the viscerocranium or facial
skeleton (Hall & Miyake, 1992; Ornitz & Marie, 2002; Berendsen & Olsen, 2015). In the
skull, the cranial vault is embryonically derived from both neural crest and mesodermal
cells, while the facial skeleton is derived solely from neural crest cells (Le Lievre, 1978;
Noden, 1978, 1984, 1988; Jiang et al., 2002; Evans & Noden, 2006; Yoshida et al.,
2008). During intramembranous ossification, osteoblasts differentiate directly from
mesenchymal condensations. These osteogenic condensations become vascularized
before the secretion of an osteoid matrix, which consists of collagens and bone proteins
(Hall, 1983, 1988; Cole & Hanley, 1991; Tracy & Mann, 1991; van der Rest, 1991).
The remainder of the skeleton, including long bones, is formed via endochondral
ossification. In the skull, endochondral ossification gives rise to the cranial base
(Berendsen & Olsen, 2015), which has both neural crest and mesodermal origins. The
anterior portion of the base of the skull is derived from neural crest while more posterior
portions of the skull are mesoderm derived (McBratney-Owen et al., 2008).
Endochondral ossification requires the formation of cartilage scaffolds, which is an
additional step not required for intramembranous ossification. Unlike osteogenic
condensations, chondrogenic condensations are avascular except when undergoing
hypertrophy and mineralization (Hall, 1983, 1988, 1992). Hypertrophic chondrocytes
within chondrogenic condensations produce a cartilage matrix that is subsequently
replaced with bone as ossification progresses (Zhou et al., 2014). Much of the growth of
the intramembranous bones of the cranial vault and facial complex occurs at distinct
areas called sutures, whereas growth of the endochondral bones of the cranial base occurs
at synchondroses (Opperman, 2000).

1.2
1.2.1

Growth of the Skull
Suture Growth

Suture growth sites consist of two opposing osteogenic bone fronts that are separated by
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undifferentiated mesenchyme (Opperman, 2000; Flaherty et al., 2016). The osteogenic
cells surrounding the mesenchyme gradually differentiate (from pre-osteoblasts to
differentiated osteoblasts) as they move closer to the bony fronts (Fig. 1) (Pritchard,
1952; Pritchard et al., 1956). In order to progress along an osteogenic fate, osteoblast
lineage cells must receive various signals, which involve Wnts, bone morphogenetic
proteins (BMPs), fibroblast growth factors (FGFs), and Runx2 transcription factor, a
master regulator of osteoblast differentiation (Komori & Kishimoto, 1998; Long, 2011).
Sutures are integral to maintaining separation between bones and regulating the growth of
the skull, and thus, require a constant population of proliferating, undifferentiated
mesenchymal cells to retain suture patency (Flaherty et al., 2016).
Until they ossify, sutures allow for rapid bone formation and growth along the edges of
the opposing bone fronts (Flaherty et al., 2016). Sutural growth is initiated in response to
extrinsic mechanical forces, such as skull expansion. Mechanosensing of the
mesenchymal cells within craniofacial sutures involves interaction among various
cytoskeletal elements, which induces mineralization of cranial bones (Frost, 1990;
Bukoreshtliev et al., 2013; Katsianou et al., 2016). For cranial sutures, this stimulus arises
from the expanding brain, from which signals are sent through the dura mater and
overlying mesenchyme of the presumptive cranial vault (Baer, 1954; Moss, 1954;
Kokich, 1986; Cohen, 2000). Similar mechanical signals stimulate growth in facial
sutures; however, it is speculated that growth of the nasal capsular cartilages are largely
responsible for stimulating growth of the facial bones (Scott, 1953a, 1953b, 1956; Moss,
1960; Sarnat, 1963). Furthermore, it is postulated that bone growth at these sites occurs
when the presumptive cranial vault and nasal cartilages exert an overall tensile force and
gradually force the bony fronts of the suture apart (Opperman et al., 2005).
Perturbations in cell signaling within craniofacial sutures can lead to delayed or
accelerated bone growth, and result in abnormal skeletal development such as that found
in individuals with craniosynostosis and cleft palate (Opperman, 2000). Thus, sutural
growth must be tightly regulated to avoid these and other related anomalies.
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Figure 1. Sutures are intramembranous growth sites.
(a) A coronal mouse skull section, for reference. B denotes the brain, BS marks the
basisphenoid bone and T marks the tongue. Outlined by the yellow square is the
interpalatine suture. (b) A magnified image of the interpalatine suture, stained with
Safranin-O/Fast Green/Hematoxlyin. Sutures consist of two opposing osteogenic bone
fronts that are separated by a midline suture (undifferentiated mesenchyme). Yellow
dashed lines represent osteogenic fronts. E denotes epithelia and S marks the suture.

1.2.2 Synchondroses Growth
Synchondroses are double-ended growth plates that lie between endochondral bones of
the cranial base. They function as growth centers and expedite endochondral bone
growth until optimal size and shape is achieved. Synchondroses are organized similarly
to epiphyseal growth plates in long bones; however, synchondroses grow bi-directionally
(Opperman et al., 2005). To achieve this, chondrocytes within synchondroses are
organized such that a resting zone is positioned in the middle, which is flanked on either
side by proliferative zones. Hypertrophic zones consisting of hypertrophic chondrocytes
border cells in proliferating zones before terminally transitioning into ossified bone (Fig.
2).
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Figure 2. Synchondroses are bi-directional cartilage growth plates.
Synchondroses reside in the cranial base and are the main growth centers for the bones of
the cranial base. (a) Chondrocytes differentiate outwards from the central resting zone
(R) through proliferating zones (P), and hypertrophic zones (H). (b) A sagittal mouse
skull section, for reference. NC denotes nasal cavity, P marks the palate, PS marks the
presphenoid bone, BS signifies the basisphenoid bone, B marks the brain, BO denotes the
basioccipital bone. Outlined by the yellow box is the presphenoidal synchondrosis (PSS)
and outlined by the green box is the spheno-occipital synchondrosis (SOS).
The presphenoidal (also known as inter-sphenoidal) synchondrosis (PSS) is situated
between the presphenoid and sphenoid bones, while the spheno-occipital synchondrosis
(SOS) is positioned between the sphenoid and occipital bones. In humans, the PSS fuses
at birth, and thus does not contribute to post-natal craniofacial growth. The SOS,
however, remains active until fusion shortly after puberty (Opperman et al., 2005). In one
of the most commonly used strains of inbred mice, C57BL/6J, the PSS and the SOS
remain patent up to post-natal day 21 (P21) and are fused by P84 (Vora et al., 2016).
Synchondroses growth centers differ from sutural growth sites in that they possess
intrinsic growth potential, rather than relying on extrinsic forces (Opperman, 2000). This
is evidenced by successful organ culture studies, as well the observation that
synchondrosal growth continues after brain expansion is complete (Copray et al., 1986;
Petrovic & Charlier, 1967; Kantomaa et al., 1991; Gakunga et al., 2000; Shum et al.,
2003). Much like suture development, the embryonic cell signaling pathways of
synchondrosal development are quite complex. Many molecules involved in chondrocyte
differentiation and proliferation are required for normal growth, and some key players
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include parathyroid-hormone-related peptide (PTHRp) and bone morphogenetic proteins
(BMPs) (Chen et al., 1995; Lee et al., 1996; Serra et al., 1997; Ishii-Suzuki et al., 1999;
Suda et al., 1999; Kramer et al., 2000). PTHRp regulates chondrocyte proliferation and
inhibition of chondrocyte hypertrophy in the proliferative zone, and BMPs facilitate
chondrocyte differentiation, hypertrophy and mineralization in the hypertrophic zone.
Indian hedgehog, FGF receptors, and transforming growth factor β (TGFβ) are also
involved in signaling pathways that help to regulate synchondrosal growth (Shiang et al.,
1994; Deng, et al., 1996; Lee et al., 1996; Ishii-Suzuki et al., 1999; Suda et al., 1999;
Visnapuu et al., 2001; Ito et al., 2002; Rosado et al., 2002). Thus, perturbations in any of
these signaling pathways can result in deformities. For instance, missense mutations in
fibroblast growth factor receptor 3 lead to achondroplasia, which is associated with
delayed endochondral growth and premature closure of cranial base synchondroses (Chen
et al., 1999). The resulting phenotype is characterized by a microcephalic skull and
skeletal dysplasia. Thus, proper growth of both intramembranous and endochondral
bones requires tightly controlled regulation of proliferation and differentiation of the cells
within these suture and synchondrosis growth centers.

1.3
1.3.1

Skeletogenic Cells
Osteochondroprogenitors

During embryonic development, neural crest as well as lateral and paraxial plate
mesoderm give rise to multipotent skeletogenic progenitor/stem cells. Skeletogenic stem
cells then proceed through a bipotent osteochondroprogenitor stage, and after further
differentiation form precartilaginous or preosteoblastic mesenchymal condensations (Liu
et al., 2017). As mentioned previously, these mesenchymal condensations subsequently
further differentiate and undergo either intramembranous or endochondral ossification.
Thus, osteochondroprogenitors represent the common cell lineage of both
intramembranous and endochondral ossification, and more specifically, osteoblasts,
chondrocytes and osteocytes (Fang & Hall, 1997). Multiple bone development studies
have produced evidence for this common cell population. For instance, cultured
embryonic calvarial cells differentiate into chondrocytes when subjected to a
chondrogenesis-permissive environment (Toma et al., 1997; Aberg et al., 2005).
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Competitive mechanisms at the molecular level thus determine whether
osteochondroprogenitor cell populations commit to an osteoblastic or chondrogenic cell
fate, which are described in detail in 1.3.2 and 1.3.3.

1.3.2

Osteoblasts

Osteoblasts progress along a presumed linear sequence wherein osteochondroprogenitors
mature into osteoprogenitors, osteoblasts, and eventually osteocytes (Aubin, 1998).
Osteoprogenitor cells enter a proliferation phase and differentiate through asynchronous
up-regulation of osteoblast-associated proteins such as alkaline phosphatase, collagen
type 1, and osteopontin (Stein et al., 1996; Aubin, 1998). Known as a master regulator of
osteoblast differentiation, the Runx2 (formerly known as Cbfa1) transcription factor is
necessary for further osteoblast maturation. Runx2 is able to self-regulate by directly
binding to its own promoter, however, it is also regulated in part by BMPs (Ducy, 2000;
Drissi et al., 2003). Evidence of the importance of Runx2 expression comes from the
generation of Runx2-deficient mice. When Runx2 is globally ablated, the skeletons of
affected mice are entirely cartilaginous, and pups die at birth due to absence of a rigid
ribcage able to sustain respiration (Komori et al., 1997; Otto et al., 1997).
Intramembranous-derived skeletal elements are missing in these mice, and only a
membranous structure exists at these sites. Similarly, humans diagnosed with
cleidocranial dysplasia, characterized by patent fontanelles and sutures, short stature, and
hypoplastic/aplastic clavicles, are Runx2 haploinsufficient (Lee et al., 1997; Mundlos et
al., 1997).
Another important transcription factor for osteoblast differentiation is Osterix (Osx). Osx
is a zinc-finger transcription factor that is a downstream target of Runx2 and is required
for differentiation of fully-functioning osteoblasts (Nakashima et al., 2002; Nakashima &
de Crombrugghe, 2003). Studies using Osx-null embryos have found that while affected
mice have normal cartilage development, they lack bone formation in both
intramembranous and endochondral skeletal elements.
Osteoblasts further differentiate and become mature through gene expression of
osteocalcin (OC), which is induced when Runx2 interacts with osteocalcin-specific
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element 2 (OSE2) and activates the OC promoter (Ducy & Karsenty, 1995; Ducy et al.,
1997). OC protein is secreted into the bone microenvironment by mature osteoblasts
when they lay down osteoid during mineralization. Afterwards, late osteoblasts
eventually become embedded in bone matrix and transform into osteocytes (FranzOdendaal et al., 2006).

1.3.3

Chondrocytes

A key regulator of chondrogenesis is the transcription factor Sox9, which is expressed as
early as the skeletogenic progenitor stage. The importance of Sox9 at this early stage is
relatively unknown, as studies have reported no defects in Sox9-deficient
fl/fl

(Sox9 Prx1Cre) mouse limb buds until after skeletogenic progenitor cells have
differentiated into prechondrocytes (Akiyama et al., 2002). Prechondrocytes within
precartilaginous condensations build cartilage primordia by proliferating and producing
cartilage extracellular matrix. Studies have shown that Sox9 protein binds and activates
chondrocyte-specific target enhancers at this stage, such as collagen type II, collagen type
I, aggrecan and cartilage-derived retinoic acid-sensitive protein (CD-RAP) (Lefebvre et
al., 1997; Bridgewater et al., 1998; Xie et al., 1999; Sekiya et al., 2000). This activation
allows for further differentiation, after which Indian hedgehog and Wnts stimulate
chondrocyte proliferation and alignment. Prehypertrophic chondrocytes then begin
expressing genes that will allow them to differentiate into hypertrophic chondrocytes,
such as collagen type 10 (Liu et al., 2017). Hypertrophic chondrocytes expand their
cytoplasmic volume and begin to secrete vascular endothelial growth factor A before
becoming terminal chondrocytes. Studies have shown that chondrocytes at this stage
either die or transdifferentiate into osteoblasts (Kirsch et al., 1992; Roach et al., 1995;
Gerstenfeld & Shapiro, 1996; Bianco et al., 1998; Zhou et al., 2014). Zhou and
colleagues investigated transdifferentiation in chondrocytes by labeling chondrocytes
with tamoxifen-induced Agc1-CreERT2 and hypertrophic chondrocytes with Col10a1Cre, allowing them to track labeled cells in vivo during prenatal development and after
birth. Their study found abundantly labeled non-chondrocytic cells in the primary
spongiosa, and co-expression studies with osteoblast markers indicated these cells are
functional osteoblasts (Zhou et al., 2014).
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1.4
1.4.1

Connexin43
Connexins (Cx)

Osteoblasts and chondrocytes, as well as every other cell type, heavily rely on
intracellular communication. Connexins comprise a family of gap junctional proteins that
oligomerize to form channels, which enables transport of electrical signals, metabolites
and small signaling molecules less than 1kD in size between adjacent cells (Laird, 2014).
Typical transports include calcium ions, cyclic adenosine monophosphate, and inositol
polyphosphates (Saez et al., 1989; Christ et al., 1992; Kam et al., 1998; Webb et al.,
2002). These gap junction channels are composed of a hemichannel from each of the two
contributing cells, and each hemichannel is formed by a hexamer of connexin proteins
(McLachlan et al., 2008). Connexin hemichannels are co-translationally synthesized
before insertion into the endoplasmic reticulum and subsequent progression along the
classical secretory pathway. At the plasma membrane, connexins function as
hemichannels, dock with adjacent cells to form gap junctions, or cluster together to form
gap junctional plaques.
There are 21 unique connexin genes in the human genome, and 20 in mice (Söhl &
Willecke, 2004; Laird, 2014). Sequence analysis of known connexin proteins has
predicted that different variants share the same topological features, consisting of four
transmembrane domains, two extracellular loop domains, one cytoplasmic loop domain,
and amino and carboxyl termini in the cytosol (Kumar & Gilula, 1992; Goodenough et
al., 1996). This structural similarity between connexins allows hemichannels to
oligomerize from the same connexin proteins (homomeric channels) as well as from
different connexins (heteromeric channels). Additionally, head-to-head docked channels
can further be classified as homotypic (two identical homomeric hemichannels) or
heterotypic (two different homomeric or heteromeric hemichannels).
In humans, expression of connexin genes can be found as early as onset of zygotic
transcription in early cleavage stages, and by adulthood they are ubiquitously expressed
throughout the body (Beyer et al., 1987; Nishi et al., 1991; Valdimarsson et al., 1991; De
Sousa et al., 1993). Consequently, germline mutations in connexin genes lead to more
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than two-dozen human diseases through loss- and gain-of-function mechanisms (Kelly et
al., 2015; Srinivas et al., 2018). Connexin-linked mutations are associated with
sensorineural hearing loss (Cx26, Cx30, Cx31), Charcot-Marie-Tooth disease (Cx32),
skin diseases (Cx26, Cx30, Cx30.3, Cx31, Cx43), and bone dysplasias (Cx43) to name a
few (Bergoffen et al., 1993; Wiszniewski et al., 2000; Di et al., 2001; Paznekas et al.,
2003; Richard et al., 2003; Laird et al., 2017). Present in nearly every vital organ, Cx43 is
the most ubiquitously expressed connexin in humans (Laird, 2006).

1.4.2

Connexin43 and Bone Development

While there are several connexin subtypes found in bone (Cx37, Cx40, Cx43, Cx45, and
Cx46), Cx43 is the most prevalent. Bone tissue is subjected to constant homeostasis and
undergoes modeling and remodeling when required. Thus, it is necessary for bone cells to
communicate tissue-level mechanical and metabolic signals in order to maintain bone
quality (Stains & Civitelli, 2016). Cx43 gap junction intercellular communication (GJIC)
is fundamental to these processes in both intramembranous and endochondral bone.
Cx43 is encoded by the GJA1 gene, and mutations in this gene have been linked to
several skeletal dysplastic syndromes. While the dominant form of craniometaphyseal
dysplasia is caused by mutations of the ANKH gene, a recessive form has been linked to a
GJA1 mutation (Hu et al., 2013). Patients afflicted by this dysplasia experience widened
phalanges, under-trabeculation and flaring of the diaphysis of long bones. Recessive
craniometaphyseal dysplasia is caused by a mutation at R239Q, which is located in the Cterminus of Cx43. Another GJA1 associated disorder is Hellermann-Streiff syndrome,
which is caused by a R76H mutation. Skeletal features of this disorder include small
stature and beaked nose, as well as features prominent in other GJA1-related syndromes,
such as craniofacial dysmorphism, enamel hypoplasia, and clynodactlyly (Pizzuti et al.,
2004). Arginine 76 (R76) is located in the first extracellular loop of Cx43, and
interestingly, a substitution of a serine instead of a histidine at this location results in
another related disorder, oculodentodigital dysplasia (ODDD).
Many GJA1 mutations manifest phenotypically as ODDD (Stains & Civitelli, 2016).
ODDD is a rare disorder that affects less than 1000 people worldwide. ODDD was first
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described in 1957 by Meyer-Schwickerath and colleagues, and since then 73 mutations in
GJA1 have been identified and associated with the disorder (Meyer-Schwickerath et al.,
1957; Laird, 2014). The ODDD phenotype includes a plethora of features, including
neurological issues, hearing loss, cardiac defects, and aberrations of the skin, hair, and
nails (Paznekas et al., 2009). Though ODDD has diffuse phenotypic effects, it is visually
characterized by craniofacial abnormalities, such as microcephaly, narrow nasal bridge,
and hypoplastic nasal alae (Paznekas et al., 2003).
Cx43 is expressed in numerous bone-related cell types such as osteocytes, osteoclasts,
osteoblasts, and chondrocytes (Stains & Civitelli, 2005). Cx43-deletion studies have
revealed interesting findings on the function of Cx43 in osteocytes. Deletion of Cx43
from cultured osteocytes results in decreased osteoprotegerin expression levels and
increased osteocyte apoptosis (Bivi et al., 2012). Cx43 is required for healthy functioning
osteocytes as in vivo deletion of Cx43 from osteocytes results in increased abundance of
apoptotic osteocytes and elevated endocortical resorption causing larger marrow
cavities (Bivi et al., 2012). Cx43 is also important for osteoclast function and
differentiation (Jones et al., 1993; Ilvesaro et al., 2000; Schilling et al., 2008). Deletion of
Cx43 from cells of the osteoblast lineage results in altered expression of osteoclast
differentiation factor RANKL and osteoclastogenesis inhibitor osteoprotegerin. This
leads to increased osteoclast formation and elevated RANKL:osteoprotegerin ratio in
cortical bone (Watkins et al., 2011; Zhang et al., 2011; Bivi et al., 2012).
As previously discussed, intramembranous bone modeling begins with osteoblasts at
suture growth sites, and endochondral bone modeling of the cranial base begins with
chondrocytes at synchondroses. Given the central role of bone development at these
growth sites, a more in-depth description of the effects of Cx43 on osteoblasts and
chondrocytes follows.

1.4.3

Connexin43 and Osteoblasts

It is well established that osteoblasts on the bone surface and embedded osteocytes
regulate bone homeostasis via coordinated gap junction signaling. Early microscopy
studies revealed the existence of gap junctions amongst osteoblasts and osteocytes (Doty
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& Schofield, 1972; Stanka, 1975; Doty, 1981; Stains & Civitelli, 2005). Since, numerous
in vitro and in vivo experiments have further characterized these gap junctions and
investigated their role in osteoblasts and osteocytes.
Similar to other bone cells, osteoblasts have been found to propagate waves of calcium
ions via GJIC in response to mechanical disruptions (Jørgensen et al., 1997; Jørgensen et
al., 2000). Studies have also found that expression levels of Cx43 and GJIC increase
during in vitro osteoblast differentiation (Donahue et al., 2000; Schiller et al., 2001).
Later, McLachlan and team investigated expression levels of osteoblast markers such as
bone sialoprotein and OC in primary mouse osteoblasts and human MC3T3-E1 cells,
which revealed that germ line reduction of Cx43 function results in reduced expression
levels of these markers, and thus impaired osteoblast differentiation (McLachlan et al.,
2008).
Other studies have focused on Cx43-dependant osteoblast signaling pathways. Stains and
colleagues identified a GJIC-sensitive minimal element in the promoter of the OC gene,
which they termed a connexin response element (CxRE) (Stains et al., 2003; Stains &
Civitelli, 2005). Further, it was found that osteoblast GJIC regulates transcription by
altering the recruitment of transcription factors called specificity proteins 1 and 3
(Sp1/Sp3) to the promoter, and that overexpression of exogenous Cx45 in an endogenous
Cx43 background to diminish Cx43-GJIC led to favored recruitment of Sp3 (the
repressor) (Stains & Civitelli, 2005). This diminution of Cx43 GJIC is the result of
decreased Sp1 phosphorylation by ERK (extracellular signal-regulated kinase), and
decreased recruitment of Sp1 to the CxRE, which inhibits gene transcription. Thus,
optimal transcription of the OC CxRE relies on ERK/PI3K (phosphatidylinositol 3kinase) signaling, and disruption of Cx43-GJIC attenuates the ability of adjacent cells to
respond to an extracellular cue (Stains & Civitelli, 2005).
Several in vivo studies using mouse models have further confirmed the necessity of Cx43
for proper osteoblast function. These are explored in more detail in section 1.5.1. Overall,
it is evident that functioning Cx43 is integral to cell lineage progression, gene
transcription, and physical signaling in osteoblasts (Stains & Civitelli, 2005)
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1.4.4

Connexin43 and Chondrocytes

While the role of Cx43 in osteoblasts has been extensively studied, fewer reports have
focused on the role of Cx43 in chondrocytes. In vitro studies have detected Cx43
transcripts in mouse limb bud mesenchymal condensations during early stages of
development, and later it was found that mechanically stimulated Cx43-GJIC in
chondrocytes propagates calcium ions and inositol 1,4,5-trisphosphate to adjacent cells
(Meyer et al., 1997; D’Andrea et al., 1998; Capozzi et al., 1999; D’Andrea et al., 2000).
Additionally, Zhang and colleagues found that the inhibition of Cx43 communication via
18α-glycyrrhetinic acid effectively decreases chondrogenic differentiation by 50% in
96hrs. Levels of chondrogenic markers such as type II collagen transcripts and
proteoglycans were also decreased, which suggests that Cx43 is required for chondrocyte
differentiation (Zhang et al., 2002).
Another study used an in vivo model wherein the C-terminus region of Cx43 was
replaced with a Cx43 gene sequence that lacked the last 125 amino acids residues
(K258stop/Cx43KO and K258stop/K258stop) (Gago-fuentes et al., 2016). Results show
that both groups of mice (aged P0, P2-4, and adult) displayed reduced Cx43-mediated
GJIC compared to the wildtype and subsequently had reduced collagen type II and
proteoglycan expression. As well, proliferation assays of C-terminus-deficient
chondrocytes revealed increased expression of Ki67, and thus increased proliferation
(Gago-fuentes et al., 2016). Overall, Cx43-mediated GJIC appears to be important for
communication in chondrocytes.

1.5

Mouse Models for Bone Research

The mouse represents a useful model system for bone research. Mice possess genetic
similarities to humans, have a relatively short reproductive cycle and are fairly low cost
to maintain (Elefteriou & Yang, 2011). Furthermore, the entire mouse genome has been
sequenced and is available for reference. Various mouse models have been developed for
studying bone tissue. These include transgenic approaches, global gene deletion,
conditional gene targeting, and inducible gene targeting (Elefteriou & Yang, 2011).
However, there are limitations in using mouse models for skeletal research. Notably,
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there are important differences between mice and humans in terms of craniofacial
architecture, such as cranial base flexion, snout orientation, and timing of sutural and
synchondrosal closure (Wealthall & Herring, 2006; Vora et al., 2016; Vora, 2017).
Additionally, the genetic background of some inbred mouse strains may alter the
phenotypic response to genetic manipulation (Threadgill et al., 1995; Tsukamoto et al.,
2008). Nonetheless, research using genetically modified mice lends invaluable insight on
important biological mechanisms that bolster our knowledge of bone physiology
(Elefteriou & Yang, 2011).

1.5.1

Connexin43 and Mouse Models to Study Bone

Multiple genetically modified mouse models have facilitated a greater understanding of
the impacts of Cx43 on bone development. The most extensively used Cx43 mouse
models can be divided into two groups: Gja1 ablation models and ODDD-associated
point mutation models (Stains & Civitelli, 2016).
A hallmark study by Reaume and colleagues was the first to generate a Gja1-/- mouse
line. They found that Gja1-/- pups die shortly after birth due to swelling and blockage of
the right ventricular outflow tract from the heart (Reaume et al., 1995). Using this same
model, Lecanda et al., found that Gja1-/- embryos exhibit delayed ossification of the
cranial vault and hypoplastic cranial bones. Furthermore, Cx43-deficient animals possess
open fontanelles at birth and display delayed ossification of the clavicles, ribs, vertebrae,
and limbs (Lecanda et al., 2000).
To overcome post-natal lethality, Gja1 conditional gene deletion models using cell-type
specific Cre drivers are used to investigate the role of Cx43 in the skeleton (Stains et al.,
2016). For example, using a Dermo1/Twist2 promoter to drive Cre expression and
selectively ablate Gja1, Watkins et al., (2011) were able to analyze the effects of Gja1
deletion in early osteogenesis. Dermo1/Twist2 is a transcription factor expressed in
condensed mesenchyme that derives osteoblasts and chondrocytes, and is thus, specific to
the osteoprogenitor lineage (Yu et al., 2003). Using Cre-mediated excision of the entire
Gja1 reading frame, Watkins and colleagues produced Gja1 conditionally deleted mice,
DM1-Cre;Gja1flox/− (cKOTW2). Similar to Gja1-/- mice, cKOTW2 mice have smaller,
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hypomineralized skulls at birth compared to wildtype mice and this difference in skull
ossification persists until one month of age. Adult cKO

TW2

mice also display skeletal

changes compared to wildtype mice including larger diaphyseal cross-sectional areas
(43% > wildtype), cortical thinning (41% < wildtype) and poor quality bone tissue with
disorganized collagen fibers (Watkins et al., 2011).
At later stages of osteogenic development, conditional deletion of Gja1 produces
comparable, albeit less pronounced results. Conditional Gja1 ablation in mid-stage
osteoblasts using a Col1a1 (cKO

Col1

) Cre resulted in mice that display reduced bone

mineral density (BMD) (5% < wildtype), widened diaphyseal cross-sectional areas (30%
> wildtype), and cortical thinning (20% < wildtype) (Chung et al., 2006; Grimston et al.,
2008). Other investigations of late-stage, osteoblast-specific deletion of Gja1 using a
human OC Cre (cKO

hOC

) have shown similar widening of the bone marrow cavity

(Zhang et al., 2011; Bivi et al., 2012). However, results from analyses of cortical bone
BMD differ among studies, as Zhang and colleagues reported reduced BMD in cKO

hOC

mice while Bivi’s team found no difference between knock-out and wildtype mice
(Zhang et al., 2011; Bivi et al., 2012). Collectively, these studies suggest that deletion of
Gja1 from cells early in the osteoprogenitor lineage has more severe consequences than
Gja1 deletion from cells in later-stage osteoblast differentiation.
Three distinct germline ODDD-associated mutant mouse models have also been
generated (Stains & Civitelli, 2016). Identified in an N-ethyl-N-nitrosourea mutagenesis
screen, and not present in human ODDD patients, Cx43G60S/+ mice carry a point mutation
in Gja1 that results in a glycine to serine substitution at position 60 in the extracellular
loop of the protein (Fig. 3) (Flenniken et al., 2005). The G60S substitution is a dominantnegative mutation, and causes an 80% reduction in Cx43-based GJIC in any tissue or cell
expressing Cx43 (Flenniken et al., 2005; Laird, 2014). Furthermore, these mice present
with many of the same phenotypic features found in ODDD, such as syndactyly, enamel
hypoplasia, and the characteristic craniofacial abnormalities. Cx43G60S/+ mice also exhibit
features not present in the human ODDD condition, such as reduced BMD, enlarged
diaphyseal marrow cavities, and thin cortical bone (Flenniken et al., 2005). Mouse
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models of mutations that are found in humans, and are perhaps more reflective of the
ODDD phenotype, include the G138R and the I130T point mutations. The G138R
mutation is located in the cytoplasmic loop of the Cx43 protein (Fig. 3) (Dobrowolski et
al., 2008). Like the Cx43

G60S/+

phenotype, Cx43

G138R/+

mice exhibit typical ODDD

craniofacial anomalies as well as significant osteopenia (reduced bone mass) and reduced
bone volume. Interestingly, while it is likely that Cx43

G138R/+

mice have a 50% reduction

in GJIC, these mice experience enhanced arrhythmogeneity as a result of leaky
hemichannels, suggestive of gain-of-function activity (Roscoe et al., 2005; Dobrowolski
et al., 2007; Dobrowolski et al., 2008). The present study uses the Cx43I130T/+ mouse
model, which is discussed in greater detail below.

Figure 3. Schematic illustration of the Cx43 protein. The protein consists of four
transmembrane domains, two extracellular loop domains, one cytoplasmic loop domain,
and amino (NH2) and carboxyl termini (COOH) in the cytosol. The schematic depicts
three ODDD mouse model missense mutations, G60S in the first extracellular loop and
G138R and I130T in the intracellular loop.

1.5.2

Cx43I130T/+ Mouse Model

To investigate the effects of a human connexin channelopathy, Kalcheva and colleagues
used site-directed mutagenesis to generate an I130T point mutation in order to create a
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murine model of ODDD (Kalcheva et al., 2007). Targeted embryonic stem cell clones
were injected into C57BL/6 blastocysts, and chimeric male mice were crossed with
wildtype CD1 females to generate F1 Cx43I130T/+ heterozygous mutant mice (Kalcheva et
al., 2007).
This mouse model shares a similar phenotype to that seen in human patients and adult
mutant mice are easily identifiable by characteristic hind limb syndactyly (Kalcheva et
al., 2007). The I130T mutation, involving an isoleucine to threonine substitution at
position 130 in the cytoplasmic loop of the protein is shown in Figure 2. The mutation is
autosomal dominant and cells with mutant Cx43I130T/+ retain residual channel function
+/+

when co-expressed with wildtype Cx43 , as Cx43-based GJIC coupling is maintained at
50% (Laird, 2014). Thus, if the overall level of Cx43-based GJIC is above 50%, overt
symptoms of the disease may not be present in patients. While the I130T mutation does
form electrically capable gap junctions, their probability of plaque formation is lower
than that of the wildtype protein (Shibayama et al., 2005). Together, sub-par channel
function and lower plaque formation can in part explain why I130T mutant mice display
a survival disadvantage. Kalcheva and team discovered that significantly less than the
Mendelian proportion of neonatal heterozygotes (Cx43I130T/+) were produced in
heterozygote/wildtype matings. Furthermore, they found that no Cx43I130T/I130T
homozygote pups survived (Kalcheva et al., 2007). Overall, the Cx43I130T/+ mouse model
is an appropriate tool for studying the effects of reduced Cx43 function on bone as the
mutation is found in some humans with ODDD.

1.6 Preliminary Study of Adult Cx43I130T/+ Mice
Through shape analyses using Euclidean Distance Matrix Analyses (EDMA) of µ-CT
images, our lab has previously found a significant difference in both shape and size of
three month-old (adult) Cx43I130T/+ skulls compared to Cx43+/+ littermates. Geometric
morphometrics using EDMA allows for the estimation of localized differences between
mouse groups through statistical comparison of pairwise distances between landmarks
(Caskenette et al., 2016). Consistent with the ODDD phenotype in humans, facial bones
of Cx43I130T/+ adult mice were significantly smaller compared to their wildtype
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littermates (Fig. 4A). However, the strongest phenotypic differences were found in the
anterior cranial base of the skull. In particular, the presphenoid bone of the cranial base
was approximately 15% larger in mutants compared to wildtype mice (Fig. 4A).
Furthermore, in 30% of Cx43

I130T/+

skulls, the palatal processes of the maxilla did not

ossify anteriorly and palatal bones did not ossify and fuse posteriorly, resulting in a submucous cleft palate (Fig. 4B). While not often described as one of the main phenotypic
characteristics of ODDD, cleft palate is more commonly found in ODDD patients. In
fact, one study reported a 3% prevalence of cleft palate in patients with ODDD compared
to 0.05% prevalence in the general population (Paznekas et al., 2009). Thus, like other
I130T/+

mouse models of reduced Cx43 function, adult Cx43

mice display altered skull

morphology compared to wildtype littermates and these changes largely mirror human
ODDD.
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Figure 4. Adult Cx43I130T/+ mice display ODDD craniofacial characteristics. (A)
Facial regions of Cx43I130T/+ adult skulls are significantly smaller compared to their
wildtype littermates. The red lines show measurements that are significantly different
between genotypes and are at least 5% smaller in Cx43I130T/+ mice. Interestingly, the
anterior cranial base is larger in Cx43I130T/+ mice compared the wildtype mice. Blue lines
indicate measurements that are significantly different between genotypes and are at least
10% larger in Cx43I130T/+ mice compared to wildtype mice. (B) Palatal defects were
observed in 30% of our Cx43I130T/+ mice, such that the palatal processes of the maxilla
(shown by red arrow) did not ossify anteriorly and palatal bones did not ossify and fuse
posteriorly (shown by green arrow), resulting in a sub-mucous cleft palate.

1.7

Rationale

While patients with ODDD display a suite of phenotypic dysmorphologies, the most
prominent alterations of the craniofacial skeleton are smaller facial bones. Preliminary
studies of adult Cx43I130T/+ mutant mice in our lab confirm that mice heterozygous for the
mutation also have smaller facial bones, which has similarly been found in other Cx43
mutant and knock-out mouse studies. Surprisingly, the greatest phenotypic changes we
observed were in the cranial base, which has not been previously reported in other mouse
models or in humans. It is unclear whether this finding is novel to this mouse model, or if
this phenotypic alteration of the cranial base has been previously overlooked given its
internal positioning.
Interestingly, alterations observed in the intramembranous-derived facial bones are
opposite to changes in the endochondral-derived cranial base. Specifically, mutants have
smaller facial bones and larger bones of the anterior cranial base. Thus, it appears that
reduced Cx43 function associated with the I130T mutation is having a differential effect
on intramembranous and endochondral ossification of the skull. In intramembranous
ossification, bones are formed via direct ossification of mesenchymal condensations, and
consequently osteoblasts are the driving force of sutural growth sites. Conversely,
endochondral bone is formed by ossification of a cartilaginous template, and thus
chondrocytes are the key players at synchondroses. Therefore, it appears that reduced
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Cx43 is having a differential effect on osteoblasts and chondrocytes. The role of Cx43 in
osteoblasts is well established in the literature (Stains & Civitelli, 2016). Generally, it
appears that reduced Cx43 function negatively affects osteoblast differentiation.
However, Cx43 function in chondrocytes has not been extensively studied. A few studies
have noted decreased chondrocyte differentiation, and one study observed increased
chondrocyte proliferation, as a result of reduced Cx43 function (Zhang et al., 2002;
Gago-fuentes et al., 2016). Little else is known about Cx43-GJIC in chondrogenesis.
Given that rapid growth of the skull occurs during late embryonic and early postnatal
development, I predict that phenotypic changes associated with reduced Cx43 will arise
during these times. As both intramembranous and endochondral ossification are disrupted
in adult Cx43

I130T/+

skulls, I also predict that localized changes in chondrocyte and

osteoblast differentiation and/or proliferation will correspond to localized differences in
gross morphology. Additionally, because sutures and synchondroses are the main growth
centers for intramembranous and endochondral ossification of the skull, respectively, I
expect that the greatest cellular changes will be detected at these sites. The present study
focuses on the interpalatine suture and cranial base synchondroses since the most
dramatic changes seen in adult Cx43I130T/+ skulls were in bones formed by these growth
centers.

1.8

Objectives and Predictions

Aim 1: To characterize and quantify craniofacial shape differences between Cx43I130T/+
and Cx43+/+ mice through late embryonic and early post-natal development.
I predict that late embryonic and early post-natal Cx43I130T/+ mice will have altered
craniofacial shape compared to their wildtype littermates and that these alterations will be
similar to those observed in adult Cx43I130T/+ mice.
Aim 2: To characterize, quantify and compare osteoblast and chondrocyte proliferation
and differentiation within the face and cranial base of Cx43I130T/+ and Cx43+/+ mice
through late embryonic and early post-natal development.
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I predict that Cx43

I130T/+

mice will display reduced osteoblast differentiation within their

palatal bones compared to their wildtype littermates. I also predict that chondrocyte
proliferation and differentiation will be increased within the synchondroses of Cx43I130T/+
mice compared to wildtype mice.
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Chapter 2
2 Materials and Methods
2.1 Mouse Model
Cx43I130T/+ heterozygote mice were created as described by Kalcheva and colleagues, and
were bred on a mixed background of C57BL/6 (Gja1tm3GFi ) and CD1 (Kalcheva et al.,
I130T/+

2007). Cx43

mice are incipient congenic on C57BL/6 (Gja1

tm3GFi

) and were

compared to wildtype littermate controls. Mice at age embryonic day 17.5 (E17.5) and
post-natal day 0 (P0) were used to study late embryonic and early post-natal
development. P0 pups were sacrificed by decapitation. E17.5 mice were obtained by
sacrifice of pregnant dams using CO2 followed by caesarean section; the embryos were
then sacrificed via decapitation. Mice from each genotype at each age were taken from at
least three litters to account for litter effects. All mice were genotyped and sexed by PCR
using DNA obtained from tail samples. The primers used for amplification of Cx43I130T/+
were as described by Paznekas and colleagues (Paznekas et al., 2003). Mice were
maintained on a 12-hour-light–12-hour-dark cycle housed in the animal care facilities at
the University of Western Ontario, and were fed standard mouse chow (2018 Teklad
Global 18% Protein Diet; Harlan Laboratories, Indianapolis, IN, USA) ad libitum. All
experiments were approved by the Animal Care Committee at Western University and
conducted according to the guidelines of the Canadian Council on Animal Care.

2.2 Aim 1 Methods
The purpose of Aim 1 is to determine if skull shape changes associated with the ODDD
phenotype that are present in adult Cx43I130T/+ mice are present at late embryonic and
early post-natal Cx43I130T/+ mice. To address this Aim, I performed multivariate statistical
analyses of skull shape and size on micro-computed tomography (µ-CT) images of E17.5
and P0 Cx43I130T/+ mice and their wildtype littermates. Generalized bone quality was
also assessed for BMD and mineralization.
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2.2.1

Skull Imaging

µ-CT images were obtained from a sample of ten Cx43

I130T/+

and ten Cx43

+/+

E17.5 and

P0 mouse skulls. Prior to scanning, the mouse skulls were fixed in 4% paraformaldehyde
overnight and were then embedded in 1% agarose in 50mL Falcon tubes to reduce
movement artifacts. Specimens were scanned using a GE Locus RS-9 scanner (GE
Healthcare, Waukesha, WI, USA) housed at the 3D Preclinical Imaging Centre at Robarts
Research Institute (London, ON). In one rotation of the beam, 900 views were acquired
every 0.4 degrees over a 360 degree rotation of the gantry. Each projection lasted for
4500 ms and two projections were averaged at each view angle. The tube potential was
measured as 80 kVp and tube current was 450 µA. Images were obtained at an isotropic
voxel size of 20 µm and were reconstructed as 3D volumes. To ensure inter-sample
consistency, calibration samples of water and cortical bone-mimicking epoxy were
included in each scan. The synthetic cortical bone-mimicking epoxy (SB3, Gamex,
Middleton, WI, USA) has a bone mineral equivalent of 1100 mg cm-3 (Beaucage et al.,
2014; Caskenette et al., 2016).

2.2.2

Landmarking

Prior to data collection, skulls were segmented from the mandible using MicroView (GE
Healthcare Biosciences) to allow visualization of skull elements obscured by the
mandible. Three-dimensional landmark coordinate data were then collected from surface
reconstructions generated from µ-CT data of each mouse skull, and was subsequently
used to compare skull morphology between Cx43I130T/+ and Cx43+/+ mice. Landmarks
provide a visual spatial map of the region of interest and represent anatomical points that
can be recognized as the same loci on all study specimens (Slice, 2007). Furthermore,
landmark-based geometric morphometric analyses allow for the preservation and analysis
of shape relationships among data points (Baab et al., 2012). A set of 32 and 57
homologous skull landmarks were collected at the E17.5 and P0 developmental time
points, respectively (Fig. 5, Appendix A) using Checkpoint software (Stratovan
Corporation, Davis, CA). These landmarks capture salient morphological features of the
entire skull, and are derived from those created by Richtsmeier and colleagues (MartínezAbadías et al., 2010; Martínez-abadías et al., 2013; Motch Perrine et al., 2014).
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Landmarks were manually collected twice per specimen by the same observer to quantify
measurement error. Deviations between the two trials were calculated and were restricted
to 0.05 mm or less (Martínez-abadías et al., 2013). The average of the two trials was
used in subsequent analyses.

Figure 5. E17.5 and P0 skull landmarks. A set of 32 and 57 homologous skull
landmarks were collected at the E17.5 and P0 developmental time points, respectively.
(A) Landmarks for E17.5 skulls. (B) Landmarks for P0 skulls. Landmarks pertaining to
both ages are in pink, P0-specifc landmarks are in green, and E17.5-specific landmarks
are in orange. Numbers correspond to list provided in Appendix A.
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2.2.3

Geometric Morphometric Analyses

Geometric morphometric analyses allow for statistical quantification and comparison of
subtle differences in shape and size. These analyses involve multivariate statistics that
enable the relationship among data points to be preserved in a biologically meaningful
way (Collyer et al., 2015).
Shape
Shape as defined by Kendall (1977), is the geographical information that remains when
scale, location, and rotational factors are removed (Zelditch et al., 2004). To remove
these factors unrelated to shape, all landmark data underwent Procrustes superimposition
using the R program geomorph (Adams et al., 2013; Adams & Collyer, 2018; R
Foundation for Statistical Computing, Vienna, Austria, 2017), which superimposes
configurations of landmarks by shifting them to a common position, rotating and scaling
them to a standard size until a best fit of corresponding landmarks is achieved (Rohlf &
Slice, 1990; Dryden & Mardia, 1998). Procrustes superimposition creates a new set of
variables, called Procrustes coordinates that replace the original landmark data. These
new Procrustes coordinate data contain only the shape information contained in the
original landmark data and maintain the relationship among points from the initial dataset
(Rohlf & Slice, 1990).
As geometric morphometric shape analyses are necessarily multivariate, it is not possible
to look at just a subset of landmarks within a Procrustes superimposition. Thus, separate
Procrustes superimpositions were done on the full complement of landmarks (whole
skull), landmarks located on the cranial base, those on the face and landmarks of the
cranial vault.
Differences in whole skull, cranial base, face and cranial vault shapes were statistically
compared between Cx43I130T/+ and Cx43+/+ at E17.5 and P0 using a non-parametric
MANOVA using the ProcD function in the R package geomorph (Adams & Collyer,
2018; R Foundation for Statistical Computing, Vienna, Austria, 2017). These analyses
were performed on the Procrustes coordinates and accounted for possible sex and litter
effects using the formula [shape ~ genotype + sex + litter + (genotype x sex) + (genotype
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x litter)]. The procedure involves a resampling function of 10,000 iterations to create a
probability distribution from which significance can be determined (α=0.05). This nonparametric approach was used as the variables in the multivariate datasets greatly exceed
the sample sizes (Collyer et al., 2015).
Differences in skull shape of Cx43I130T/+ and Cx43+/+ E17.5 and P0 mice were visually
compared using principal components analysis (PCA), a data reduction technique that
allows for detection of the main axes of variation within a dataset. In this case, the PCA
was performed on the variance/covariance matrix of Procrustes coordinates using the
geomorph package in R (Adams & Collyer, 2018; R Foundation for Statistical
Computing, Vienna, Austria, 2017). The first principal component (PC1) is the axis that
accounts for the greatest amount of variation in the dataset. The second principal
component represents the axis of second greatest variation and is orthogonal to PC1.
Each mouse is assigned a score for each principal component and these scores can be
used to visually depict the relationships among mice along these axes using a scatterplot.
A qualitative difference in shape is indicated if mice within each genotype are tightly
clustered and there is a separation between genotypes along one or more principal
components.
Visualization of shape changes between Cx43I130T/+ and Cx43+/+ mice along PC1 was
accomplished by morphing the Procrustes superimposed landmark data of the mice at the
extreme negative and positive ends of PC1 onto the wildtype mouse with a PC1 score
closest to zero. Distances between landmark data were represented by a heat map on a
volumetric mesh of the skull with distances that accounted for differences at the positive
end of PC1 in warmer colours (yellow, orange, and red) and those at the negative end of
PC1 in cooler colours (blue).
Size
Differences in overall skull size as well as size of the cranial base, cranial vault and face
were compared between Cx43I130T/+ and Cx43+/+ mice at E17.5 and P0 using centroid
size. Centroid size is measured as the square root of the summed squared distances
between each landmark coordinate and the centroid of the landmark configuration
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(Dryden & Mardia, 1998). It is preferable to a scalar measure such as skull length or
width as it accounts for all the geometry captured by the landmark data. Centroid size
was calculated as part of the Procrustes superimposition performed using the geomorph
package in R (Adams et al., 2013; R Foundation for Statistical Computing, Vienna,
Austria, 2017). Differences in size were compared using a 2-way mixed model ANOVA
that included litter and sex interactions in R (R Foundation for Statistical Computing,
Vienna, Austria, 2017). Significance of these analyses were adjusted using a Bonferroni
correction (α=0.0125) for multiple comparisons.

2.2.4
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Bone mineral density (BMD) of the skull was calculated for each mouse from scan data
as the ratio of the average Hounsfield unit value of the bone region of interest to the
measured Hounsfield unit value of the synthetic cortical-bone mimicking epoxy
calibrator using a script written for MicroView software (Beaucage et al., 2014;
Caskenette et al., 2016). BMD was calculated for a sample of bones from the face, cranial
vault and cranial base and include: maxilla, palatine, basisphenoid and basioccipital
bones (E17.5), as well as pre-maxillary, maxillary, palatine, parietal, presphenoid,
basisphenoid, and basioccipital bones (P0). Fewer bones were measured at E17.5 as
many did not have enough ossification to reliably place the region of interest. At least 3
ROI (region of interest) samples were taken from each bone of interest and were
consistent across individuals. These measurements were averaged within each bone. As
well, ROI sizes varied depending on bone and mouse age. This was done to ensure
sampling of cortical bone and to minimize sampling of air. At E17.5, two different ROI
sizes were used: x, y, and z coordinates for basisphenoid and basioccipital bones was
0.0605mm, while x, y, and z coordinates of maxilla and palatine bones was 0.0403mm.
At P0, presphenoid, basisphenoid, basioccipital bones required x, y and z coordinates of
0.1009mm, while maxilla, palatine, premaxilla, and parietal bones required an ROI size
of 0.0605mm for all x, y and z coordinates. Differences in BMD measurements for these
different bones were compared between Cx43I130T/+ and Cx43+/+ mice at E17.5 and P0
separately using a MANOVA (α=0.05) that included litter and sex interactions. All
analyses were performed in R (R Foundation for Statistical Computing, Vienna, Austria,
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2017).

2.2.5

Alizarin Red/Alcian Blue Staining

Skull mineralization was qualitatively compared between Cx43I130T/+ and Cx43+/+ mice at
E17.5 and P0 using a double stain of alizarin red and alcian blue. Alizarin red stains
ossified bone red while alcian blue stains cartilage blue. Mice were dissected and taken
through a series of ethanol and acetone washes before addition of the staining solution
and subsequent tissue digestion in KOH. Staining followed established protocols (see
Appendix B) (McLeod, 1980). Double stained skulls were examined using a Leica
DM1000 microscope and representative images were taken using a Leica DFC 295
camera (Leica Microsystems, Wetzlar, Germany).

2.3

Aim 2 Methods

The purpose of Aim 2 is to determine if osteoblast and chondrocyte proliferation and
differentiation are altered in the growth centers of the face and cranial base in Cx43I130T/+
mice compared to wildtype littermates. I addressed this Aim using immunohistochemical
markers for proliferation and different stages of osteoblast and chondrocyte
differentiation in E17.5 and P0 mice. Specifically, I focused on the interpalatine suture of
the face and the presphenoidal and spheno-occipital synchondroses of the cranial base.
Sample
Tissue morphology and cell proliferation and differentiation within the palatine bones at
the interpalatine suture, and within the presphenoidal and spheno-occipital synchondroses
were compared between Cx43

I130T/+

and Cx43

+/+

mice at E17.5 and P0. Samples were

fixed overnight in 4% paraformaldehyde, processed and embedded in paraffin. To
capture the interpalatine bones, skulls were sectioned in the coronal plane, whereas
sagittal sections were used for analyses of the synchondroses. All sections were cut to
five µm. A sample of five Cx43I130T/+ and five Cx43+/+ skulls for each age group and
section plane were used for subsequent histological and immunohistochemical staining.
Male and female mice from at least three litters were used to account for possible sex and
litter effects.
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2.3.1

Histomorphology

Cellular organization of the palatine bones at the interpalatine suture and of the
presphenoidal and spheno-occipital synchondroses was visualized using Safranin-O/Fast
Green/Hematoxylin (Sigma, S8884; EMD Millipore, 210-M; Fisher Chemical, SH26-4D)
staining and was qualitatively compared between Cx43I130T/+ and Cx43+/+ mice at E17.5
and P0. Safranin-O stains the proteoglycans within the cartilage matrix red, Fast Green
stains cytoplasm green, and hematoxylin stains cellular nuclei purple. Staining
procedures followed established protocols (see Appendix C, Appendix F) (Dako, 2013;
Kiernan, 1990).

2.3.2

Immunohistochemistry

Osteoblast and chondrocyte proliferation and differentiation of the palatine bones at the
interpalatine suture and the presphenoidal and spheno-occipital synchondroses were
compared between Cx43I130T/+ and Cx43+/+ E17.5 and P0 mice using
immunohistochemistry. A list of the antibodies used in this Aim can be found in
Appendix D, and the staining protocols can be in Appendix G. Osteoblast and
chondrocyte proliferation was determined using Proliferating Cell Nuclear Antigen
(PCNA) staining (rabbit anti-PCNA, 1:1600, Abcam, ab18197). PCNA is a proliferation
marker as it acts as a DNA sliding clamp during DNA replication and has been found to
increase during S-phase of the cell cycle (Miyachi et al., 1978; Bravo & Celis, 1980;
Celis & Celis, 1985). As PCNA is nuclear, staining is visible intracellularly.
The degree of early-, mid- and late-stage osteoblast differentiation was determined using
antibodies for Runx2 (rabbit anti-Runx2, 1:400, Abcam, ab23981), Osterix (rabbit antiSp7/Osterix, 1:800, Abcam, ab22552) and Osteocalcin (rabbit anti-Osteocalcin, 1:400,
Abcam, ab93876). Runx2 is a transcription factor expressed during early-stage osteoblast
differentiation, and is a marker used for detecting osteoprogenitors that is visible
intracellularly (Ducy et al., 1997; Lima et al., 2009). Osterix is also a transcription factor,
and is visible intracellularly, and is expressed in immature proliferating osteoblasts (Day
et al., 2005; Hill et al., 2005; Huang, 2007). Osteocalcin is a protein secreted by latestage differentiated osteoblasts, and is therefore a marker of late-stage osteoblast
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differentiation and is visible extracellularly (Ducy & Karsenty, 1995; Huang, 2007).
Chondrocyte differentiation was examined using Sox9 (rabbit anti-Sox9, 1:800, Abcam,
ab185966). Sox9 is a useful chondrocyte differentiation marker as it is a transcription
factor required for chondrocyte differentiation and subsequent cartilage formation (Bi et
al., 1999). It is found in resting, proliferative and pre-hypertrophic chondrocytes, but is
absent in hypertrophic chondrocytes. It is also nuclear and therefore visible
intracellularly.
Antigen retrieval for Runx2 and PCNA antibodies was performed using a de-cloaking
chamber with citrate buffer pH 6.0, while the remaining antibodies were treated with
0.1% TritionX-100. Application of the secondary antibody was performed using
ImmPRESS Anti-Mouse Ig Peroxidase Polymer Detection Kit (Vector Laboratories, Cat.
No. MP-7402) and was subsequently labeled with DAB (DAB Peroxidase Substrate Kit,
3,3’–diaminobenzidine, Vector Laboratories, Cat. No. SK-4100) as per standard
protocols (Vector Laboratories, 2010, 2013). Methyl Green (Sigma, 67060) was used to
counterstain sections.
To differentiate true positive staining from false positive staining, negative controls were
included for all antibodies used. Negative and isotype control slides were generated using
sections from Cx43+/+ E17.5 and P0 mouse skulls that underwent the same procedures as
outlined above except for the application of the primary antibody (see Appendix E). Two
isotypes were used in lieu of primary antibody: rabbit IgG monoclonal (ab172730) for
Sox9, and rabbit IgG polyclonal (ab37415) for the remaining antibodies.

2.3.3

Imaging and Quantification

Safranin-O/Fast Green/Hematoxylin and immunohistochemical stained slides were
examined using a Zeiss A1 light microscope and images were taken using a Zeiss
AxioCam MRc microscope-mounted camera (Oberkochen, Germany). Images of the
palatine bones at the interpalatine suture were taken at either 40X or 63X magnifications.
Synchondroses images were taken at 20X and merged using Adobe Photoshop CS6 (San
Jose, USA).
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The histomorphology of Safranin-O/Fast Green/Hematoxylin stained interpalatine sutures
was qualitatively compared for overall organization of the suture and general size of the
bones. Synchondroses stained with Safranin-O/Fast Green/Hematoxylin underwent both
qualitative and quantitative comparison between genotypes. Qualitative assessment was
based on the general organization and shape of the synchondroses. Quantitative
assessment included area measurements of the whole synchondrosis as well as measures
of relative areas of the resting, proliferative and hypertrophic areas within each
synchondrosis using Fiji (Schindelin et al., 2012). Synchondroses growth zones (resting,
proliferative, and hypertrophic) were delineated based on cellular appearance and
organization. Each growth zone was standardized by dividing the area of the image by
the area of the entire synchondrosis. Synchondroses area measurements were compared
between Cx43

I130T/+

and Cx43

+/+

using 2-way mixed model ANOVAs in R (R Foundation

for Statistical Computing, Vienna, Austria, 2017) and included interaction effects for sex
and litter.
Quantification of anti-Sp7/Osterix-positive cells of the palatine bones at the interpalatine
suture and anti-Sox9-positive cells of the synchondroses were performed using a semiautomated macro for Fiji modified from Bergmeister and colleagues (Bergmeister et al.,
2016). Cell size exclusions were optimized and kept the same for counts of the same cell
type. Positive-cell thresholding was compared and adjusted against the controls for each
staining run, thus an optimum threshold was determined for each run to properly capture
positively-stained cells. Cell density counts were used as a relative measure of
differences in differentiation of osteoblasts and chondrocytes between wildtype and
mutants. Intra-rater reliability was calculated for average difference error between
manual and macro counts. Overall average difference error for manual counts was 15%
whereas overall average difference error for macro counts was 0%. Macro cell counts
produced the same result consecutively whereas different trials of manual counts resulted
in more error. Computed cell counts were divided by the area (µm2) of interest, and
compared between genotypes using a 2-way mixed model ANOVA in R and included
interaction effects for sex and litter (R Foundation for Statistical Computing, Vienna,
Austria, 2017).
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Chapter 3
3 Results
3.1 Cx43I130T/+ Mice Display Typical ODDD Skull Characteristics
at P0
Skull shape analyses were performed on landmark data taken on μ-CT images to compare
shape between Cx43I130T/+ mice and their wildtype littermates at E17.5 and P0. These
analyses were conducted to localize and quantify shape differences between genotypes
and to determine whether late embryonic and early postnatal Cx43I130T/+ mice displayed
craniofacial traits typical of ODDD. Statistical comparisons of shape of the whole skull,
face, cranial vault and cranial base were conducted using non-parametric MANOVAs
that accounted for potential sex and litter effects. At E17.5, significant shape differences
were detected between Cx43I130T/+ and Cx43+/+ mice for the whole skull (p=0.042),
cranial vault (p=0.044) and cranial base (p=0.032). The facial region was not
significantly different between genotypes, an unexpected result given the strong changes
to facial morphology typically associated with ODDD. Shape changes were far more
prominent at P0 with significant changes detected for all regions: whole skull (p=0.0009),
face (p=0.0002), cranial vault (p=0.037) and cranial base (p=0.00001). These shape
changes at P0 are similar to our findings in adult Cx43I130T/+ mice with differences largely
localized to the facial skeleton and cranial base. Indeed, as with adult mice, the greatest
difference in shape between genotypes at P0 were detected in the cranial base.
The potential effects of sex and litter on shape data were also analyzed. Sex had no effect
on shape differences at E17.5, but litter significantly affected shape for the whole skull
(p=0.0016), cranial vault (p=0.024) and cranial base (p=0.0060) at this age. At P0,
significant sex effects were found for the whole skull (p=0.019) and cranial base
(p=0.0022). Significant litter effects were detected for all regions of the skull: whole skull
(p=0.00001), face (p=0.00001), cranial vault (p=0.0053) and cranial base (p=0.00001).
Thus, while the effects of the Cx43I130T/+ mutation significantly alter craniofacial shape,
sex and litter also strongly influence skull shape in these mice.
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PCAs conducted on Procrustes superimposed coordinate data were used to help visualize
differences in shape. As the Procrustes superimposition scales the data, PC1 is a measure
of allometric size rather than overall size. Thus, while it accounts for the most variation
in the data, the eigenvalues for PC1 are mostly smaller than that typically found for
morphological data using traditional measures such as lengths. PCA for E17.5 mice are
presented in Figure 5. For the whole skull (Fig. 6Aa), PC1 accounts for 38% of the total
variation and PC2 accounts for 15%. There is some distinction between genotypes along
the first PC with Cx43I130T/+ mice tending towards the left and wildtype mice tending
towards the right, but there is much overlap. These results visually depict the small, but
statistically significant difference in whole skull shape determined by MANOVA. The
cranial base shows the greatest differentiation between genotypes of all the regions
analyzed (Fig. 6Ab), which is in alignment with the MANOVA results. PC1 accounts for
31% of cranial base shape variation and PC2 accounts for 15% of the variation.
Cx43I130T/+ mice separate from their wildtype littermates along PC1, but there is still
overlap of the genotypes. The cranial vault PCA scatterplot (PC1 47% of variation, PC2
18% of variation) does not differentiate the two groups along either PC (Fig. 6Ac),
though there is some clustering of wildtype mice on the left along PC1 and Cx43I130T/+
mice on the right. Again, these PCA results confirm the statistically significant, but
relatively minor differences in cranial vault shape. The PC scatterplot for the face (Fig.
6Ad) shows two groups, one at the left side of PC1 and a larger cluster at the right end of
PC1. Importantly, this division does not separate the genotypes and thus confirms the
insignificant difference in face shape identified through MANOVA. PC1 accounts for
61% of the total variation, a value that is similar to morphological data that includes
overall size. It appears that allometric size differences contribute largely to the overall
shape variation in the face and that these size differences are not differentiated by
genotype.
Changes in E17.5 skull shape associated with variation along PC1 for the whole skull
were illustrated using a heat map (Fig. 6Bc,d, e). Shape differences in the skull between
Cx43I130T/+ mice and their wildtype littermates at E17.5 are quite minimal as
demonstrated by the neutral colours (light blue/green/yellow) found for most of the
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Figure 6. E17.5 PC plots and morphs. (A) Principle component analyses of E17.5
Cx43I130T+ and Cx43+/+ skulls (a) Whole skull (b) Cranial base (c) Cranial vault and (d)
Face. While statistically significant differences in shape were detected by MANOVA for
the whole skull, cranial base and cranial vault, these differences are relatively minor as
demonstrated by the large overlap between genotypes along the first two PCs. (B)
Representative μ-CT isosurfaces of E17.5 wildtype and Cx43I130T/+ skulls (a) inferior
view and (b) lateral view. Visualization of shape differences between genotypes at E17.5
along PC1 using heat morphs again demonstrates that changes to morphology at this age
are subtle. Superior (c), lateral (d) and inferior (e) views of the skull morph show that the
greatest differences in shape between genotypes are found in structures of the posterior
cranial base and cranial vault as denoted by their dark blue colour.
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bones. The posterior portions of the occipital bone and some cranial vault structures show
a difference in shape between genotypes as depicted by the dark blue colouration,
indicating that relatively large differences in shape variation exist between genotypes for
these skull elements and that these differences are due to variation within Cx43I130T/+
mice.
Shape changes between genotypes were far more prominent at P0 than at E17.5 and
largely mirror the differences found between adult Cx43I130T/+ and Cx43+/+ mice. PCA
results for P0 mice are presented in Figure 6. For the whole skull (Fig. 7Aa), PC1
accounts for 28% of the total variation and PC2 accounts for 12%. There is apparent
distinction between genotypes along the first PC with Cx43I130T/+ mice tending towards
the right and wildtype mice tending towards the left. These results visually display the
statistically significant difference in whole skull shape determined by MANOVA.
Similar to E17.5, the cranial base again displays the greatest differentiation between
genotypes of all the regions analyzed (Fig. 7Ab). PC1 accounts for 17% of cranial base
shape variation and PC2 accounts for 14% of the variation. Cx43I130T/+ mice separate
from their wildtype littermates along PC1 but there is still some overlap of the genotypes.
The PCA scatterplot of the cranial vault (PC1 38% of variation, PC2 14% of variation)
does differentiate between the two groups well along PC1, however PC2 shows
considerable overlap (Fig. 7Ac). These PCA findings corroborate with statistically
significant differences found in P0 cranial vault shape. Lastly, the P0 PC plot for the face
(Fig. 7Ad) shows two groups, with wildtypes clustering at the left side of PC1 and
mutants clustering more so to the right end of PC1. There is a distinct division between
the genotypes, which highlights the significant differences found in face shape identified
through MANOVA. PC1 accounts for 37% of the total variation, while PC2 accounts for
12%.
Again, differences in skull shape between genotypes associated with variation along PC1
were illustrated using a heat map (Fig. 7Bc,d, e). Shape differences in the skull between
Cx43I130T/+ mice and their wildtype littermates at P0 are much more marked compared to
E17.5. The facial bones are warmer in colour (yellow-green and yellow) indicating that
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Figure 7. P0 PC plots and morphs. (A) Principle component analyses of P0 Cx43I130T+
and Cx43+/+ skulls (a) Whole skull (b) Cranial base (c) Cranial vault (d) Face.
Visualization of shape differences along the first two PCs confirms results obtained by
MANOVA with the largest differences found within facial structures and the cranial
base. (B) Representative μ-CT isosurfaces of P0 wildtype and Cx43I130T/+ skulls (a)
inferior view and (b) lateral view. Visualization of shape differences between genotypes
at P0 along PC1 using heat morphs in superior (c), lateral (d) and inferior (e) views
highlight that similar to E17.5 mice, the greatest changes occur within the cranial base as
indicated by the dark blue colouring, and within the facial bones as denoted by the
warmer yellow colours.
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there are prominent changes in the facial bones and that these changes are driven through
variation within wildtype mice. The cranial base and posterior portions of the skull are
displayed in dark blue indicating that these regions differ largely between genotypes and
that this difference is caused by variation within Cx43I130T/+ mice.

3.2 Skull Size is Smaller in Cx43I130T/+ Mice than their Wildtype
Littermates at P0
Size differences between genotypes were quantified using a 2-way mixed model
ANOVA using centroid size – a unit-free measure calculated during the Procrustes
superimposition process. Centroid size was calculated separately for the whole skull,
face, cranial vault and cranial base. At E17.5, no size differences were detected between
Cx43I130T/+ and their wildtype littermates for any of the regions of the skull (Fig. 8A). Sex
and litter effects were included in the statistical model and while no significant sex
effects were found, significant litter effects were detected for the cranial vault after
Bonferroni correction (p=0.0028).
At P0, significant differences in size between Cx43I130T/+ and Cx43+/+ mice were found
for the whole skull (p=0.012) and the facial skeleton (p=0.00059) after Bonferroni
correction (Fig. 8B). For both the whole skull and face, Cx43I130T/+ mice were smaller
than their wildtype littermates. Males were significantly larger than females after
Bonferroni correction for the whole skull (p=0.00053), face (p=0.0051) and cranial vault
(p=0.00017). Additionally, litter effects were significant for size differences after
Bonferroni correction for all regions analyzed (whole skull p=0.00017, face p=0.00049,
cranial vault p=0.00075 and cranial base p=0.00065).

39

40

Figure 8. Skull centroid size comparisons between Cx43I130T/+ and Cx43+/+ mice at
E17.5 and P0. (A) Comparison of centroid sizes between Cx43I130T/+ and their wildtype
littermates at E17.5 indicate that skull size is not different between genotypes at this age.
(B) Comparison of centroid sizes at P0 indicate that the whole skull and face are
significantly smaller (p<0.0125 with Bonferroni correction) in Cx43I130T/+ mice than their
wildtype littermates.
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3.3 Cx43I130T/+ Mice Display Slight Hypomineralization of the
Cranial Vault at P0
Mouse skulls were stained with alizarin red and alcian blue to detect mineralized bone
and cartilage, respectively. Representative images for both genotypes at E17.5 and P0
are provided in Figure 9A, and show the skull in lateral and inferior views. Alizarin red
staining is less pronounced in the cranial vault of Cx43I130T/+ mice compared to their
wildtype littermates and though this effect is slight at both ages, hypomineralization of
the cranial vault is more prominent at P0 (Fig. 9Aa,b,e,f). Mineralization of the cranial
base bones appears to be unaffected by the mutation at these ages.
Additionally, the quality of mineralization was assessed by measuring BMD from μ-CT
scan data. Results of these measures are summarized in Figure 9Ba,b. At E17.5, many of
the bones of the skull have just begun to ossify and there was not enough bone to capture
reliable BMD measures. Bones that were sufficiently ossified to measure BMD include
the basioccipital, basisphenoid, maxilla and palatine. A MANOVA was used to compare
BMD for each of these bones between Cx43I130T/+ and Cx43+/+ mice with sex and litter
included as factors. There was no significant difference in BMD between genotypes
(Fig. 9Ba). Sex effects were also not significant, but litter had a marginally significant
effect on BMD (p=0.042).
At P0, more bones were sufficiently ossified to capture BMD. Thus, the comparison of
BMD between genotypes included basioccipital, basisphenoid, maxilla, palatine, parietal,
premaxilla and presphenoid bones. Again, there was no statistically significant
difference in BMD between Cx43I130T/+ mice and their wildtype littermates, and no sex
effects were detected (Fig. 9Bb). However, as with the E17.5 mice, litter had a significant
effect on BMD (p=0.033).
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Figure 9. Skull mineralization and bone mineral density comparisons between
Cx43I130T/+ and Cx43+/+ mice at E17.5 and P0. (A) E17.5 alizarin red/alcian blue stained
mouse skulls shown laterally (a,b) and inferiorly (d,e). P0 alizarin red/alcian blue stained
skulls shown lateral (e,f) and inferior (g,h) views. Cranial vault appears less mineralized
in Cx43I130T/+ mouse skulls than wildtype mice particularly at P0 (arrow denotes undermineralized interparietal bone of Cx43I130T/+ skull). Mineralization of the palate and
cranial base bones are similar for both genotypes. (B) Bone mineral density (BMD)
comparisons between genotypes for several skull bones at E17.5 (a) and P0 (b). Results
from both MANOVAs indicate that BMD in the skull is unaffected by the Cx43 I130T
mutation at these ages. At E17.5, only the basioccipital, basisphenoid, maxilla and
palatine bones were sufficiently ossified to be included in this analysis.
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3.4 The Histomorphology of the Interpalatine Suture in
Cx43I130T/+ Mice is Disorganized Compared to Wildtype Mice
Representative images of the palatine bones at the interpalatine suture for both genotypes
at E17.5 and P0 are presented in Figure 10. Coronal sections were stained with SafraninO/Fast Green/Hematoxylin to highlight histomorphological features of the bones and
suture. At E17.5, wildtype mice displayed more organized, compact interpalatine sutures
compared to Cx43I130T/+ mice (Fig. 10a, b). Similar findings were observed in the P0 age
group (Fig. 10c, d). Additionally, the presence of chondrocyte-like cells (indicated by the
red Safranin-O staining and arrowhead) are noticeable along the osteogenic fronts of the
palatine bones of wildtype mice at P0 but were absent in Cx43I130T/+ mice.
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Figure 10. Comparison of the histomorphology of the palatine bones at the
interpalatine suture between Cx43I130T/+ and their wildtype littermates at E17.5 and
P0. Coronal sections of the palatine bones at the interpalatine suture were stained with
Safranin-O/Fast Green/Hematoxylin for visualization and comparison of these structures
between Cx43I130T/+ and Cx43+/+ mice at E17.5 and P0. Yellow dashed lines represent
osteogenic fronts meeting along suture mesenchyme. (a, b) E17.5 Cx43+/+ sutures appear
more compact compared to Cx43I130T/+. (c, d) P0 Cx43+/+ sutures are more organized than
Cx43I130T/+. Arrowhead points to increased incidence of chondrocyte-like cells along
osteogenic fronts of P0 Cx43+/+ compared to Cx43I130T/+.
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3.5 Mid- and Late-Stage Osteoblast Differentiation of the
Palatine Bones is Reduced in Cx43I130T/+ Mice at P0
Osteoblast proliferation of the palatine bones at the interpalatine suture was assessed
using the proliferative marker PCNA. Qualitative assessment of PCNA staining indicates
that there were no overt differences in osteoblast proliferation between Cx43I130T/+ and
Cx43+/+ mice at E17.5 (Fig. 11Aa,b) but increased staining is visible in wildtype mice
compared with Cx43I130T/+ mice at P0 (Fig. 11Ac,d).
Immunohistochemistry was also used to assess osteoblast differentiation of the palatine
bones at the interpalatine suture. Different differentiation markers were used to compare
early-stage differentiation (Runx2), mid-stage differentiation (Osx) and late-stage
differentiation (OC) between genotypes. Levels of Runx2 protein were similar across
both genotypes at both ages (Fig. 11Ae, f, g, h). Qualitative differences in Osx protein
levels between genotypes were not evident at E17.5 (Fig. 11Ai,j), but were quite
prominent at P0 (Fig. 11Ak,l). These qualitative observations were confirmed by
statistical results based on relative cell counts of Osx-positive cells per area. While no
significant differences were found at E17.5, relative amounts of Osx staining in
osteogenic fronts of P0 Cx43I130T/+ palatine bones was significantly reduced compared to
wildtype mice (p=0.023) (Fig. 11B). A significant litter effect for Osx staining at P0 was
also detected (p=0.031). Late-stage osteoblast differentiation of the palatine bones also
appeared reduced in P0 Cx43I130T/+ mice compared with wildtype mice (Fig. 11Ao,p)
while no such difference was found at E17.5 (Fig. 11Am,n).
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Figure 11. Comparison of osteoblast proliferation and differentiation of the palatine
bones at the interpalatine suture between Cx43I130T/+ and Cx43+/+ mice at E17.5 and
P0. (A) Cx43I130T/+ and Cx43+/+ mouse palatine bones at the interpalatine suture stained
with proliferation and osteoblast differentiation markers. Diaminobenzidine (DAB)
immunohistochemistry of differentiation and proliferation markers stains brown, methyl
green counterstain stains green. (a,b) PCNA staining at E17.5 appears similar between
I130T/+

Cx43

and wildtype mice. (c,d) PCNA staining at P0 is more prominent in wildtype

mice than Cx43

I130T/+

mice. (e,f,g,h) Runx2 staining is similar for both genotypes at both

ages. (i,j) Osx staining is comparable between Cx43
is greater in wildtype mice compared with Cx43

I130T/+

I130T/+

and Cx43

+/+

mice at E17.5, but

mice at P0 (k,l). Likewise, OC

staining is similar between genotypes at E17.5 (m,n), but it is more pronounced in
wildtype mice at P0 (o,p). (B) Osx density was measured as the number of Osx-positive
cells/µm2 within the palatine bones at the interpalatine suture and compared using a 2way mixed model ANOVA. Osx density was significantly greater in wildtype mice than
Cx43I130T/+ mice at P0, whereas no difference was detected at E17.5.
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3.6 Histomorphology and Area Measures of Synchondroses are
Similar in Cx43I130T/+ and Cx43+/+ Mice
Sagittal sections of mouse skulls were stained with Safranin-O/Fast Green/Hematoxylin
to highlight the histomorphological features of the PSS and SOS. Qualitative assessment
of the synchondroses was made based on images of stained sections and compared
between genotypes for both E17.5 and P0 mice (Fig. 12A, 12B). At both E17.5 and P0,
no overt qualitative differences in synchondrosis size or general organization between
genotypes were detected for either the PSS (Fig. 12Aa,b; Fig. 12Ba,b) or SOS (Fig.
12Ae,f; Fig. 12Be,f). Quantitative assessment of the synchondroses involved area
measurements of the whole synchondrosis as well as relative area measures of the
different growth zones (resting, proliferative and hypertrophic). These measurements
were taken using Fiji (Schindelin et al., 2012) and compared between genotypes using a
2-way mixed model ANOVA that included sex and litter effects. No statistically
significant differences in total area or relative area of the growth zones between
Cx43I130T/+ and Cx43+/+ mice were detected for either synchondrosis or age group (Fig.
12Ac,d,g,h; Fig. 12Bc,d,g,h).
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Figure 12. Comparison of the histomorphology of the presphenoidal and sphenooccipital synchondroses between Cx43I130T/+ and Cx43+/+ Mice at E17.5 and P0. (A)
Representative images of E17.5 Cx43I130T/+ and Cx43+/+ presphenoidal synchondroses
(PSS) and spheno-occipital synchondroses (SOS) stained with Safranin-O/Fast
Green/Hematoxylin (a, b, e, f) indicate that there are no overt differences in overall PSS
or SOS organization between genotypes. Additionally, measures of total synchondrosis
area for both PSS (c) and SOS (g) are the same for Cx43I130T/+ and Cx43+/+ mice.
Relative areas of the resting, proliferative and hypertrophic zones measured as a
percentage of the total synchondrosis area are the same for Cx43I130T/+ and their wildtype
littermates for both the PSS (d) and SOS (h) growth centers. (B) As with E17.5,
representative images of P0 Cx43I130T/+ and Cx43+/+ presphenoidal synchondroses (PSS)
and spheno-occipital synchondroses (SOS) stained with Safranin-O/Fast
Green/Hematoxylin (a, b, e, f) indicate that there are no overt differences in overall PSS
or SOS organization between genotypes. Similarly, total area (c, d) and relative areas of
the resting, proliferative and hypertrophic zones (d, h) are the same between genotypes
for both synchondroses at P0.
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3.7 Chondrocyte Proliferation and Differentiation within Cranial
Base Synchondroses are Similar in Cx43I130T/+ and Cx43+/+ Mice.
Chondrocyte proliferation within the synchondroses was assessed using
immunohistochemical staining of sagittal sections using the proliferative marker PCNA.
Qualitative assessment of PCNA staining indicates that there were no overt differences in
chondrocyte proliferation between Cx43I130T/+ and Cx43+/+ mice at either E17.5 or P0
(Fig.13Aa-h).
Chondrocyte differentiation was also assessed using the chondrocyte differentiation
marker Sox9. Relative amounts of Sox9 staining were measured using a cell counting
macro for Fiji (Schindelin et al., 2012) and statistically compared between genotypes at
both E17.5 and P0 using a 2-way mixed model ANOVA that included sex and litter as
factors. Qualitative assessments of Sox9-stained sections indicate that chondrocyte
differentiation within the PSS and SOS was similar for both genotypes at both ages (Fig.
13Ba-h), and statistical analyses confirm these results (Fig. 13Ca, b). Additionally, no
significant sex or litter effects were detected
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Figure 13. Comparison of chondrocyte proliferation and differentiation at the
presphenoidal and spheno-occipital synchondroses between Cx43I130T/+ mice and
their wildtype littermates at E17.5 and P0. Diaminobenzidine (DAB)
immunohistochemistry of differentiation and proliferation markers stains brown, methyl
green counterstain stains green. (A) Proliferation of chondrocytes at the PSS and SOS
was visualized using immunohistochemical staining for PCNA and compared between
genotypes at both E17.5 and P0. No overt differences in PCNA staining were found for
either synchondrosis at both age groups. B. Chondrocyte differentiation at the PSS and
SOS was visualized using DAB immunohistochemical staining for Sox9, and no visually
detectable differences were found between genotypes for either PSS or SOS at both
E17.5 and P0. (C) Statistical comparisons of Sox9 density (calculated as the number of
Sox9 positive cells per synchondrosis area) between genotypes indicate that chondrocyte
differentiation within both the PSS and SOS at E17.5 and P0 is the same for both
Cx43I130T/+ mice and their wildtype littermates.
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Chapter 4
4 Discussion
4.1 Newborn Cx43I130T/+ Mice Display Craniofacial Alterations
Similar to Patients with ODDD and Adult Cx43I130T/+ Mice
This study represents the first investigation of the effects of the Cx43 I130T mutation on
the skull phenotype in the mouse. Here, skull morphology of E17.5 and P0 mice was
examined using geometric morphometrics. At E17.5, significant shape differences were
detected between Cx43I130T/+ mice and their wildtype littermates for the whole skull,
bones of the cranial vault and cranial base. Interestingly, significant alterations to the
facial skeleton, a hallmark characteristic of human patients with ODDD, were not
detected at this age. At P0, Cx43I130T/+ mice displayed significantly different morphology
of the whole skull, cranial vault, face and cranial base. The facial skeleton was strongly
affected by the mutation in both shape and size, but the greatest differences in shape were
detected in the bones of the cranial base. These findings match those of analyses of adult
Cx43I130T/+ mice and the large changes to facial morphology are in agreement with other
mouse models of ODDD (Flenniken et al., 2005; Dobrowolski et al., 2007; Dobrowolski
et al., 2008). Given that the Cx43 I130T mutation has been described in the human
ODDD population and that the results from these morphometric studies confirm an
ODDD-like craniofacial phenotype, the Cx43I130T/+ mouse is an appropriate model to
study craniofacial features associated with this disorder.
Unexpectedly, the greatest change in phenotype associated with the mutation is within
the cranial base in both newborn (P0) and adult mice. The characteristic craniofacial
features of ODDD include alterations to the facial skeleton and few reports of human
patients discuss altered cranial base morphology (Paznekas et al., 2003). However, early
studies detail changes to the cranial base as a feature of patients with ODDD (David &
Palmer, 1958; Pfeiffer et al., 1968; Reisner et al., 1969; Beighton et al., 1979). For
example, Beighton and colleagues (1979) describe the physical features of two patients
with ODDD and report that in addition to the characteristic microphthalmia, enamel
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hypoplasia and hypoplastic nasal alae, radiographic imaging revealed that both patients
also presented with hyperostosis of the cranial base. Thus, it could be that many
individuals with ODDD have alterations to their cranial base, but given its internal
positioning, changes may often go undetected. Alternatively, it is possible that our
Cx43I130T/+ mouse model does not fully mirror the human condition. Future studies of
cranial base morphology in other mouse models of ODDD could help determine whether
changes to the base of the skull are indeed key craniofacial features of the disorder.
While there are some changes in skull morphology present at E17.5, shape differences in
Cx43I130T/+ mice become far more pronounced, particularly within the facial skeleton, at
P0 and this newborn phenotype persists until adulthood. Thus, it appears that in the
Cx43I130T/+ mouse model, the ODDD phenotype arises between E17.5 and birth. The
timing of these phenotypic changes might be due to the timing of pronounced facial
growth in mice.
Vora et al (2016) analyzed postnatal craniofacial development (P7-P112) of C57BL/6J
mice using morphometrics, and found rapid increases in facial growth, including the
premaxilla, maxilla, and zygomatic bones, from P7-P56, and increasing growth of the
palatal bones from P7-P28. Furthermore, the authors reported that close to 80% of facial
growth is completed between P14-P21 (Vora et al., 2016). While Vora and colleagues did
not examine mice younger than P7, the results suggest that much of facial growth occurs
during early post-natal development.

4.2 P0 Cx43I130T/+ Mice Display Slight Hypomineralization of the
Cranial Vault
Alizarin red/alcian blue staining of skulls revealed slight hypomineralization of the bones
of the cranial base in Cx43I130T/+ mice. Mutant mice have larger fontanelles than their
wildtype littermates, but the mineralization of their cranial base bones appeared to be
unaffected.
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Analyses of BMD of various craniofacial bones revealed no differences between
genotypes at either E17.5 or P0. While reduced BMD is not reported in patient studies of
ODDD, these findings contrast with previous Cx43 bone studies in mice. For instance,
BMD was significantly decreased in conditional GJA1 ablation models using the Col1a1
promoter (cKOCol1) and the human OC promoter (cKOhOC), as well as in Cx43G60S/+ mice
(Flenniken et al., 2005; Chung et al., 2006; Grimston et al., 2008; Zhang et al., 2011).
However, it is noteworthy that these studies, like most Cx43 bone reports, measured
BMD in long bones rather than elements of the skull. Additionally, Cx43 function is
maintained at a greater level in Cx43I130T/+ mice than many other mouse models of altered
Cx43 function. For instance, Cx43I130T/+ junctional conductance is maintained at
approximately 50%, while Cx43G60S/+ channels operate at ~20% and are considered
functionally dead (Flenniken et al., 2005; Kalcheva et al., 2007; Stewart et al., 2013).
Given these results, it is possible that Cx43 function in Cx43I130T/+ mice is maintained
above the threshold required for altering bone mineralization.

4.3 Interpalatine Sutures of Cx43I130T/+ Mice are Disorganized
Compared to Cx43+/+ Littermates
Safranin-O/Fast Green/Hematoxylin stained coronal sections revealed alterations in the
interpalatine suture in Cx43I130T/+ mice at both E17.5 and P0. Interpalatine sutures were
wider in mutant than in wildtype mice at both ages and the cells within these widened
sutures appeared less organized and condensed along the midline. Martínez-Abadías and
colleagues reported similar findings within the interpalatine suture in their study of
FGFR2 Apert syndrome mouse models (Martínez-Abadías et al., 2013). Apert syndrome
is a congenital disorder that causes marked craniofacial abnormalities including
craniosynostosis and cleft palate. Compared to wildtype mice, Apert Fgfr2+/S252W mice
have thicker and more widely spaced interpalatine sutures (Martínez-Abadías et al.,
2013). FGFR2 is a receptor for FGF2, and mutations in FGF/FGFR signaling are known
for their involvement in cleft palate pathogenesis, and it is proposed that 3-5% of all nonsyndromic cleft palate cases occur as a result of these perturbations (Riley et al., 2007;
Martínez-Abadías et al., 2013). Indeed, the second messengers produced in response to
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FGFR activation, such as inositol polyphosphates and Ca2+, are small enough to travel
through Cx43 channels. Investigations by Lima and colleagues have found links between
FGFR signaling and Cx43 using MC3T3 osteoblasts (Lima et al., 2009). These authors
discovered that FGF2 is regulated in a Cx43-dependant manner, such that reduction of
Cx43 decreases FGF2 stimulation of Runx2 activity, while its overexpression produced
the opposite effect (Lima et al., 2009). Thus, it is possible that reduced Cx43 function is
indirectly affecting FGFR2 function in Cx43I130T/+ mice, potentially contributing to the
observed altered palatine bone and interpalatine suture phenotypes.
Interestingly, chondrocyte-like cells formed “caps” at the osteogenic fronts of the palatine
bones in wildtype P0 interpalatine sutures. These caps were absent in E17.5 wildtype
mice as well as both E17.5 and P0 Cx43I130T/+ mice. Despite the description of palatal
bones as derived through intramembranous ossification, previous studies have observed
the formation of sutural cartilage in response to mechanical forces, such as mastication
and suckling forces (Hinton, 1988; Peptan et al., 2008). Thus, it is possible that Cx43
GJIC may play a role in the mechanical response, or transmission of such forces, which
could explain why cells of Cx43I130T/+ sutures lacked this chondrocyte-like morphology.

4.4 Localized Changes in Osteoblast Differentiation Correspond
to Alterations in P0 Cx43I130T/+ Skull Morphology
Osteoblast proliferation within the palatine bones was unaffected in Cx43I130T/+ mice at
E17.5. These findings are in agreement with previous cell culture and ex vivo studies that
found reduced Cx43 function did not alter osteoblast proliferation (Lecanda et al., 2000;
McLachlan et al., 2008). However, osteoblast proliferation appeared to be reduced in
Cx43I130T/+ mice compared with their wildtype littermates at P0 as indicated by less
intense PCNA staining. This latter finding was surprising and could indicate a role for
Cx43 function in osteoblast proliferation.
I hypothesized that osteoblast differentiation would be reduced in Cx43I130T/+ mice at both
E17.5 and P0. The results reported here partially support my hypothesis as this reduction
was only found for mid- and late-stage differentiation and only at P0. The connection
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Comment [10]: Do you mean its knockout or
knockdown or is it the reduction in activity?

between reduced Cx43 function and impaired osteoblast differentiation is well
established in the literature (Stains & Civitelli, 2016). Studies using Gja1 ablation and
ODDD mouse models have produced hypomineralized skulls at birth (Lecanda et al.,
2000; Flenniken et al., 2005; Dobrowolski et al., 2007, 2008; Watkins et al., 2011).
Reduced osteoblast differentiation due to reduced Cx43 function has also been reported
for long bones, such that selective ablation of Gja1 from the Dermo1/Twist2 promotor
results in enlarged diaphyseal cross-sectional areas and poor bone quality (Watkins et al.,
2011). Furthermore, real-time quantitative PCR of affected long bones revealed reduced
Osx expression (Watkins et al., 2011). While this study confirms previous work, it also
demonstrates that in Cx43I130T/+ mouse palatine bones, this apparent reduction in midstage osteoblast differentiation does not arise until after E17.5.
Furthermore, reduced osteoblast differentiation found in the interpalatine sutures of P0
mice may account for the phenotypic differences in shape detected in the facial region.
Alterations in osteoblast differentiation and facial shape changes occur at P0, so it is
possible that these occurrences are related. Moreover, deficits in osteoblast differentiation
may in part explain the increased incidence of submucous cleft palate observed in threemonth Cx43I130T/+ mice. Further study of osteoblast differentiation of other craniofacial
bones may provide more insight as to whether this association between reduced
differentiation and changes to skull shape is a consistent theme.

4.5 Cx43I130T/+ Cranial Base Morphology Is Not Indicative of
Localized Chondrocyte Proliferation and Differentiation Within
Synchondroses
While the role of Cx43 in osteoblast differentiation has been well studied (Stains &
Civitelli, 2016), the function of Cx43 in chondrocyte proliferation and differentiation is
poorly understood. One of the aims of this study was to clarify the role of Cx43 in
chondrocyte proliferation and differentiation. Specifically, chondrocyte proliferation and
differentiation were assessed in the PSS and SOS of the cranial base, as preliminary
studies of adult Cx43I130T/+ mice indicated that the endochondral bones of the cranial base
demonstrate the most severe phenotypic changes in the skull. Surprisingly, and contrary
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to the hypothesis, no differences in either chondrocyte proliferation or differentiation
were detected between genotypes at either age through histomorphological or
immunohistochemical assessments. A previous study using an in vivo mouse model,
demonstrated that reduced Cx43 GJIC resulted in increased chondrocyte proliferation and
decreased chondrocyte differentiation (Gago-fuentes et al., 2016). A possible explanation
for the disparity between the results reported here and those of Gago-fuentes and
colleagues, is that the alteration to the Cx43 protein in the Cx43I130T/+ mutation occurs in
the intracellular loop, as opposed to the C-terminus.
Given that the synchondroses are the main growth centers for the cranial base and form
the cartilaginous templates for the resulting bones, the lack of chondrocyte alteration in
Cx43I130T/+ mutants is unexpected. The pronounced changes in cranial base morphology
that were evident at E17.5, P0, and three months (preliminary study) could potentially be
due to changes in osteoblast behavior of the surrounding cranial base bones, as osteoblast
differentiation was found to be affected in palatine bones of this model. Future studies
aimed at determining osteoblast differentiation in the cranial base bones of Cx43I130T/+
mutants and their wildtype littermates may provide an explanation for the altered cranial
base phenotype observed in these mutant mice.

4.6

Litter Variation Effects

Litter variation significantly influenced most of the phenotypic and histological features
analyzed in this study. Variation between animal model litters can be due to a variety of
factors, such as genetic effects, maternal environment and early post-natal environments
(Lazic & Essioux, 2013). However, as it is difficult to control the time of mating, age
differences can also play a role in litter variation. Mouse breeding cages are typically set
up in the afternoon with the assumption that the mice will mate overnight. However, the
mice may mate anytime during that period until they are checked for vaginal plugs, as
evidence of successful mating, the following day (Musy et al., 2018). Thus, depending on
the time of mating, it is possible for the E17.5 embryos to be older or younger than this
prescribed age. If so, similar discrepancies could also occur for the P0 pups. Though
cages are checked consistently for newborn pups when dams are due, the pups may arrive
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earlier than expected and may actually be closer to P0.5 before they are collected.
Incorporation of a more reliable embryonic staging system, such as eMOSS (embryonic
Mouse Ontogenetic Staging System) would be helpful in circumventing these issues
(Musy et al., 2018). eMOSS staging uses an algorithm based on hindlimb bud
ontogenetic trajectories on an uploaded image of the embryo, and measures
developmental time using embryonic hours as opposed to days, thus improving staging
accuracy. Unfortunately, this system is only able to characterize development from ~E10
to E15, as limb shape complexity increases after E15 (Musy et al., 2018). Nonetheless,
incorporating a reliable staging system for future embryonic mouse studies would likely
aid in reducing litter-to-litter variation.

4.7 Relationship between Cellular and Phenotypic Changes in
Cx43I130T/+ Mouse Skulls
An overarching goal of this study was to understand the relationship between changes in
cellular processes and phenotypic changes in the skull of Cx43I130T/+ mice. Reduced
osteoblast differentiation in the palatine bones of P0 Cx43I130T/+ mice corresponds with
pronounced changes in the facial skeleton of newborn mutant mice. These results suggest
a possible cause and effect relationship; reduced Cx43 function caused by the I130T
mutation reduces osteoblast differentiation within bones of the face, which led to smaller,
misshapen facial bones. Cranial base shape is also profoundly altered in Cx43I130T/+ mice,
but these differences did not correspond to changes in chondrocyte proliferation or
differentiation within the synchondroses. No changes in synchondroses chondrocyte
proliferation or differentiation were detected in Cx43I130T/+ mice; a surprising result given
that changes in cranial base morphology are often a result of changes in chondrocyte
behaviour (Marcucio et al., 2011; Parsons et al., 2015). The changes in cranial base shape
observed in Cx43I130T/+ mice must be due to some other cellular disruption. One
possibility is that the cartilage templates are unaffected by the mutation, but osteoblast
differentiation is reduced (as detected in the palatine bones), and this reduction disrupts
the subsequent ossification process leading to altered cranial base morphology. These
results add to our understanding of how cellular processes are related to the gross
morphology of the skull. Furthermore, this connection between bone cells and shape can
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be used to determine common causal mechanisms among a variety of craniofacial
dysmorphologies, potentially leading to therapeutic strategies based on these common
mechanisms.

4.8

Limitations and Future Studies

While μ-CT imaging provides detailed morphology of ossified tissue, it does not easily
allow for visualization of both soft and hard tissues. Given that at P0 and particularly at
E17.5, much of the presumptive skull is either membranous or cartilaginous, μ-CT scan
data does not capture a sizeable portion of cranial morphology. This study would have
benefitted greatly from visualization of cartilage, as a main focus of Aim 2 was
characterizing and comparing the morphology of the cartilaginous cranial base
synchondroses. To capture soft tissue morphology using μ-CT, some researchers have
used contrast stains such as iodine and phosphotungstic acid (Metscher, 2009a, 2009b;
Hsu et al., 2016). While these stains allow for visualization of soft tissues, they do not
differentiate cartilage from other soft tissues and therefore would not improve this study’s
shape analyses. Optical projection tomography (OPT) is another imaging modality that
has been used to capture 3D morphological data of both ossified and non-ossified tissues
(Sharpe et al., 2002). OPT uses visual light and can take advantage of tissue-specific
stains such as alizarin red and alcian blue. Image resolution can be obtained at isotropic
voxel dimension of 5μm and 3D surfaces can be reconstructed from these images. Thus,
OPT imaging of alizarin red and alcian blue stained mouse skulls would allow for
visualization, landmarking and analyses of both bony and cartilaginous structures.
However, tissue processing for alizarin red/alcian blue staining is extremely timeconsuming and the delicate structures of the mouse skull are prone to damage during this
process.
Significant differences in skull shape between Cx43I130T/+ and their wildtype littermates
were detected at both E17.5 and P0. However, significant sex and litter effects were also
detected. A larger sample size would allow for a better understanding of the role that sex
and litter play in skull phenotype in these mice. Additionally, the use of a dependable
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embryo/early post-natal staging system would help to differentiate true litter effects from
differences in age.
Given that one of the goals of this study was to determine the relationship between cell
processes and gross phenotype, the localization of cell changes through analysis of
localized protein levels via immunohistochemistry was appropriate. Additionally, looking
at relative protein amounts was ideal as it represents functional outcome better than
mRNA levels. However, protein quantification using immunohistochemistry is extremely
challenging and subject to high variation associated with methodology and not
necessarily biology. Analyses using RT-qPCR could be used to help confirm the results
obtained from immunohistochemistry. RT-qPCR analyzes mRNA expression and as its
name suggests allows for quantification. Given that mRNA is analyzed, these results
would not correlate completely with protein localization, but if the results are similar,
such analyses would strengthen the immunohistochemistry data. Additionally, RT-qPCR
requires very small amounts of mRNA, such that micro-dissection of specific regions of
the skull would supply sufficient mRNA to quantify various markers and would allow for
some localization.

Greg Kelly 2018-8-27 11:49 PM
Comment [11]: Are there any limitations that
you can think of pertaining to the uCT work? I am
not familiar with that analyses so I cannot provide
you with any details.
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Appendices
Appendix A. Names and locations of E17.5 and P0 landmarks
Numbers correspond to Fig. 5.
Number
1

2

3

4

5

6

7

8

9
10
11

12

13

14

15

16

17

18

19

20

Landmarks
lflac - Intersection of frontal process
of maxilla with frontal and lacrimal
bones, left side
rflac - Intersection of frontal process
of maxilla with frontal and lacrimal
bones, right side
lfpl - Most lateral intersection of the
frontal and parietal bones, taken on
the frontal, left side
lpfl - Most lateral intersection of the
frontal and parietal bones, taken on
the parietal, left side
lpfm - Most medial intersection of the
frontal and parietal bones, taken on
the parietal, left side
rpfm - Most medial intersection of
the frontal and parietal bones, taken
on the parietal, right side
rfpl - Most lateral intersection of the
frontal and parietal bones, taken on
the frontal, right side
rpfl - Most lateral intersection of the
frontal and parietal bones, taken on
the parietal, right side
lpto - Most postero-medial point on
the parietal, left side
rpto - Most postero-medial point on
the parietal, right side
lzygo - Intersection of zygoma with
zygomatic process of maxilla, taken
on zygoma, left side
lzya - Intersection of zygoma with
zygomatic process of maxilla, taken
on maxilla, left side
lzyt - Intersection of zygoma with
zygomatic process of temporal, taken
on zygoma, left side
lsqu - Most superior point on the
squamous temporal, intersection of
the coronal suture, left side
rzygo - Intersection of zygoma with
zygomatic process of maxilla, taken
on zygoma, right side
rzya - Intersection of zygoma with
zygomatic process of maxilla, taken
on maxilla, right side
rzyt - Intersection of zygoma with
zygomatic process of temporal, taken
on zygoma, right side
rsqu - Most superior point on the
squamous temporal, intersection of
the coronal suture, right side
rpsq - Most posterior point on the
posterior extension of the forming
squamosal, right side
ethma - Most antero-superior point of
the intersection of the left and right
anterior turbinates
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Skull Region
Face

Face

Vault

Vault

Vault

Vault

Vault

Vault

Vault
Vault
Face

Face

Vault

Vault

Face

Face

Vault

Vault

Vault

Base

21
22

23

24

25

26
27
28

29

30
31
32
33
34
35

36

37
38

39

40
41

42

43
44
45

ethmp - Most posterior point of the
intersection of the posterior turbinates
lapsh - Postero-medial point of the
inferior portion of the left alisphenoid,
left side
rapsh - Postero-medial point of the
inferior portion of the left alisphenoid,
right side
loci - The superior posterior point on
the ectocranial surface of occipital
lateralis on the foramen magnum, left
side
roci - The superior posterior point on
the ectocranial surface of occipital
lateralis on the foramen magnum,
right side
raalf - Most anterior point of the
anterior palatine foramen, right side
laalf - Most anterior point of the
anterior palatine foramen, left side
rpmx - Most infero-lateral point of
the premaxillary-maxillary suture,
taken on premaxilla, right side
lpmx - Most infero-lateral point of the
premaxillary-maxillary suture, taken
on premaxilla, left side
ampsh - Most antero-medial point on
the body of the sphenoid
rptyp - Most posterior tip of the
medial pterygoid process, right side
lptyp - Most posterior tip of the
medial pterygoid process, left side
rsyn - Most antero-lateral point on
corner of the basioccipital, right side
lsyn - Most antero-lateral point on
corner of the basioccipital, left side
bas - Mid-point on the anterior
margin of the foramen magnum, taken
on basioccipital
lfbc - Most lateral point of the frontal
bone taken along the basal part of the
coronal suture, between the frontal
and parietal, left side
lplp - Most posterolateral point on the
parietal, left side
lpsq - Most posterior point on the
posterior extension of the forming
squamosal, left side
rfbc - Most lateral point of the frontal
bone taken along the basal part of the
coronal suture, between the frontal
and parietal, left side
rplp - Most posterolateral point on
the parietal, right side
lmaxi - The midline point on the
premaxilla between the incisor and
the nasal cavity just anterior of the
incisive foramen, left side
rmaxi - The midline point on the
premaxilla between the incisor and
the nasal cavity just anterior of the
incisive foramen, right side
lnsla - Most antero-medial point of
the nasal bone, left side
rnsla - Most antero-medial point of
the nasal bone, right side
lnsll - Most postero-lateral point of
the nasal bone, right side
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Base
Base

Base

Base

Base

Face
Face
Face

Face

Base
Base
Base
Base
Base
Base

Vault

Vault
Vault

Vault

Vault
Face

Face

Face
Face
Face

46
47
48
49

50

51
52

53
54

55

56

57

58
59
60

61

62
63

64

lnslp - Most postero-medial point of
the nasal bone, left side
rnslp - Most postero-medial point of
the nasal bone, right side
rnsll - Most postero-lateral point of
the nasal bone, right side
lfpi - Most medial intersection of the
frontal and parietal bones, taken on
the frontal, left side
lfpi - Most medial intersection of the
frontal and parietal bones, taken on
the frontal, right side
lpip - Most postero-inferior point on
the parietal, left side
lpsq - Most posterior point on the
posterior extension of the forming
squamosal, left side
lpip - Most postero-inferior point on
the parietal, right side
lpsh - Most anterior point on the
anterior projection on the
presphenoid, left side
cpsh - Most anterior point of the
indentation in the center of the
presphenoid
rpsh - Most anterior point on the
anterior projection on the
presphenoid, right side
maxi - The midline point on the
premaxilla between the incisor and
the nasal cavity just anterior of the
incisive foramen
rpalf - Most posterior point of the
anterior palatine foramen, right side
lpalf - Most posterior point of the
anterior palatine foramen, left side
rpns - Most antero-lateral indentation
at the posterior edge of the palatine
plate, right side
lpns - Most antero-lateral indentation
at the posterior edge of the palatine
plate, left side
rocc - Most infero-lateral point on the
squamous occipital, right side
opi - Mid-point on the posterior
margin of the foramen magnum, taken
on squamous occipital
locc - Most infero-lateral point on the
squamous occipital, left side
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Appendix B. Alizarin red/Alcian Blue staining protocol
Day 1
● Put pups in PBS-filled 6 well plates on ice
● Transfer each put to PBS-filled petri dish to dissect. Remove skin some muscle,
neck fat, and internal organs. Organs are very difficult to dissect out later do not
digest as quickly as other tissue in KOH.
● Place dissected embryos/early postnatal pups back in 6-well plates filled with
95% ethanol. Fix overnight rocking gently.
Day 2
● Fix pups in acetone overnight rocking gently. Make sure containers are either
glass or polypropylene as acetone will break down other plastics.
Day 3
● Wash in double-distilled water and then add staining solution.
Staining solution: Alizarin red 0.05%
Alcian blue 0.015%
Acetic acid 5%
This is made in 70% ethanol (Eg. for 100ml 70%
EtOh, add 0.05g

alizarin red, 0.015g alcian blue, and 5 ml of acetic

acid.)
● Leave in stain for 4-5 days rocking gently.
Day 7/8
● Wash in water
● Place pups in 2% potassium hydroxide (KOH) which is made in PBS for one day.
Again this should be done in polypropylene or glass. Gently rock. For embryos
this may be too harsh and might want to use 1% KOH. Also, for young embryos,
consider 1% KOH:50% glycerol. This helps support structures, particularly the
skull.
Day 8/9
● Change the solution to 1% KOH until it is almost clean. You can put KOH down
drain with lots of water.
● You can pick away excess tissues, but ensure that you transfer to PBS as KOH
might ruin dissecting tools.
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● When almost clean place in 0.5% KOH:50% glycerol. Leave until completely
clean.
● When clean, store in 1:1, 70% ethanol (EtOH):Glycerol.
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Appendix C. Safranin-O/Fast Green/Hematoxylin protocol
Preparation of Solutions:
0.03% Fast Green (FCF) Solution
Add 0.075 g of Fast Green (FCF) into a 250 mL volumetric flask and fill to the mark with
distilled water. Cover with parafilm and invert flask several times to mix well.
1% Acetic Acid Solution
Add 2.5 mL of Acetic Acid into a 250 mL volumetric flask and fill to the mark with
distilled water. Cover with parafilm and invert flask several times to mix well.
1.5% Safranin-O Solution
Add 1.5 g of Safranin-O into a 100 mL volumetric flask and fill to mark with distilled
water. Cover with parafilm and invert flask several times to mix well.
250 mL of solution is sufficient for 2 racks of slides.
Procedure:
Place each solvent into separate clear containers and line them up as follows.
NB: Each time the rack is moved into a new container, slowly dip it twice before
allowing it to sit in solution for the allotted time.
1. Deparaffinize
First container of Xylene for 5 min
Second container of Xylene for 8 min
2. Rehydrate (Clean Ethanol)
First container of 100% (1) Ethanol for 2 min
Second container of 100% (2) Ethanol for 2 min
95% Ethanol for 2 min
70% Ethanol for 2 min
ddH2O for 2 min
3. Hematoxylin
Dip into hematoxylin for 30 seconds
4. Tap water
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Place rack into a container of tap water, then place the container under slowly
running water to remove excess hematoxylin. Now, slowly dip the slides for
approximately 5 min
5. Fast Green (0.03%)
Let rack sit in fast green solution for 30 min, then blot it briefly on paper towels
6. Acetic Acid solution (1%)
Dip in acetic acid solution for 10 to 15 seconds
7. Safranin-O solution (1.5%)
Place rack into safranin-o for 5 min
8. Rinse in ddH2O
Dip 1 or 2 times (to avoid ruining ethanols)
9. Dehydrate (Dirty Ethanol)
70% Ethanol for 8-10 dips
95% Ethanol for 8-10 dips
100% Ethanol (2) for 8-10 dips
100% Ethanol (1) for 8-10 dips
Xylene (2) for 8-10 dips
Xylene (1) for 8-10 dips
10. Drying
Place the rack over paper towels and let the slides dry overnight in the fumehood
11. Coverslip application
Using a glass pipette and rubber bulb, obtain approximately 1 mL of
SHUR/Mount. Hold it upright in the pipette till ready for use (Be sure not to get
SHUR/Mount in the bulb)
Pipette an “I” on glass coverslip and gently place a slide onto it, evenly
distributing glue
Place the slide onto a holder and allow it to dry overnight
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Appendix D. Antibodies for Immunohistochemistry
Marker
Proliferation marker

Antibody
PCNA (Proliferating Cell
Nuclear Antigen)

Osteoblast differentiation
markers

Runx2

Osterix

Osteocalcin

Chondrocyte differentiation Sox9
marker
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Description
Protein that acts as a DNA
sliding clamp during DNA
replication. Known to
increase during S-phase of
the cell cycle (Miyachi et
al., 1978; Bravo & Celis,
1980; Celis & Celis, 1985).
Visible intracellularly.
Is a master regulator
transcription factor
expressed during osteoblast
differentiation (early and
late-stage), used for
detecting osteoprogenitors
(Ducy et al., 1997; Lima et
al., 2009). Visible
intracellularly.
Transcription factor
expressed in immature
proliferating osteoblasts
(Day et al., 2005; Hill et
al., 2005; Huang et al.,
2007). Visible
intracellularly.
Osteoblast specific protein,
secreted by differentiated
osteoblasts (Ducy et al.,
1995; Huang et al., 2007).
Visible extracellularly.
Transcription factor
required for chondrocyte
differentiation and
subsequent cartilage
formation (Bi et al., 1999).
Visible intracellularly.

Appendix E
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Appendix E Immunohistochemical antibodies and istoype controls. (A) E17.5
Cx43+/+ and Cx43I130T/+ isotype controls. Minimal to no staining is present in the controls
(a-h). (B) Similarly, P0 Cx43+/+ and Cx43I130T/+ no primary controls show little
background staining (a-h).
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Appendix F. Paraffin embedding protocol
Day 1
•
•
•
•

•

Decapitate pups. Take small skin sample and place in 1.5ml conical tube for
genotyping.
Place in 6-well plate with PBS on ice. Skin. Rinse in PBS
Place into 10X volume (or more) of 4% paraformaldehyde overnight on rocker
(for P0, can place heads in 6-well plate with 7ml of PFA).
Pour dissected material from petri dish full of PBS into funnel with kimwipe
filter. Bag dissected material and put in -20. Mix gross PBS with bit of bleach
for 10 minutes and then down sink. Petri dishes used for dissection put in bleach
and water and then thrown out.
Container for PFA must go in special waste.

Day 2
•
•

Rinse with PBS and transfer into PENCIL-labeled tissue cassette tub of 70%
ethanol.
Print out processing order and take to Robart’s Molecular Pathology (4th floor
room 4242 past Krembil door) for processing.

Day 3
•

•

•
•
•

In Robarts room 4217, float processed tissue cassette in paraffin bath for about
10-15 minutes. Don’t put more than about 10 cassettes in at once or it will cool
down the bath too much.
Choose appropriate metal holder, fill with bit of wax and place tissue as wanted.
Fill rest of the holder with wax,and use the top part of the cassette with label to
top it off. Place on cold plate and let it set. Should have a clear sheen to it.
Pop out of metal holder and clean off edges.
All waste including gloves go into biohazard.
Must have gloves and safety glasses.
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Appendix G. Immunohistochemistry protocol
Paraffin sections may be baked at 52C for 1hr (however this is not recommended for
good IHC), 37C overnight is preferred.
Deparaffinization:
Take slides through a series of Xylenes: 5 min, 2 min, 3 min, 2 min.
Then, rehydrate: [100% Ethanol, 100% Ethanol, 95% Ethanol] for 2 min each, followed
by [95% Ethanol and 70% Ethanol] for 1 minute each.
Let slides sit in ddH20 for 2 minutes.
Block endogenous peroxidase activity:
Prepare fresh 3% hydrogen peroxide in methanol (1:10 of 30% stock kept at 4C)
•

180ml methanol + 20ml of 30% H2O2

Put solution and slides in opaque slide staining jar for 5 minutes. Dispose of
methanol:hydrogen peroxide in fumehood waste container.

•

Rinse slides in distilled water for 5 minutes, then subsequently immerse in
phosphate buffered saline (PBS) for 5 minutes on shaker.

Antigen retrieval: Steps dependant on antibody.
For Runx2 and PCNA: Antigen retrieval is performed in citrate buffer pH 6.0 in a decloaking chamber
•
•

500 mL distilled water in bottom of pressure cooker
Decloaker:
i. Turn on, press start
ii. Select Sp1 (may have to adjust - 101 degrees, 1:30)
Let warm to degrees until it beeps (will go a few degrees past
the set temperature), press start, and check pressure reading
(make sure pressure has increased)
iii. Wait till cools and beeps and turn off, unplug
iv. Wait until pressure reaches zero, twist off lid. Using oven
mitts, place slides under cold running tap water for 5 min.
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v. Rinse in PBS on shaker 5min.
For Rest: transfer slides into 0.1% Triton X-100 in water at room temperature for 13
minutes (If many slides, use a staining jar, if 8-10 use a glass Coplin jar, if only a few,
use 100ul flooded on section)
•

Wash slides in dH2O for 15 minutes at room temperature

Blocking step:
Incubate in 10% horse serum for 30 minutes at room temperature; the blocking serum is
then drained onto a paper towel (just fill up horse serum to 15 mL with PBS).
•

Slides are not rinsed with PBS

Primary antibody step:
Incubate slides for 1hr with 100ul of appropriate dilution of primary antibody prepared
in 1:10 dilution of HS in PBS (for no primary antibody control, use 1:10 HS in PBS).
Appropriate dilution should be optimized for each antibody.
•

Rinsed thoroughly with PBS for 5 minutes on shaker

Secondary antibody step:
Incubate with ImmPress kit anti-rabbit horse-radish peroxidase micropolymer solution
for no longer than 30 minutes at room temperature.
•

Rinsed thoroughly with PBS for 5 minutes on shaker

Visualize specific binding - DAB:
WARNING: Diaminobenzidine is carcinogenic. Caution must be used when
preparing the working solution and in the visualization of colour development so as
not to contaminate oneself or the designated microscope.
Timing of DAB staining will be antibody dependant. Some antibodies produce a brown
colour within seconds and others take a few minutes to develop. You must be consistent
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with DAB staining, all slides should be stained for exactly the same amount of time and
from the same working solution in order to allow comparison of intensity of stain.
Pipette 100ul of DAB solution to each section. DAB reaction should be stopped as soon
as colour becomes apparent, allowing overstaining will make comparisons difficult.
The reaction is stopped by transferring the slide into water (swished 2X in water boxes)
where it can be held until all slides have been stained.
Counterstain:
Counterstain slides with 0.5% Methyl Green prepared in 0.1M acetate buffer pH 4.2 for 5
min.
Wash slides in dH2O for 5 minutes
Dehydrate slides through 70% ethanol, 95% ethanol, 2X 100% ethanol (10 dips each)
then through 2X xylenes (10 dips each)
Coverslip using ShurMount xylene-based liquid mounting media.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Diaminobenzidine (DAB) Solution:
To 5 mL distilled H2O, add 2 drops of buffer, 4 drops of DAB, and 2 drops of H2O2, in
that particular order, with vortexing after each step (may half this for small batches)
Citrate Buffer Preparation:
•
•
•
•

950 mL of distilled water + 2.1 g of citric acid, anhydrous
Put on mixer and place both temperature and pH electrode in solution
o Remove storage bottle from pH electrode
Slowly add Sodium Hydroxide (NaOH) 10.00N from base cabinet using a
pipette until pH reaches 6.0
Top up to 1000 mL with distilled water
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Dilutions:
Type of Marker

Antibody

Dilution

Osteoblast Markers

Osterix

1/800

Osteocalcin

1/400

Runx2

1/800, 2 min

Chondrocyte Marker

Sox9

1/800

Proliferation Marker

PCNA

1/800, 2 min

* unless otherwise specified, DAB times are 4-5min
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Appendix H. Animal Use Protocol

PI :
Laird, Dale W
Protocol #
2015-030
Status :
Approved (w/o Stipulation)
Approved :
05/19/2015
Expires :
05/01/2019
Title :
The Role of Gap Junction in Diseases
Table of Contents
•
•
•
•
•
•
•

Animal Use Protocol Overview
Funding Source List
Purpose of Animal Use
Hazardous Materials
Animal Movement Between Sites
Animal Groups and Experimental Timelines Overview
Mouse
o Tissue Collection
o Justification for Choice of Species
o the 3Rs: Replace, Reduce, Refine
o Species Strains
o Animal Transfers
o Environmental Enrichment
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Animal Holding/Housing and Use Location Information
Holding beyond 12 hours
Acclimatization Period & Quarantine
Breeding Information
Experimental Agents Information
SOP List
Procedures Checklist for Reporting and Training
Procedures Narrative
Procedural Consequences & Monitoring
Endpoint Method Information
Animal Numbers Requested
Personnel List
Protocol Attachments
Amendment Reason
o
o
o
o
o
o
o
o
o
o
o

•
•
•

Protocol Introduction
The questions on this page activate specific sections within the AUP form.
Note that species selection is part of this introductory page
Does this AUP involve teaching?
Yes

No

Is the animal work on this project shared by another Animal Care Committee?
Yes

No

Will you be using hazards?
Yes

No

Will live animals be moved outside of their housing facility?
Yes

No

Will field studies be conducted?
Yes

No

Add/Update/Remove Species Used on this Protocol
Species Agents Drugs Restraint Breeding
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Species Agents Drugs Restraint Breeding
Mouse Yes

No

No

Yes

Animal Use Protocol Overview
Animal Use Protocol Title
The Role of Gap Junction in Diseases
Application Type. If this is a post-pilot project, please attach the Pilot Report to this
section, below.
Full Renewal
Provide Associated Previous Protocol Number
2006-101-10
Please provide a report detailing the previous AUP's use of Animals
Replacement We continue to use tissue culture models and three dimensional organotypic
models in many of our experimental designs. However, the use of transgenic mutant
mouse models remain essential for our studies as they can not be replaced by standard in
vitro studies. Reduction We often use the same mouse in multiple studies that involve
distinct sets of tissues and organs. Refinement Analgesia and anesthesia are 2 areas we
have worked to refine. Gas anesthesia has proven to be a superior alternative for short
procedures . The addition of ketoprofen to the existing buprenorphine protocol for
analgesia has been shown to be compatible with our wound healing assay and provided
benefit to the mice.
Using non-scientific language, please describe the project's purpose, expected benefit,
and a brief summary of your work with the animal model(s).
Please be aware that in the event of communications with Western Media Relations and
the PI is not available, this summary will be sent to Western Media Relations.
Our research involves two types of structures in cells which provide communication
between cells. The first group are gap junctions , which are specialized channels formed
between adjacent cells. These allow the cells to communicate with each other by allowing
the passage of small molecules and ions. The proteins which form these channels are
known as connexins . Connexins are a family of proteins in both humans and mice whose
members share structural similarities but have different sizes. They have been implicated
in human diseases such as breast cancer and skin disease. Pannexins , the second group of
structures, are large channels crossing the cell membrane which connect the spaces inside
the cell to that of the outside . By allowing the passage of ions and small molecules such
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as ATP, signals can be sent from one cell to another . They differ from gap junctions in
that the cells are not directly coupled to each other. Pannexins are a family of 3 closely
related proteins and they have been shown to be involved in the cardiovascular system ,
skin, bone and melanoma. Thus both pannexins and connexins are important for
communication between cells and to produce normal function and structure in the tissues
which they comprise. Mice with altered or deleted connexin and pannexin genes produce
either faulty proteins or no protein of the targeted type. By studying function and
structure of tissues and cells from these mice we can further our understanding of what is
not only the normal function , but also what occurs in the human disease when those
genes mutate. Mice are used in several different ways . The first group are non
geentically mutated , "wild type " mice from which we use use organs such as skin to set
up cell cultures for in vitro sudies of the way in which connexins and pannexins function.
A second method is the use of mice with genetic mutation in pannexins or connexins ,
often matching those present in human disease . Physiological and developmental studies
such as wound healing, blood pressure measurements , hemodynamic measurements or
hearing testing can be done with these models . Comparison to the wild type
demonstrates the effect of the mutation and its implication in the roles of the "nexin"
molecules and their part in human disease. A third use is the harvesting of tissues from
mutant mouse models and either examining them histologically and immuno
histologically or using them to prepare cell cultures for in vitro studies.
Again,comparison is made to the wild type structure and in vitro function. In addition to
mild skin and hearing abnormalities, Cx30 A88V mutant mice display curious
neurological phenotypes that warrant further investigation. Therefore, these mice will
undergo behavioural testing using the rodent neurobehavioural core facilities subsidized
by the BrainsCAN project.
GLOSSARY OF TERMS - Identify each individual scientific term and abbreviation
using CAPITAL LETTERS, and then briefly define each term to be referenced in any
section of this protocol.
e.g. ALLELE - The genetic variant of a gene responsible for the different traits of certain
characteristics and genetic diseases.
Here is the link to CCAC's Policy on Scientific Merit and Ethical Review of Animalbased Research:
http://www.ccac.ca/Documents/Standards/Policies/Scientific_merit_and_ethical_review_
of_animal-based_research.pdf
Has the work outlined in this AUP received favourable scientific peer review?
Yes

No

Do you wish to provide a funding peer review assessment, which may be considered in
lieu of internal scientific peer review? If 'YES', please attach the funding assessment.
Yes

No
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If this is a RESEARCH AUP, please provide a list of one to three publications relevant to
the work outlined in this AUP.
If this is a resarch AUP, attach an OUTLINE for scientific merit reviewers that provides
sufficient information that another scientist working in the same field of study could
effectively review this AUP's scientific merit, below. PIs may utilize whichever format
best describes its scientific merit, e.g. background, rationale, hypothesis, objectives,
experimental procedures
Using only key words, specify the animal models and procedures described within this
AUP.
Genetically modified and mice are used for wound healing surgery with isoflurane
anesthesia,,hearing testing under ketamine xylazine anesthesia , ECG, blood pressure
measurement and tissue harvesting.
Funding Source List

Fund Source

Grant Title

Funded?

Grant
Grant
Start Date
Number
Holder

Investigation of auditory
function in pannexin1 and Yes
pann

R2791A22 04/08/2014

Canadian Breast Cx26 and Panx1 as breast
Cancer
tumor suppressors:
Yes
Foundation
potential therapeutic targets

R2791A15 04/11/2011

The novel channel-forming
Canadian Cancer protein pannexin1 as a
Yes
Society
viable target for melanoma
treatment

R2791A18 06/06/2012

Canadian
Role of Cx26 and Cx30 in
Institutes of
Yes
skin aging
Health Research

R2791A16 07/26/2012

Canadian
Modeling connexin-linked
Institutes Of
Yes
disease
Health Research

R2791A25 08/03/2016

Canadian
Connexins and pannexins
Institutes Of
in hearing loss
Health Research

R2791A26 08/03/2016

Action On
Hearing Loss
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Yes

Fund Source

Grant Title

Funded?

Canadian
The cellular life and
Institutes Of
functions of pannexins
Health Research

Grant
Grant
Start Date
Number
Holder

Yes

R2791A21 06/06/2013

Canadian
Research Chair - CRC in Gap Junctions and
Yes
Government Of Disease
Canada

X0910B79 07/01/2011

Phenotypic and
Natural Sciences Biomechanical Effects of
& Engineering
Altered Cell Proliferation
Research Council and Differentiation in the
Mouse Skull

Yes

R5211A02 04/12/2017

Zealand Pharma
Research Contract
A/s

Yes

R2791A24 09/30/2015

Funding Source Name
Action On Hearing Loss
Proposal Title
Investigation of auditory function in pannexin1 and pann
Is this award currently funded?

Please provide the associated GRANT #
R2791A22
Funding START date mm/dd/yy
04/08/2014
PI on Grant (if different than PI on Protocol)
Funding Source Name
Canadian Breast Cancer Foundation
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Proposal Title
Cx26 and Panx1 as breast tumor suppressors: potential therapeutic targets
Is this award currently funded?

Please provide the associated GRANT #
R2791A15
Funding START date mm/dd/yy
04/11/2011
PI on Grant (if different than PI on Protocol)
Funding Source Name
Canadian Cancer Society
Proposal Title
The novel channel-forming protein pannexin1 as a viable target for melanoma treatment
Is this award currently funded?

Please provide the associated GRANT #
R2791A18
Funding START date mm/dd/yy
06/06/2012
PI on Grant (if different than PI on Protocol)
Funding Source Name
Canadian Institutes of Health Research
Proposal Title
Role of Cx26 and Cx30 in skin aging
Is this award currently funded?
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Please provide the associated GRANT #
R2791A16
Funding START date mm/dd/yy
07/26/2012
PI on Grant (if different than PI on Protocol)
Funding Source Name
Canadian Institutes Of Health Research
Proposal Title
Modeling connexin-linked disease
Is this award currently funded?

Please provide the associated GRANT #
R2791A25
Funding START date mm/dd/yy
08/03/2016
PI on Grant (if different than PI on Protocol)
Funding Source Name
Canadian Institutes Of Health Research
Proposal Title
Connexins and pannexins in hearing loss
Is this award currently funded?

Please provide the associated GRANT #
R2791A26
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Funding START date mm/dd/yy
08/03/2016
PI on Grant (if different than PI on Protocol)
Funding Source Name
Canadian Institutes Of Health Research
Proposal Title
The cellular life and functions of pannexins
Is this award currently funded?

Please provide the associated GRANT #
R2791A21
Funding START date mm/dd/yy
06/06/2013
PI on Grant (if different than PI on Protocol)
Funding Source Name
Canadian Research Chair - Government Of Canada
Proposal Title
CRC in Gap Junctions and Disease
Is this award currently funded?

Please provide the associated GRANT #
X0910B79
Funding START date mm/dd/yy
07/01/2011
PI on Grant (if different than PI on Protocol)
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Funding Source Name
Natural Sciences & Engineering Research Council
Proposal Title
Phenotypic and Biomechanical Effects of Altered Cell Proliferation and Differentiation in
the Mouse Skull
Is this award currently funded?

Please provide the associated GRANT #
R5211A02
Funding START date mm/dd/yy
04/12/2017
PI on Grant (if different than PI on Protocol)
Funding Source Name
Zealand Pharma A/s
Proposal Title
Research Contract
Is this award currently funded?

Please provide the associated GRANT #
R2791A24
Funding START date mm/dd/yy
09/30/2015
PI on Grant (if different than PI on Protocol)
Purpose of Animal Use
Identify PRIMARY purpose of animal use
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1-Fundamental Research
Hazardous Materials
Microorganism, Biological Agent or Hazardous Species Used?
Yes

No

Institute Biosafety Committee #
Recombinant DNA or Viral Vector Directly into Animals Used?
Yes

No

Experimental Agents or Veterinary Drug Used?
Yes

No

Nuclear Substance, Radiation, or Imaging Device Used?
Yes

No

Radiation Permit #
Animal Movement Between Sites
Will live animals leave the housing facility?
Yes

No

Will live animals move to or from citywide or external sites?
Yes

No

State the specific purpose for moving animals from animal facility or between citywide
sites.
Procedures in lab
Will either SOP 432, or SOP 443 See below be followed?
Yes

No
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Outline the method(s) used to transport animals between sites: Detail in chronological
order the transfer route, including all Citywide 'Source' and 'Destination' sites, transport
duration and frequency, and animal containment used.
Animal Groups and Experimental Timelines Overview
'C', 'D' and 'E'-level AUPs
Using simple diagrams the following must be attached:
•

Animal Groups - names the animal groups (with unique identifiers) as well as the
number of animals requested

•

Experimental Timelines - names, in chronological order, ALL procedures that
animals undergo (note that the description of each of these procedures is detailed
in the Procedure Narrative section of the AUP

and

'B'-level AUPs
•

Attach Animals Groups and Experimental Timeline diagrmas as described above

•

Attach a document that describes the same information in paragraph format.

or

In the textbox below, please list file names of the most recent attachments
Laird 2015 030 mod Nov 2017 Behavioural testing timeline
Please attach your Groups and Timelines documents above.

Mouse
Tissue Collection
Will live animals be used in this study?
Yes
Will this species be used exclusively for tissue collection?
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Yes

No

Justification for Choice of Species
Justify the choice of species by stating why
a) this is the most appropriate species, and
b) a species lower on the phylogenic scale is not appropriate.
Effort has been made to minimize mouse use through the use of cell lines. However, our
approach is based on the use of genetically modified mice from which we will generate
primary cultures, use mouse tissue and organs or use the whole organism in the study. An
intact animal is necessary to study complex processes such skin differentiation or
mammary gland development and function. The role of Panxs in cancer is relatively
limited. To date, only 3 studies have evaluated the role of Pannexins in tumourigenesis
(Lai 2007, Lai 2009, Bao 2012). Panx1 and Panx2 were shown to act as tumour
suppressors in C6 glioma cells in which ectopic expression decreased proliferation,
reverted cells to a normal cell morphology, decreased motility, reduced anchorage
independent growth in vitro and tumour growth in vivo (Lai 2007, Lai 2009). From the
same group of researchers, it was demonstrated that exogenous Panx1 expression
decreases tumour spheroid size and accelerates 3D compaction of C6 glioma cells
through the release of ATP (Bao 2012). Recently, in vitro and in vivo data suggests that
Panx1 may act as a tumour promoter in melanoma suggesting that the role of pannexins
in cancer may be more complicated than originally thought and is distinct in different
cancers (Penuela 2012). To date, our preliminary evaluation of Panx1 in breast cancer in
vitro suggest that overexpression of Panx1 in SUM159 cells may suppress cell migration
and proliferation as well as decrease expression of the EMT marker vimentin suggesting
that Panx1 may act as a tumour suppressor in breast cancer. Taken together, an in vivo
animal model is needed to assess whether Panx1 acts as a tumour suppressor in breast
cancer. Our study will be the first evaluation of pannexins in tumourigenesis using a
chemically induced mouse model of cancer. The second proposed project aims to
discover whether the newly discovered Pannexin gene family is important for hearing.
All three Panx subtypes are highly expressed in the ear, therefore, we predict that Panxs
are crucial for normal ear function. To investigate this we will use mice with Panx1 and
Panx3 gene deletions. Using auditory brainstem responses (ABRs) we will be able to
determine whether hearing thresholds are elevated in developing and aged mutant mice.
In addition, H&E staining and immunofluorescent labelling will be used to determine
whether ear development and structure is affected. We will also be able to perform ABRs
under normal conditions and after loud noise exposure, which will indicate whether
Panxs are important for auditory protection. These experiments are highly dependent on
our mouse models, one of which is not available anywhere else in the world
the 3Rs: Replace, Reduce, Refine
The Three Rs concept originated from the scientific community and is a widely accepted
cornerstone of policies on animal-based science around the world.
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Ethical animal use requires consideration of animal welfare needs http://3rs.ccac.ca
Prior to any animal-based science, the 3 Rs should be considered.
Replacement refers to methods which avoid or replace the use of animals in an area
where animals would otherwise have been used
Please show how you've considered the tenet of Replacement in your AUP.
For more information, please see Western's Alternative Use Guide.
Replacement Consideration
Replacement We continue to use tissue culture models and three dimensional organotypic
models in many of our experimental designs. However, the use of transgenic mutant
mouse models remain essential for our studies as they can not be replaced by standard in
vitro studies. Reduction We often use the same mouse in multiple studies that involve
distinct sets of tissues and organs. Refinement Analgesia and anesthesia are 2 areas we
have worked to refine. Gas anesthesia has proven to be a superior alternative for short
procedures . The addition of ketoprofen to the existing buprenorphine protocol for
analgesia has been shown to be compatible with our wound healing assay and provided
benefit to the mice.
Reduction refers to any strategy that will result in fewer animals being used.
Please show how you've considered the tenet of Reduction in your AUP.
For more information, please see Western's Alternative Use Guide.
Reduction Consideration
Replacement We continue to use tissue culture models and three dimensional organotypic
models in many of our experimental designs. However, the use of transgenic mutant
mouse models remain essential for our studies as they can not be replaced by standard in
vitro studies. Reduction We often use the same mouse in multiple studies that involve
distinct sets of tissues and organs. Refinement Analgesia and anesthesia are 2 areas we
have worked to refine. Gas anesthesia has proven to be a superior alternative for short
procedures . The addition of ketoprofen to the existing buprenorphine protocol for
analgesia has been shown to be compatible with our wound healing assay and provided
benefit to the mice.
Refinement refers to the modification of husbandry or experimental procedures to
minimize pain and distress in your animals.
Please show how you've considered the tenet of Refinement in your AUP.
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For more information, please see Western's Alternative Use Guide.
Refinement Consideration
Replacement We continue to use tissue culture models and three dimensional organotypic
models in many of our experimental designs. However, the use of transgenic mutant
mouse models remain essential for our studies as they can not be replaced by standard in
vitro studies. Reduction We often use the same mouse in multiple studies that involve
distinct sets of tissues and organs. Refinement Analgesia and anesthesia are 2 areas we
have worked to refine. Gas anesthesia has proven to be a superior alternative for short
procedures . The addition of ketoprofen to the existing buprenorphine protocol for
analgesia has been shown to be compatible with our wound healing assay and provided
benefit to the mice.
Species Strains

Species Strain

Age/Weight Vendor Stock#

C57BL/6-Panx1tm1.2Vmd

Various

C57BL/6-Panx1tm1.2Vmd

Various

C57BL/6-Gja5tm1Paul

Various

C57BL/6-Gja5tm1Paul

Various

C57BL/6-Panx3tm1a(KOMP)Wtsi

Various

C57BL/6-Panx3tm1a(KOMP)Wtsi

Various

B6.C-Tg(CMV-cre)1Cgn/J

8 Wks

C57BL/6-Panx1tm1.2Vmd,Panx3tm1a(KOMP)Wtsi

Various

B6;129-Gjb2tm2.1Kwi

Various

B6.129-Gt(ROSA)26Sortm1(cre/ERT2)Tyj/J

>6 Wks

C57BL/6-Gja5tm1Paul,Panx1tm1.2Vmd

Various

C57BL/6-Gjatm3Gfi

Various

B6;129-Gjb6tm1Kwi

Various
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Jax 006054

Jax 008463

Species Strain

Age/Weight Vendor Stock#

ICR;C57BL6-Gjb6tm2.2Kwi

Various

B6;C3-Gja1tm1Jrt

Various

Stock-Gjb6tm1Kwi Gjb2tm2.1Kwi Tg(KRT14cre)1Amc

Various

Crl:CD1(ICR)

5- 6 wks

Charles River
022

STOCK-Tg(KRT14-cre)1Amc/J

> 6 Weeks

004782

B6.Cg-Gjb6tm1KwiTg(KRT14-cre)1Amc

Various

C3H/HeNCrl

6 wks

CRC 025

C57BL/6

3 Months

Crc 027

Strain Name
C57BL/6-Panx1tm1.2Vmd
Is this strain acquired commercially?
Yes

No

Are the animals coming from a non-commercial source or another AUP?
Provide 'supplier name' and stock #, if available
Age or weight at procurement
Various
Provide phenotype detail for non-genetically altered strains
Is this strain genetically altered?
Yes

No

If Genetically Altered Animals are COMMERCIALLY AVAILABLE, insert VENDOR
STRAIN INFO URL - This page is now complete.
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If Genetically Altered Animals are from a NON-COMMERCIAL SOURCE, PROVIDE
the Original Source of Animal(s)
Genentech Inc.
Describe the NATURE of the genetic modification in heterozygous and homozygous
animals. Identify the SYSTEMS AFFECTED and SPECIAL CARE required.
This mouse has the gene encoding Panx1 ablated. The mouse does not required any
special needs and can be maintained as homozygotes.
Strain Name
C57BL/6-Panx1tm1.2Vmd
Is this strain acquired commercially?
Yes

No

Are the animals coming from a non-commercial source or another AUP?
Provide 'supplier name' and stock #, if available
Age or weight at procurement
Various
Provide phenotype detail for non-genetically altered strains
C57BL6
Is this strain genetically altered?
Yes

No

If Genetically Altered Animals are COMMERCIALLY AVAILABLE, insert VENDOR
STRAIN INFO URL - This page is now complete.
If Genetically Altered Animals are from a NON-COMMERCIAL SOURCE, PROVIDE
the Original Source of Animal(s)
Genentech Inc
Describe the NATURE of the genetic modification in heterozygous and homozygous
animals. Identify the SYSTEMS AFFECTED and SPECIAL CARE required.
This mouse has the gene encoding Panx1 ablated. The mouse does not required any
special needs and can be maintained as homozygotes.
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Strain Name
C57BL/6-Gja5tm1Paul
Is this strain acquired commercially?
Yes

No

Are the animals coming from a non-commercial source or another AUP?
Provide 'supplier name' and stock #, if available
Age or weight at procurement
Various
Provide phenotype detail for non-genetically altered strains
C57BL6
Is this strain genetically altered?
Yes

No

If Genetically Altered Animals are COMMERCIALLY AVAILABLE, insert VENDOR
STRAIN INFO URL - This page is now complete.
If Genetically Altered Animals are from a NON-COMMERCIAL SOURCE, PROVIDE
the Original Source of Animal(s)
David Paul , Harvard University
Describe the NATURE of the genetic modification in heterozygous and homozygous
animals. Identify the SYSTEMS AFFECTED and SPECIAL CARE required.
The gja1 ( Connexin 40)gene has been deleted. Both heterozygotes and homozygotes
breed well and have good health . Cardiac conduction abnormalities have been
characterized.
Strain Name
C57BL/6-Gja5tm1Paul
Is this strain acquired commercially?
Yes

No

Are the animals coming from a non-commercial source or another AUP?
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Provide 'supplier name' and stock #, if available
Age or weight at procurement
Various
Provide phenotype detail for non-genetically altered strains
C57BL6
Is this strain genetically altered?
Yes

No

If Genetically Altered Animals are COMMERCIALLY AVAILABLE, insert VENDOR
STRAIN INFO URL - This page is now complete.
If Genetically Altered Animals are from a NON-COMMERCIAL SOURCE, PROVIDE
the Original Source of Animal(s)
David Paul , Harvard University
Describe the NATURE of the genetic modification in heterozygous and homozygous
animals. Identify the SYSTEMS AFFECTED and SPECIAL CARE required.
The gja5 ( Connexin 40)gene has been deleted. Both heterozygotes and homozygotes
breed well and have good health . Cardiac conduction abnormalities have been
characterized.
Strain Name
C57BL/6-Panx3tm1a(KOMP)Wtsi
Is this strain acquired commercially?
Yes

No

Are the animals coming from a non-commercial source or another AUP?
Provide 'supplier name' and stock #, if available
Age or weight at procurement
Various
Provide phenotype detail for non-genetically altered strains
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This strain is currently being generated on a C57BL6 back ground from C57BL6/N
embryonic stem cells. Mice with germline transmission of the transgene will be crossed
with flp and cre deleter strains to produce the knockout mice , based on the KOMP
knockout first , promoter driven targeting vector Panx3 tm1a(KOMP) Wtsi targeting
vector.
Is this strain genetically altered?
Yes

No

If Genetically Altered Animals are COMMERCIALLY AVAILABLE, insert VENDOR
STRAIN INFO URL - This page is now complete.
If Genetically Altered Animals are from a NON-COMMERCIAL SOURCE, PROVIDE
the Original Source of Animal(s)
London Regional Transgenic and Gene Targeting Facility
Describe the NATURE of the genetic modification in heterozygous and homozygous
animals. Identify the SYSTEMS AFFECTED and SPECIAL CARE required.
In the knockout , the second exon of the Panx3 gene will be deleted . This knockout
mouse has not been made previously but we anticipate possible effects in bone and
cartilage.
Strain Name
C57BL/6-Panx3tm1a(KOMP)Wtsi
Is this strain acquired commercially?
Yes

No

Are the animals coming from a non-commercial source or another AUP?
Provide 'supplier name' and stock #, if available
Age or weight at procurement
Various
Provide phenotype detail for non-genetically altered strains
C57BL6
Is this strain genetically altered?
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Yes

No

If Genetically Altered Animals are COMMERCIALLY AVAILABLE, insert VENDOR
STRAIN INFO URL - This page is now complete.
If Genetically Altered Animals are from a NON-COMMERCIAL SOURCE, PROVIDE
the Original Source of Animal(s)
London Regional Transgenic and Gene Targeting Facility
Describe the NATURE of the genetic modification in heterozygous and homozygous
animals. Identify the SYSTEMS AFFECTED and SPECIAL CARE required.
In the knockout , the second exon of the Panx3 gene will be deleted . This knockout
mouse has not been made previously and are following possible effects in bone and
cartilage.
Strain Name
B6.C-Tg(CMV-cre)1Cgn/J
Is this strain acquired commercially?
Yes

No

Are the animals coming from a non-commercial source or another AUP?
Provide 'supplier name' and stock #, if available
Jax 006054
Age or weight at procurement
8 Wks
Provide phenotype detail for non-genetically altered strains
In this transgenic strain, deletion of loxP-flanked genes occurs in all tissues, including
germ cells. The cre gene in this strain is under the transcriptional control of a human
cytomegalovirus minimal promoter and is likely to be expressed before implantation
during early embryogenesis.
Is this strain genetically altered?
Yes

No
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If Genetically Altered Animals are COMMERCIALLY AVAILABLE, insert VENDOR
STRAIN INFO URL - This page is now complete.
http://jaxmice.jax.org/strain/006054.html
If Genetically Altered Animals are from a NON-COMMERCIAL SOURCE, PROVIDE
the Original Source of Animal(s)
Describe the NATURE of the genetic modification in heterozygous and homozygous
animals. Identify the SYSTEMS AFFECTED and SPECIAL CARE required.
Strain Name
C57BL/6-Panx1tm1.2Vmd,Panx3tm1a(KOMP)Wtsi
Is this strain acquired commercially?
Yes

No

Are the animals coming from a non-commercial source or another AUP?
Provide 'supplier name' and stock #, if available
Age or weight at procurement
Various
Provide phenotype detail for non-genetically altered strains
C57BL6
Is this strain genetically altered?
Yes

No

If Genetically Altered Animals are COMMERCIALLY AVAILABLE, insert VENDOR
STRAIN INFO URL - This page is now complete.
If Genetically Altered Animals are from a NON-COMMERCIAL SOURCE, PROVIDE
the Original Source of Animal(s)
in house
Describe the NATURE of the genetic modification in heterozygous and homozygous
animals. Identify the SYSTEMS AFFECTED and SPECIAL CARE required.
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This cross in a unique double knockout of both the pannexin 1 and 3 genes produced
from our 2 existing single null strains. mice seem to be viable without any health
problems
Strain Name
B6;129-Gjb2tm2.1Kwi
Is this strain acquired commercially?
Yes

No

Are the animals coming from a non-commercial source or another AUP?
Provide 'supplier name' and stock #, if available
Age or weight at procurement
Various
Provide phenotype detail for non-genetically altered strains
C57BL6 and 129
Is this strain genetically altered?
Yes

No

If Genetically Altered Animals are COMMERCIALLY AVAILABLE, insert VENDOR
STRAIN INFO URL - This page is now complete.
If Genetically Altered Animals are from a NON-COMMERCIAL SOURCE, PROVIDE
the Original Source of Animal(s)
Klaus Willecke , U of Bonn
Describe the NATURE of the genetic modification in heterozygous and homozygous
animals. Identify the SYSTEMS AFFECTED and SPECIAL CARE required.
The gene of interest ( connexion 26 ) is floxed and the mutant gene ( S17F) is not
transcribed until carrier mice are crossed with a Cre recombinase expressing mouse.
Strain Name
B6.129-Gt(ROSA)26Sortm1(cre/ERT2)Tyj/J
Is this strain acquired commercially?
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Yes

No

Are the animals coming from a non-commercial source or another AUP?
Provide 'supplier name' and stock #, if available
Jax 008463
Age or weight at procurement
>6 Wks
Provide phenotype detail for non-genetically altered strains
A conditional Cre-ERT2 (estrogen receptor T2) cassette was inserted to intron 1 of the
gene. The mutation was created in 129S4/SvJae-derived J1 embryonic stem (ES) cells
and backcrossed 8 times to C57BL/6 by the donating laboratory.
Is this strain genetically altered?
Yes

No

If Genetically Altered Animals are COMMERCIALLY AVAILABLE, insert VENDOR
STRAIN INFO URL - This page is now complete.
https://www.jax.org/strain/008463
If Genetically Altered Animals are from a NON-COMMERCIAL SOURCE, PROVIDE
the Original Source of Animal(s)
Describe the NATURE of the genetic modification in heterozygous and homozygous
animals. Identify the SYSTEMS AFFECTED and SPECIAL CARE required.
Strain Name
C57BL/6-Gja5tm1Paul,Panx1tm1.2Vmd
Is this strain acquired commercially?
Yes

No

Are the animals coming from a non-commercial source or another AUP?
Provide 'supplier name' and stock #, if available
Age or weight at procurement
Various
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Provide phenotype detail for non-genetically altered strains
C57BL6
Is this strain genetically altered?
Yes

No

If Genetically Altered Animals are COMMERCIALLY AVAILABLE, insert VENDOR
STRAIN INFO URL - This page is now complete.
If Genetically Altered Animals are from a NON-COMMERCIAL SOURCE, PROVIDE
the Original Source of Animal(s)
in house
Describe the NATURE of the genetic modification in heterozygous and homozygous
animals. Identify the SYSTEMS AFFECTED and SPECIAL CARE required.
This is a new cross from 2 lines which are both healthy and good breeders . Both the
connexion 40 and Pannexin 1 genes have been deleted
Strain Name
C57BL/6-Gjatm3Gfi
Is this strain acquired commercially?
Yes

No

Are the animals coming from a non-commercial source or another AUP?
Provide 'supplier name' and stock #, if available
Age or weight at procurement
Various
Provide phenotype detail for non-genetically altered strains
C57BL6
Is this strain genetically altered?
Yes

No

If Genetically Altered Animals are COMMERCIALLY AVAILABLE, insert VENDOR
STRAIN INFO URL - This page is now complete.
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If Genetically Altered Animals are from a NON-COMMERCIAL SOURCE, PROVIDE
the Original Source of Animal(s)
Glenn Fishman , New York Medical School
Describe the NATURE of the genetic modification in heterozygous and homozygous
animals. Identify the SYSTEMS AFFECTED and SPECIAL CARE required.
This mouse has a missense mutation in the gene encoding Cx43 where isoleucine is
replaced with threonine at position 130. This mouse has no special needs and is
maintained as heterozygotes as homozygotes are not viable.
Strain Name
B6;129-Gjb6tm1Kwi
Is this strain acquired commercially?
Yes

No

Are the animals coming from a non-commercial source or another AUP?
Provide 'supplier name' and stock #, if available
Age or weight at procurement
Various
Provide phenotype detail for non-genetically altered strains
C57BL6 and 129
Is this strain genetically altered?
Yes

No

If Genetically Altered Animals are COMMERCIALLY AVAILABLE, insert VENDOR
STRAIN INFO URL - This page is now complete.
If Genetically Altered Animals are from a NON-COMMERCIAL SOURCE, PROVIDE
the Original Source of Animal(s)
Klaus Willecke , U of Bonn
Describe the NATURE of the genetic modification in heterozygous and homozygous
animals. Identify the SYSTEMS AFFECTED and SPECIAL CARE required.
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These mice lack the connexin 30 gene (Gjb6). Homozygous mutants are born at a
Mendelian frequency , develop normally and are fertile. These mice do have severe
hearing impairment from the time of hearing onset.
Strain Name
ICR;C57BL6-Gjb6tm2.2Kwi
Is this strain acquired commercially?
Yes

No

Are the animals coming from a non-commercial source or another AUP?
Provide 'supplier name' and stock #, if available
Age or weight at procurement
Various
Provide phenotype detail for non-genetically altered strains
CD1 and C57BL6
Is this strain genetically altered?
Yes

No

If Genetically Altered Animals are COMMERCIALLY AVAILABLE, insert VENDOR
STRAIN INFO URL - This page is now complete.
If Genetically Altered Animals are from a NON-COMMERCIAL SOURCE, PROVIDE
the Original Source of Animal(s)
Klaus Willecke , U of Bonn
Describe the NATURE of the genetic modification in heterozygous and homozygous
animals. Identify the SYSTEMS AFFECTED and SPECIAL CARE required.
This is a A88V mutation in the connexion 30 gene. Heterozygotes show no phenotype.
Homozygotes may show evidence of a Clouston Syndrome -like phenotype , which in
humans is characterized by partial or total alopecia, dystrophy of the nails,
hyperpigmentation of the skin (especially over the joints), and clubbing of the fingers.
Sparse scalp hair and dysplastic nails are seen early in life. We have no description of the
homozygotic phenotype but expect these characteristics based on the human mutation in
the connexin30 gene.
Strain Name
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B6;C3-Gja1tm1Jrt
Is this strain acquired commercially?
Yes

No

Are the animals coming from a non-commercial source or another AUP?
Provide 'supplier name' and stock #, if available
Age or weight at procurement
Various
Provide phenotype detail for non-genetically altered strains
C3H and C57BL6
Is this strain genetically altered?
Yes

No

If Genetically Altered Animals are COMMERCIALLY AVAILABLE, insert VENDOR
STRAIN INFO URL - This page is now complete.
If Genetically Altered Animals are from a NON-COMMERCIAL SOURCE, PROVIDE
the Original Source of Animal(s)
Center for Mouse Models of Human Disease, Toronto
Describe the NATURE of the genetic modification in heterozygous and homozygous
animals. Identify the SYSTEMS AFFECTED and SPECIAL CARE required.
This mouse carries a missense mutation in the gene encoding Cx43 at residue 60 where
glycine is replaced with serine. This mutant mouse has been used extensively in our
facility by Dr. Kidder and myself. Due to small body size, this mouse is often put on a
soft food diet to assist in growth and overall health . This mouse is maintained as
heterozygotes as homozygotes are not viable.
Strain Name
Stock-Gjb6tm1Kwi Gjb2tm2.1Kwi Tg(KRT14-cre)1Amc
Is this strain acquired commercially?
Yes

No
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Are the animals coming from a non-commercial source or another AUP?
Provide 'supplier name' and stock #, if available
Age or weight at procurement
Various
Provide phenotype detail for non-genetically altered strains
mixed
Is this strain genetically altered?
Yes

No

If Genetically Altered Animals are COMMERCIALLY AVAILABLE, insert VENDOR
STRAIN INFO URL - This page is now complete.
If Genetically Altered Animals are from a NON-COMMERCIAL SOURCE, PROVIDE
the Original Source of Animal(s)
in house
Describe the NATURE of the genetic modification in heterozygous and homozygous
animals. Identify the SYSTEMS AFFECTED and SPECIAL CARE required.
This mouse will be the result of crossing 3 different strains . The parent phenotypes
involve skin disease ( Cx26S17F) and deafness ( Cx30KO); the aim here is to determine
how the skin disease from a connexin 26 mutation is modified by the connexin 30 null
mutation.
Strain Name
Crl:CD1(ICR)
Is this strain acquired commercially?
Yes

No

Are the animals coming from a non-commercial source or another AUP?
Provide 'supplier name' and stock #, if available
Charles River 022
Age or weight at procurement
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5- 6 wks
Provide phenotype detail for non-genetically altered strains
Is this strain genetically altered?
Yes

No

If Genetically Altered Animals are COMMERCIALLY AVAILABLE, insert VENDOR
STRAIN INFO URL - This page is now complete.
If Genetically Altered Animals are from a NON-COMMERCIAL SOURCE, PROVIDE
the Original Source of Animal(s)
Describe the NATURE of the genetic modification in heterozygous and homozygous
animals. Identify the SYSTEMS AFFECTED and SPECIAL CARE required.
Strain Name
STOCK-Tg(KRT14-cre)1Amc/J
Is this strain acquired commercially?
Yes

No

Are the animals coming from a non-commercial source or another AUP?
Provide 'supplier name' and stock #, if available
004782
Age or weight at procurement
> 6 Weeks
Provide phenotype detail for non-genetically altered strains
C57BL6 and Swiss Webster
Is this strain genetically altered?
Yes

No

If Genetically Altered Animals are COMMERCIALLY AVAILABLE, insert VENDOR
STRAIN INFO URL - This page is now complete.
http://jaxmice.jax.org/strain/004782.html
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If Genetically Altered Animals are from a NON-COMMERCIAL SOURCE, PROVIDE
the Original Source of Animal(s)
Describe the NATURE of the genetic modification in heterozygous and homozygous
animals. Identify the SYSTEMS AFFECTED and SPECIAL CARE required.
Strain Name
B6.Cg-Gjb6tm1KwiTg(KRT14-cre)1Amc
Is this strain acquired commercially?
Yes

No

Are the animals coming from a non-commercial source or another AUP?
Provide 'supplier name' and stock #, if available
Age or weight at procurement
Various
Provide phenotype detail for non-genetically altered strains
Is this strain genetically altered?
Yes

No

If Genetically Altered Animals are COMMERCIALLY AVAILABLE, insert VENDOR
STRAIN INFO URL - This page is now complete.
If Genetically Altered Animals are from a NON-COMMERCIAL SOURCE, PROVIDE
the Original Source of Animal(s)
in house breeding
Describe the NATURE of the genetic modification in heterozygous and homozygous
animals. Identify the SYSTEMS AFFECTED and SPECIAL CARE required.
This is a mutation ( S17F) in the Connexin26 gene which is transcribed in offspring of
matings of carriers of the floxed gene with Cre recombinase expressing mice.
Homozygous mice are not viable Heterozygotes show hyperplasia of tail and foot
epidermis and annuular tail restrictions and are smaller than their wild type littermates.
They also have a 35dB increased hearing threshold .
Strain Name
C3H/HeNCrl
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Is this strain acquired commercially?
Yes

No

Are the animals coming from a non-commercial source or another AUP?
Provide 'supplier name' and stock #, if available
CRC 025
Age or weight at procurement
6 wks
Provide phenotype detail for non-genetically altered strains
Is this strain genetically altered?
Yes

No

If Genetically Altered Animals are COMMERCIALLY AVAILABLE, insert VENDOR
STRAIN INFO URL - This page is now complete.
If Genetically Altered Animals are from a NON-COMMERCIAL SOURCE, PROVIDE
the Original Source of Animal(s)
Describe the NATURE of the genetic modification in heterozygous and homozygous
animals. Identify the SYSTEMS AFFECTED and SPECIAL CARE required.
Strain Name
C57BL/6
Is this strain acquired commercially?
Yes

No

Are the animals coming from a non-commercial source or another AUP?
Provide 'supplier name' and stock #, if available
Crc 027
Age or weight at procurement
3 Months
Provide phenotype detail for non-genetically altered strains
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Is this strain genetically altered?
Yes

No

If Genetically Altered Animals are COMMERCIALLY AVAILABLE, insert VENDOR
STRAIN INFO URL - This page is now complete.
If Genetically Altered Animals are from a NON-COMMERCIAL SOURCE, PROVIDE
the Original Source of Animal(s)
Describe the NATURE of the genetic modification in heterozygous and homozygous
animals. Identify the SYSTEMS AFFECTED and SPECIAL CARE required.
Animal Transfers
Will animals originate from a DIFFERENT CITYWIDE PROTOCOL NUMBER?
Yes

No

Are any animals being transferred from another AUP that have previous use?
Yes

No

List AUP number and PI name from which animals will be transferred
Describe the previous use of animals sourced from different citywide AUPs.
Environmental Enrichment
Will all animals be group housed?
Yes

No

Justify why group housing is not planned and specify which experimental animals will be
singely housed
Fighting animals will be separated
May Animal Care staff provide ENVIRONMENTAL ENRICHMENT to all animals of
this species, as per its facility-specific Environmental Enrichment SOPs?
Yes

No

May FOOD TREATS be given to all animals of this species by animal care staff as per
its facility-specific Environmental Enrichment SOPs?
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Yes

No

Explain why additional enrichment and/or food treats may not be provided by Animal
Care staff
Will any animals of this species undergo fasting at any point in the project?
Yes

No

Provide justification and duration of fasting.
Mice undergoing glucose tolerance testing will be fasted overnight ( 16 h)
If this species has other specialized caging, dietary or environmental requirements that
you wish the animal facility manager(s) to be aware of, please identify them here.
The G60S mice may be placed on a soft food diet to facilitate nutrient intake.
Animal Holding/Housing and Use Location Information
Location/Building

Room

Type

DENTAL SCIENCES BUILDING - OTHER 00066A

USE

MEDICAL SCIENCES - OTHER

249

USE

*Advanced Facility for Avian Research

140B

USE

MEDICAL SCIENCES - OTHER

475

USE

*Robarts Facilities

*Housing Room BOTH

*West Valley Animal Care Facility

*Housing Room HOUSING

ROBARTS-OTHER

4213

USE

*Health Sciences Animal Care Facility

6026

USE

*Health Sciences Animal Care Facility

521

USE

*Health Sciences Animal Care Facility

5548

USE

*Health Sciences Animal Care Facility

UN-ASSIGNED HOUSING
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Location/Building

Room

*West Valley Animal Care Facility

115

ANIMAL LOCATION
DENTAL SCIENCES BUILDING - OTHER 00066A
Location Type
USE
Identify the Procedure Location PURPOSE
Euthanasia and dissection ; glucose tolerance testing
ANIMAL LOCATION
MEDICAL SCIENCES - OTHER 249
Location Type
USE
Identify the Procedure Location PURPOSE
ANIMAL LOCATION
*Advanced Facility for Avian Research 140B
Location Type
USE
Identify the Procedure Location PURPOSE
QMR instrument
ANIMAL LOCATION
MEDICAL SCIENCES - OTHER 475
Location Type
USE
Identify the Procedure Location PURPOSE
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Type
USE

ANIMAL LOCATION
*Robarts Facilities *Housing Room
Location Type
BOTH
Identify the Procedure Location PURPOSE
Behaviour Testing;Holding Beyond 12 Hours
ANIMAL LOCATION
*West Valley Animal Care Facility *Housing Room
Location Type
HOUSING
Identify the Procedure Location PURPOSE
ANIMAL LOCATION
ROBARTS-OTHER 4213
Location Type
USE
Identify the Procedure Location PURPOSE
Non invasive blood pressure measurement ( Gros lab)
ANIMAL LOCATION
*Health Sciences Animal Care Facility 6026
Location Type
USE
Identify the Procedure Location PURPOSE
Hazard room for DMBA gavage
ANIMAL LOCATION
*Health Sciences Animal Care Facility 521
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Location Type
USE
Identify the Procedure Location PURPOSE
Recovery Surgery
ANIMAL LOCATION
*Health Sciences Animal Care Facility 5548
Location Type
USE
Identify the Procedure Location PURPOSE
Collection of tissue samples for genotyping
ANIMAL LOCATION
*Health Sciences Animal Care Facility UN-ASSIGNED
Location Type
HOUSING
Identify the Procedure Location PURPOSE
ANIMAL LOCATION
*West Valley Animal Care Facility 115
Location Type
USE
Identify the Procedure Location PURPOSE
genotyping
Holding beyond 12 hours
Will animals be held outside an arms-length-managed animal holding facility beyond 12
hours?
Yes

No
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Explain and justify why animals must be held outside of an arms-length-managed facility
for more than 12 hours.
.
Identify the frequency and duration of animal 'holding' or 'use' (live animal work) outside
an arms-length-managed facility beyond 12 hours.
Acclimatization Period & Quarantine
Will this species be held for the species-appropriate holding period prior to any form of
USE, as per SOP 310?
Yes

No

Provide Justification for this exemption
.
Will this species require quarantine?
Yes

No

If quarantine requirements differ from the animal holding/housing facility's standard
practice, please outline the requested QUARANTINE DETAIL.
Breeding Information
Provide JUSTIFICATION for maintaining a breeding colony for each of your bred
strains
The mutant mice identified in this protocol must be maintained in breeding colonies to
ensure the supply of necessary mice to carry out the proposed studies in our current
operating grant. Many of these mouse lines are hard to get and would result in costly time
and financial delays if the lines were not maintained. Breeding pairs will be set up with 6
week females and 8 week males and maintained after birth of the litter . Pups will be
weaned at 21 days.
For breeding for multiple protocols, list PI's and their specific PROTOCOL NUMBERS
(if available) to USE animals produced via THIS BREEDING PROJECT.
Beier 2007 045
What percentage of the bred animals will be used experimentally?
0 Retired breeders will be sac'd
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Strain Genotyping?

Estimated %
Surplus

Breeding
Scheme

Maintained State of
Homozygosity

Please attach your breeding scheme to this page.
Experimental Agents Information
Select all agents, materials, drugs and devices that are included in the experimental
design of this AUP for this species.
Note: Veterinary drugs to be used for planned veterinary treatments, e.g. anaesthesia,
analgesia, post-op care, and euthanasia, are to be included on the previous Veterinary
Drugs web page.

Agent Name

Common /trade
name

Class

Category

Bromodeoxyuridine (5bromo-2&#8242;deoxyuridine Brdu)

5-bromo-2'deoxyuridine ;
BrdU

Health Hazard
(ghs) - Complete Chemical
Safety Form

Tamoxifen

Tamoxifen

Health Hazard
(ghs) - Complete Chemical
Safety Form

Isoflurane

Forane

Health Hazard
(ghs) - Complete Chemical
Safety Form

Nair

Health Hazard
Nair Depilatory (ghs) - Complete Chemical
Safety Form

Buprenorphine

Controlled Drug,
Exempt From
Pharmaceutical
Safety Review

Atipamezole

Non-hazardous
(ghs) - Exempt
From Safety
Review

Antisedan
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Pharmaceutical

Pharma
Grade

Agent Name

Common /trade
name

Ketoprofen

Class

Category

Exempt From
Safety Review

Pharmaceutical

Propranolol

Inderal

Exempt From
Safety Review

Agent

Dextrose

Glucose

Exempt From
Safety Review

Agent

Atropine Sulphate

Atropine sulfate

Exempt From
Safety Review

Pharmaceutical

Carbon Dioxide

Carbon Dioxide.

Exempt From
Safety Review

Agent

Ketamine-xylazine

Xylazine
=Rompun
Ketamine =
Vetalar

Controlled Drug,
Exempt From
Pharmaceutical
Safety Review

Lidocaine

Exempt From
Safety Review

Pharmaceutical

Lidocaine/prilocain Cream
(emla)

Exempt From
Safety Review

Pharmaceutical

Medetomidine (domitor)

Non-hazardous
(ghs) - Exempt
From Safety
Review

Pharmaceutical

Domitor

Pentobarbital Sodium

Controlled Drug,
Exempt From
Pharmaceutical
Safety Review

Quantitative Magnetic
Resonance Scanner

Non-ionic Laser
Device Imaging &
Complete Safety Laser
Form

Corn Oil

EchoMRI

Exempt From
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Agent

Pharma
Grade

Agent Name

Common /trade
name

Class
Safety Review

Agent
Bromodeoxyuridine (5-bromo-2&#8242;-deoxyuridine Brdu)
Category
Chemical
Common /trade name
5-bromo-2'-deoxyuridine ; BrdU
Concentration of agent
1 mg /ml
Dose administered
0.5 mg
Volume administered
0.5ml
Route of Administration
IP
Other Route of Administration
Frequency of administration
once
Will this agent be modified?
Yes

No

Please list all modifications to the agent
Is this a Pharmaceutical Grade Agent?
Yes

No
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Category

Pharma
Grade

Please justify the use of this agent and indicate how it is sterilized or determined to be
pathogen-free.
Agent
Tamoxifen
Category
Chemical
Common /trade name
Tamoxifen
Concentration of agent
10 mg /ml
Dose administered
1 mg
Volume administered
100 ul
Route of Administration
IP
Other Route of Administration
Frequency of administration
Daily for 5 consecutive days
Will this agent be modified?
Yes

No

Please list all modifications to the agent
Is this a Pharmaceutical Grade Agent?
Yes

No
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Please justify the use of this agent and indicate how it is sterilized or determined to be
pathogen-free.
Agent
Isoflurane
Category
Chemical
Common /trade name
Forane
Concentration of agent
Dose administered
5% by inhalation for induction and 2% for maintenance for each procedure
Volume administered
Route of Administration
Inhalation
Other Route of Administration
Frequency of administration
Will this agent be modified?
Yes

No

Please list all modifications to the agent
Is this a Pharmaceutical Grade Agent?
Yes

No

Please justify the use of this agent and indicate how it is sterilized or determined to be
pathogen-free.
Agent
Nair
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Category
Chemical
Common /trade name
Nair Depilatory
Concentration of agent
Dose administered
A one inch squarepatch will be shaved using a #40 cliper blade from the dorsal surface of
the mouse and Nair (calcium thioglycolate) will be administered to a separate one
centimeter square just caudal to the shaved area. After the Nair treated skin shows signs
of hair loss (5-10 minutes- previous testing will be performed on euthanized mice to
optimize hair removal times), the Nair treated skin will be washed with water. To
determine if bulb regeneration is affected in G60S mice, a 1 inch square will also be cut
to a hair length of 0.5 inches and then waxed using a cold wax hair removal kit(Nair) to
remove the hair bulb from the underlying dermis. Nair will be removed carefully with
soap and water to prevent inflammation and the area will be monitored. Mice will then be
revived and will be returned to their housing cage. Hair length will be measured in three
day intervals.
Volume administered
Route of Administration
Other Route of Administration
topical
Frequency of administration
Will this agent be modified?
Yes

No

Please list all modifications to the agent
Is this a Pharmaceutical Grade Agent?
Yes

No

Please justify the use of this agent and indicate how it is sterilized or determined to be
pathogen-free.
Agent
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Buprenorphine
Category
Pharmaceutical
Common /trade name
Concentration of agent
Dose administered
70 ug /kg
Volume administered
0.3ml
Route of Administration
SC
Other Route of Administration
Frequency of administration
once
Will this agent be modified?
Yes

No

Please list all modifications to the agent
Is this a Pharmaceutical Grade Agent?
Yes

No

Please justify the use of this agent and indicate how it is sterilized or determined to be
pathogen-free.
Agent
Atipamezole
Category
Pharmaceutical
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Common /trade name
Antisedan
Concentration of agent
Dose administered
0.1mg/100g
Volume administered
0.1ml
Route of Administration
SC
Other Route of Administration
Frequency of administration
Once
Will this agent be modified?
Yes

No

Please list all modifications to the agent
Is this a Pharmaceutical Grade Agent?
Yes

No

Please justify the use of this agent and indicate how it is sterilized or determined to be
pathogen-free.
Agent
Ketoprofen
Category
Pharmaceutical
Common /trade name
Concentration of agent
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Dose administered
3mg / kg
Volume administered
0.3ml
Route of Administration
SC
Other Route of Administration
Frequency of administration
once perioperatively and a repeat 24 hr post op
Will this agent be modified?
Yes

No

Please list all modifications to the agent
Is this a Pharmaceutical Grade Agent?
Yes

No

Please justify the use of this agent and indicate how it is sterilized or determined to be
pathogen-free.
Agent
Propranolol
Category
Agent
Common /trade name
Inderal
Concentration of agent
1 mg /ml
Dose administered
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0.1 ml
Volume administered
1 mg /kg
Route of Administration
IP
Other Route of Administration
Frequency of administration
once
Will this agent be modified?
Yes

No

Please list all modifications to the agent
Is this a Pharmaceutical Grade Agent?
Yes

No

Please justify the use of this agent and indicate how it is sterilized or determined to be
pathogen-free.
Agent
Dextrose
Category
Agent
Common /trade name
Glucose
Concentration of agent
10% w/v
Dose administered
1 g / kg body wt
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Volume administered
0.3ml
Route of Administration
IP
Other Route of Administration
Frequency of administration
once
Will this agent be modified?
Yes

No

Please list all modifications to the agent
Is this a Pharmaceutical Grade Agent?
Yes

No

Please justify the use of this agent and indicate how it is sterilized or determined to be
pathogen-free.
Agent
Atropine Sulphate
Category
Pharmaceutical
Common /trade name
Atropine sulfate
Concentration of agent
0.15 mg / ml
Dose administered
0.5 mg /kg
Volume administered
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0.1 ml
Route of Administration
IP
Other Route of Administration
Frequency of administration
once
Will this agent be modified?
Yes

No

Please list all modifications to the agent
Is this a Pharmaceutical Grade Agent?
Yes

No

Please justify the use of this agent and indicate how it is sterilized or determined to be
pathogen-free.
Agent
Carbon Dioxide
Category
Agent
Common /trade name
Carbon Dioxide.
Concentration of agent
Dose administered
N/A
Volume administered
N/A
Route of Administration
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Inhalation;Inhalation
Other Route of Administration
N/A
Frequency of administration
N/A
Will this agent be modified?
Yes

No

Please list all modifications to the agent
Is this a Pharmaceutical Grade Agent?
Yes

No

Please justify the use of this agent and indicate how it is sterilized or determined to be
pathogen-free.
Agent
Ketamine-xylazine
Category
Pharmaceutical
Common /trade name
Xylazine =Rompun Ketamine = Vetalar
Concentration of agent
Dose administered
Ketamine 2 ml + xylazine 0.25 ml / 24 ml injectable
Volume administered
0.3 ml / 20 g
Route of Administration
IP
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Other Route of Administration
Frequency of administration
once
Will this agent be modified?
Yes

No

Please list all modifications to the agent
Is this a Pharmaceutical Grade Agent?
Yes

No

Please justify the use of this agent and indicate how it is sterilized or determined to be
pathogen-free.
Agent
Lidocaine
Category
Pharmaceutical
Common /trade name
Concentration of agent
0.2% - diluted from 2% stock
Dose administered
17ug
Volume administered
8UL
Route of Administration
Epicutaneous
Other Route of Administration
Frequency of administration
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Once
Will this agent be modified?
Yes

No

Please list all modifications to the agent
Is this a Pharmaceutical Grade Agent?
Yes

No

Please justify the use of this agent and indicate how it is sterilized or determined to be
pathogen-free.
Agent
Lidocaine/prilocain Cream (emla)
Category
Pharmaceutical
Common /trade name
Concentration of agent
0.2% ( diluted from 2% stock)
Dose administered
17 ug
Volume administered
8 ul
Route of Administration
Epicutaneous
Other Route of Administration
Frequency of administration
Once
Will this agent be modified?
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Yes

No

Please list all modifications to the agent
Is this a Pharmaceutical Grade Agent?
Yes

No

Please justify the use of this agent and indicate how it is sterilized or determined to be
pathogen-free.
Agent
Medetomidine (domitor)
Category
Pharmaceutical
Common /trade name
Domitor
Concentration of agent
Dose administered
0.1 mg/100g ip
Volume administered
0.3ml
Route of Administration
IV
Other Route of Administration
Frequency of administration
once
Will this agent be modified?
Yes

No

Please list all modifications to the agent
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Is this a Pharmaceutical Grade Agent?
Yes

No

Please justify the use of this agent and indicate how it is sterilized or determined to be
pathogen-free.
Agent
Pentobarbital Sodium
Category
Pharmaceutical
Common /trade name
Concentration of agent
540 mg /ml
Dose administered
Volume administered
Route of Administration
IP
Other Route of Administration
Frequency of administration
Will this agent be modified?
Yes

No

Please list all modifications to the agent
Is this a Pharmaceutical Grade Agent?
Yes

No

Please justify the use of this agent and indicate how it is sterilized or determined to be
pathogen-free.
Agent
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Quantitative Magnetic Resonance Scanner
Category
Imaging & Laser
Common /trade name
EchoMRI
Concentration of agent
NA
Dose administered
NA
Volume administered
NA
Route of Administration
Other Route of Administration
Frequency of administration
2 min scan time ; once only
Will this agent be modified?
Yes

No

Please list all modifications to the agent
Is this a Pharmaceutical Grade Agent?
Yes

No

Please justify the use of this agent and indicate how it is sterilized or determined to be
pathogen-free.
Agent
Corn Oil
Category
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Agent
Common /trade name
Concentration of agent
na
Dose administered
na
Volume administered
0.1 ml
Route of Administration
Gavage
Other Route of Administration
Frequency of administration
weekly for 5 times total
Will this agent be modified?
Yes

No

Please list all modifications to the agent
Is this a Pharmaceutical Grade Agent?
Yes

No

Please justify the use of this agent and indicate how it is sterilized or determined to be
pathogen-free.
Please attach all requested documentation, as applicable, including:
Hazardous Materials Safety Questions Documents - If the classification of the agent
selected requires it, please fill out and append the appropriate safety review sheet:
•
•
•
•

Biological
Chemical/Pharmaceutical
Imaging & Laser
Nuclear/Radiation
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Material Safety Data Sheet (MSDS) or Equivalent - Occupational Health & Safety
requires that you attach the current MSDS for each newly added agent as this is an
essential element of safety review.
SOP List
Add all Standard Operating Procedures that will be followed within this AUP.
Go to the ACVS SOPs web page for SOP details - http://uwo.ca/animalresearch/sops/index.html
SOP Name

Divergences

330 - Post-operative Care - Rodents
336 - Scoring Sheets
341 - Genotyping And Identification
343 - Surgical Prep - Rodent - Recovery Surgery
345 Anesthesia And Intraoperative Care - Rodent
Cln-320 - Methods Of Euthanasia
Cln-321 - Criteria For Early Euthanasia In Rodents
Cln-323 - Euthanasia By C02 Asphyxia
Cln-355 - Peri-operative Analgesia In Rodents
Select an SOP
330 - Post-operative Care - Rodents
Are you following the SOP exactly?
Yes

No

If you are not following the SOP exactly, please list and justify all divergences from the
SOP
Select an SOP
336 - Scoring Sheets
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Are you following the SOP exactly?
Yes

No

If you are not following the SOP exactly, please list and justify all divergences from the
SOP
Select an SOP
341 - Genotyping And Identification
Are you following the SOP exactly?
Yes

No

If you are not following the SOP exactly, please list and justify all divergences from the
SOP
Select an SOP
343 - Surgical Prep - Rodent - Recovery Surgery
Are you following the SOP exactly?
Yes

No

If you are not following the SOP exactly, please list and justify all divergences from the
SOP
Select an SOP
345 Anesthesia And Intraoperative Care - Rodent
Are you following the SOP exactly?
Yes

No

If you are not following the SOP exactly, please list and justify all divergences from the
SOP
Select an SOP
Cln-320 - Methods Of Euthanasia
Are you following the SOP exactly?
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Yes

No

If you are not following the SOP exactly, please list and justify all divergences from the
SOP
Select an SOP
Cln-321 - Criteria For Early Euthanasia In Rodents
Are you following the SOP exactly?
Yes

No

If you are not following the SOP exactly, please list and justify all divergences from the
SOP
Select an SOP
Cln-323 - Euthanasia By C02 Asphyxia
Are you following the SOP exactly?
Yes

No

If you are not following the SOP exactly, please list and justify all divergences from the
SOP
Select an SOP
Cln-355 - Peri-operative Analgesia In Rodents
Are you following the SOP exactly?
Yes

No

If you are not following the SOP exactly, please list and justify all divergences from the
SOP
Procedures Checklist for Reporting and Training
Use the checklist below to identify all AUP elements to be used with this species. If
none of the listed AUP elements pertain to this species, select *Not Applicable.
Entries selected here will be linked to other AUP pages, including Personnel Training
Requirements and the eSirius Training Module where animal user training records are
maintained. Therefore, please ensure that this list is complete.
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Procedure Name
04. Injections - Sq
06. Injections - Ip
13. Cervical Dislocation - Without Anaesthesia
15. Decapitation - Without Anesthesia
16. Anesthesia - Gas
17. Anesthetics - Injectable
19. Surgery - Recovery
20. Surgery - Non-recovery
22. Skin Incisions - No Closure
I. Behavioral Testing
Procedures Narrative
In view of the live animal activities identified within this AUP and listed below, provide
a concise description of the procedural events identified within the Groups and
Timelines page associated with this specific species.
The intent is to name and briefly describe the procedural events and associate them with
each experimental group within this species.
Specific detail pertaining to drug dosage, monitoring, euthanasia/endpoint method,
breeding, and physical restraint methods have been captured within other AUP sections,
so they do not need to be described in detail here.

Species Description
Use the following formatting method to complete each procedure listed within this
section:
1. Bold Font for Procedure Name - e.g. Anesthesia
2. Italicized Font for Group Identifiers - e.g. Groups 1, 2, and 6
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3. Regular Font for Procedure Description - e.g. Animals will be placed in a clean
cage for transport to the OR
Please note that the AUP will be returned for updates if this section does not align with
the above formatting method.
Procedures Narrative
Tissue collection
Group 1
The development, differentiation and function of various tissues such as skin, mammary
gland, bone and cartilage will be assessed in mutant mice . Mice will be bred and
euthanized at various stages of development and differentiation, including prenatal,
postnatal day one, 3-6 week old, and adult. At the time of euthanasia by CO2 inhalation,
tissues will be collected and used to establish cell cultures or to prepare frozen and
paraffin-embedded tissue sections for histological analysis. Neonates will be additionally
decapitated following CO2, as per SOP SOP323
Genotyping
Group 2
Genotyping of offspring: All genotyping will be done by PCR. For fetuses and neonates,
a tail sample will be obtained at the time of euthanasia by CO2 inhalation & decapitation.
For pups, an earpunch sample will be used, taken before 3 weeks of age to individually
mark the pups. Sampling will be done in accordance with SOP GEN-ANIML-104.
Wound healing assay ( adult & neonate )Wound healing assay ( ad
Group 3 & 7
Mice, 2 months of age and older , will be anesthetized with isoflurane gas and the dorsal
skin skin shaved and Nair treated. Under isoflurane anesthesia, the site will then be
prepared using a 3 stage prep and a sterile disposable 5mm bore biopsy tool will be used
to obtain a full thickness excisional epidermal and dermal skin biopsy . Mice are allowed
to recover in a cage whose bottom is warmed by a 37C circulating water pad.
Buprenorphine (70ug /kg) and ketoprofen (3 mg / kg) will be administered peri
operatively and ketoprofen re administered 24 hr post op as per ACVS recommendations
for post op pain control. The area of wound closure will be measured at days 1,3,6,9,and
12 days post operatively. Mice are euthanized at day 12> This procedure has been
previously published : J.Churko et al ,Hum Mutat. 2011 April; 32(4): 456466. Incisional
wounding Unsexed 4 day old mice will be anaesthetized using the standard isofurane
protocol of 4% induction and 2% maintenance. The area of the incision wound will be
prepared using a 3 stage prep and 0.2% lidocaine (8 ul)injected at the site. (Anesthetic

162

and analgesia as per I. Welch). A 3mm long, full thickness incisional wound will be made
between the shoulder blades. Pups will be identified by toe clips. Surgery and recovery
will be on a 37C circulating water pad. Pups will be allowed to recover from the
anesthetic and when conscious, gently rubbed (away from surgical site) with bedding
from the home cage to encourage re- acceptance of the pup by the mother mouse. Wound
healing will be monitored at 6 hrs following the procedure and then daily for a period of
13 days. Wounds will be measured using a digital caliper and recorded with digital
photography. Body weights will be recorded daily and scored for activity and body
appearance. At the end of the study , pups will be sacrificed and tissues taken for
histology References Qui C, Cotinho P , Frank S , Franke S, Law L-Y, Martin P Green
CR , Becker DL (2003) Targetting Connexin43 expression accelerates the rate of wound
repair . Curr. Biol. 13:1697-1703. Ghatnekar GS, O'Quinn MP, Jourdan LJ, Gurjarpadhye
AA, Draughn RL, Gourdie RG.( 2009) Connexin43 carboxyl-terminal peptides reduce
scar progenitor and promote regenerative healing following skin wounding. Regen . Med
4: 205-223.
Blood pressure and cardiac hemodynamic measurements using the Millar
catheterization
Group 4
(Performed in the Laboratory of Dr. Robert Gros).
To validate the non invasive blood pressure measurements and provide additional
hemodynamic data , we intend to use the Millar catheterization method.
Blood pressure and cardiac hemodynamic measurements will be obtained in mice at the
time of sacrifice using the invasive Millar catheterization approach as previously
described (Roy et al., FASEB J. 2013; Tutunea-Fatan, et al., 2015). Briefly, mice will be
anesthetized using 2% isoflurane and placed on a warming pad. The right common
carotid artery will isolated after midline neck incision and cannulated using a Millar
Mikro-tip pressure transducer (1.4F sensor, 2F catheter; Millar Instruments, Houston,
TX). The tip of transducer will be guided into the aortic arch to obtain blood pressure
recordings following which the tip will be advanced into the left ventricle to obtain
cardiac hemodynamic measurements.
When measurements are complete the mouse will be euthanized.

Tamoxifen administration
Group 21
All procedures will follow GUIDELINES FOR THE USE OF TAMOXIFEN IN
ANIMAL RESEARCH. 6 week old mice will be injected ip with tamoxifen (100 ul of
10mg /ml in 5% ethanol /95% corn oil) for 5 consecutive days.
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Electrocardiograph
Group 10
This procedure will be performed in the lab of Qingpeng Feng which has the equipment
and expertise. The mice will be anesthetized with ketamine / xylazine and 6 subdermal
electrodes placed. Following the ECG recording ( approx. 10 min) electrodes are
removed and the mouse placed in a recovery cage.
Non-Invasive Blood Pressure Measurements
Group 11
(Performed in the Laboratory of Dr. Robert Gros) Blood pressure measurements will be
performed in mice using the Kent Scientific CODA6 non-invasive tail-cuff system (as
previously described Roy, et al., 2013; Tutunea-Fatan, et al., 2014). This procedure will
be performed in conscious (awake) mice using a gentle restraining system. Most
scientific journals now require conscious BP measurements and will generally not accept
anesthetized BPs only. This procedure will take ~20-30 minutes. Briefly, mice will be
trained for 3 days prior to obtaining the actual blood pressure measurements. Due to the
non-invasiveness of the procedure, blood pressures can be obtained over time (aging of
the mice).
Ambulatory electrocardiogram
Group 20
Ambulatory electrocardiogram (ECG) (Performed in the Laboratory of Dr. Robert Gros).
To obtain ambulatory electrocardiogram (ECG) analysis in the conscious state, a dorsally
mounted radio frequency transmitter (TA10EA-F20, Data Sciences International, St.
Paul, Minnesota, USA) and wire leads (in the lead II configuration) will be implanted
subcutaneously under anesthesia (2% isoflurane) as we have previously described (Mol.
Cell Biol 2010 30(7):1746). Surgical and anesthesia procedures will follow established
procedures in the R. Gros lab (SOPs 354 , 343,345); analgesia will follow SOP 355.
Following one-week recovery, chronic ECG recordings from conscious mice will be
acquired with the Data Sciences International telemetry system. All recordings will be
performed in the conscious state between 9:00 AM and 3:00 PM in a constant
environment. To examine baseline HR dynamics and the effects of autonomic blockade,
we propose to utilize the following protocol: After a 15-min control period for HR
stabilization, the baseline ECG will be recorded for 30 60 min. To study the frequencyspecific contributions of the principal cardiovascular control systems, we will use the
following specific pharmacological agents: atropine (0.5 mg/kg ip) for parasympathetic
blockade, propranolol (1 mg/kg ip) for sympathetic blockade, and atropine (0.5 mg/kg ip)
plus propranolol (1 mg/kg ip) for combined autonomic blockade. After a 5-to 10-min
equilibration phase after drug administration to allow for HR stabilization, ECG
recordings will be repeated in the same fashion as in the baseline state. These
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pharmacological experiments will be performed on different days to prevent interference
among drugs. When testing is complete ( 2 weeks after device implantation ) , the
transmitter will be removed in a minor surgery (as above) and allowed to recover.
Bromodeoxyuridine (BrdU) injection
Group 13
To further assess cell proliferation in situ, mice will be injected with 5-bromo-2 deoxyuridine (BrdU; 0.5 mg in 0.5 ml, i.p.) and 24 hrs later, the mice will be sacrificed,
and processed for immunohistochemical localization of BrdU in sections of skin (Yang,
S.H. et al. An absence of both lamin B1 and lamin B2 in keratinocytes has no effect on
cell proliferation or the development of skin and hair. Hum Mol Gen 20, 3537-44
(2011).)
Hearing test
Group 14
This procedure is to be performed in collaboration with Brian Allman (AUP 2013 041)
who has the setup and experience to do the procedures. John Kelly will assist with the
procedure In order to assess hearing status, we will measure the auditory brainstem
response (ABR) using subdermal electrodes while the animal is anesthetized. Mice of
several ages ( 3 wk , 3 mo , 9-12 mo) will be deeply anesthetized with ketamine and
xylazine (intraperitoneal injection), and positioned on a homeothermic heating pad
located inside an electrophysiology recording booth in the Allman lab. Body temperature
will be monitored using a rectal probe, and maintained at 37 degrees Celsius using the
homeothermic heating pad. Once the mouse does not withdraw to a toe pinch, 3 short
needle electrodes will be inserted under the skin on the head (locations: vertex, left pinna,
right pinna) to record the ABR: the neural response to various sound stimuli (e.g., tone
bursts, clicks and noise at 10-100 dB) which are presented to the mouse via speakers
positioned near its ears. By varying the loudness of the sound stimuli, the mouse s
hearing can be tested; a lack of neural activity in response to a sound stimulus indicates
that the mouse could not hear it. Total test time is typically 1 h. Every 15 minutes
throughout the procedure, the level of anesthesia will be assessed using the toe pinch
withdrawal reflex, and supplemental doses of ketamine and xylazine will be administered
(ip injection) as needed. mice will be either euthanized following this procedure or
submitted to the noise exposure procedure( #16) if not previously done . Mice undergoing
an ABR recheck following noise exposure will be euthanized following the recheck.

Noise exposure under anesthesia
Group 15
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This procedure is to be performed in collaboration with Brian Allman (AUP 2013 041)
who has the setup and experience to do the procedures. John Kelly will assist with the
procedure To determine the effect of hearing loss on auditory processing, anesthetized
mice will be exposed to noise that is loud enough to damage their hearing. Mice ( 3 mo of
age) will be deeply anesthetized with ketamine and xylazine (intraperitoneal injection),
and positioned on a homeothermic heating pad located inside a sound-attenuating booth
in the Allman lab. Body temperature will be monitored using a rectal probe, and
maintained at 37 degrees Celsius using the homeothermic heating pad. Once the mouse
does not withdraw to a toe pinch, a loud noise (90-123 dB; 10-60 min duration) will be
presented to the mouse via speakers positioned near its ears. It is important to note that
when the door of the sound-attenuating booth is closed, lab personnel are completely safe
from the loud noise that is being presented to the mouse. Using a camera positioned
inside the sound-attenuating booth, the experimenter can observe the mouse for the
duration of the noise exposure. Every 15 minutes of the noise exposure, the loud noise
will be paused and the experimenter will assess of the level of anesthesia using the toe
pinch withdrawal reflex, and supplemental doses of ketamine and xylazine will be
administered (ip injection) as needed. In Brian Allman's experience, mice do not show
signs of pain or discomfort associated with noise-induced hearing loss; however, these
mice will be monitored. and allowed to recover for 1 week before the hearing is retested
(ABR test).
Alternatively, broadband noise (8-16 kHz) at 100 dB for 2 hours will be substituted for
the loud noise listed above. This will allow for the determination of cochlear
synaptopathy in our mouse models. ( Fernandez KA et al (2015) J. Neurosci. 35:7509
Incisional wound healing study
Group 18
Mice, 2 months of age and older , will be anesthetized with isoflurane gas . The site will
then be prepared using a 3 stage prep and a sterile disposable scalpel blade will be used to
make a longitudinal full thickness incision , 1 cm in length , in the tail . Mice are allowed
to recover in a cage whose bottom is warmed by a 37C circulating water pad.
Buprenorphine (70ug /kg) and ketoprofen (3 mg / kg) will be administered peri
operatively and ketoprofen re administered 24 hr post op as per ACVS recommendations
for post op pain control. The extent of wound closure will be measured at days
1,3,6,9,and 12days post operatively. Mice are euthanized at day 12> This procedure has
been previously published : Jensen ,MA et al Nat Struct Mol Biol. 2014 Feb;21(2):18997
Behavioral Testing
Group 22
Male and female ICR;B6-Gjb6tm2.2Kwi mice , 3 months old , will be used in behavioral
testing using the Neurobehavioural Core Facility in Robarts Research.
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According to the SOPs regarding animal behavioural testing at Robarts Research
Institute, experiments will be carried out on separate days and in the following order:
- Open-field locomotor
- Grip strength and wire hang
- Elevated plus maze
- Tail suspension
- Morris water-maze
Before commencing any sensorimotor or cognitive testing, the mice will be left
undisturbed in the testing room for 20 minutes. A cohort of at least (8 x 3 genotypes =
24) mice will perform all behavioural tests. Mice will perform every test in the same
sequential order to allow time for rest between trials that occur on the same day. The
cohort will first perform 1 trial of open-field locomotor analysis in which general activity
in the chamber is recorded for 30 minutes according to SOP (RNC-005). The cohort will
also perform 3 trials of the grip strength test and 1 trial of the wire hang exercise to assess
sensorimotor function . All mice will be given at least 1 hr of rest in their home cage
before beginning the wire hang test. The cohort will also perform 1 trial of the elevated
plus maze, which assesses anxiety-like behaviour over a period of 10 minutes according
to SOP (RNC-004). The cohort will also perform 1 trial of the tail suspension test in
which mice will be secured to an elevated bar by their tail and left to hang to analyze
depressive behaviour for 6 minutes according to SOP (RNS-003). Last, the cohort will
perform the Morris water-maze, wherein the experimenter will sequentially train all mice
to perform the test in the water bath followed by 4 one-minute experimental trials each
day for 4 consecutive days according to SOP (RNC-006). (Timeline attached)
A. Locomotor Activity Test Procedure- Mice SOP# RNC-005
Mice are placed in the locomotor activity chamber and allowed to explore for the length
of the experiment (e.g. 24 sessions, 5 min per session).
B. Grip Strength
The grip strength meter is positioned horizontally and the subjects are held by the tail and
lowered towards the apparatus. The animals are allowed to grasp the metal grid or
triangular pull bar and are then pulled backwards in the horizontal plane. The force
applied to the grid or to the bar just before it loses grip is recorded as the peak tension.
C. Wire hang
1. The mouse, handled by the tail, is allowed to grasp the middle of the wire with its fore
limbs and is gently lowered so that its hind paws will grasp the wire a few cm apart from
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the fore paws. The mouse is then gently accompanied while it turns upside-down along
the axis of the wire. The tail is released while the mouse is still grasping the wire with its
four paws. Upon release, a timer is started. Using the two fore limbs start position, a clear
distinction can be made between mice who manage to grasp the wire with their hind
limbs and those who are incapable to do so. The time until the mouse completely
releases its grasp and falls down is recorded.
D. Morris Water Maze Procedure- Mice SOP# RNC-006
The mouse is released from the first start position on the inside edge of the tank at the
surface of the water, facing the tank wall and the mouse allowed to swim until it reaches
platform. If mouse has not reached platform in 60 seconds experimenter will guide the
mouse to the platform. Once mouse reaches platform it is allowed to sit for 30 seconds
then returned to its holding cage to dry. Starting location is changed for each trial. 4
trials each day for 4 consecutive days
E. Tail-suspension test for use in mice SOP#RNC-003
The mouse is positioned so that the lower edge of the suspension bar touches the midpoint along the length of the tail. The tail is secured above the mid-point to the
suspension bar with the broad masking tape. The tape is molded around the tail to hold it
firmly without crushing it against the upper or lower edge of the suspension bar. R Video
is recorded for 6 minutes.
F. Elevated Plus-maze SOP#RNC- 004
The moused is placed in the center of the maze where all 4 arms meet facing an open
arm. Video recording is started and watched live to ensure mouse’s entry into each arm
is being tracked. The mouse is allowed to explore the apparatus for a total of 10 minutes
Procedural Consequences & Monitoring
From both the project overview & detail perspectives, identify and describe specific
procedural or other/combined elements of this AUP that may produce pain, distress, or
impairment - and identify all possible consequences - Behavioural, Physical,
Biochemical, Physiological, and Reproductive - for this species.
Mice restrained for the QMR and non invasive BP measurement are acclimatized to the
restraints and appear to suffer little distress as a consequence. The wound healing assay ,
as a minor surgical procedure , has the potential to produce pain . NOISE EXPOSURE
UNDER ANESTHESIA: A subset of mice in this Animal Group will be anesthetized and
exposed to noise that is loud enough to damage their hearing. Furthermore, following
noise exposure, it is likely that some of the mice will experience tinnitus (i.e., the
phantom perception of a sound, similar to a ringing in the ears). In the experience of our
collaborator ( Brian Allman), rats do not show signs of pain or discomfort associated with
either noise-induced hearing loss or tinnitus. However, these mice will be monitored
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closely throughout the duration of the study and will be subject to early euthanasia if they
show signs of stress or physical health problems Mice recover well from
electrocardiography ; electrode placement is equivalent to a sc injection and is done
under anesthesia Our experience indicates that 4 day old pups which have undergone the
wound healing surgery are readily accepted by their moms. Ambulatory ECG : As a
minor surgical procedure , the placement of the transmitter has the potential to produce
pain and discomfort. There is also a possibility of irritation to the animal from the
subcutaneous transmitter itself. Administration of propranolol or atropine have not been
reported to have any distress or impairment in mice. Euthanasia by drug overdose (
pentobarbital ) is a preferred method to minimize distress. Mice injected ip with
tamoxifen should not have any ill effects specific to tamoxifen injections . Using the
tamoxifen induced Cre to induce the Cx26S17F mutation in adults will produce mutant
mice and bypass the negative effects of the mutation on neonatal mice from a
constitutively expressed Cre recombinase. Mice undergoing behavioural testing may
experience distress or possible physical harm.
Detail relief to be provided for each of the above-stated potential consequences, and, if
relief is not planned, offer scientific justification for not doing so.
For the wound healing study, both buprenorphine and ketoprofen will be used for pain
control. Mice will be examined daily for the first 3 days to ensure proper recovery.
General physical appearance, appearance of the wound site and behaviour will be
considered and the monitoring sheet used. Abnormalities will be reported to the
AUS/ACVS and/or mice sacrificed if pain or indicators of poor recovery present. This
applies to both wound healing study surgeries. Anesthetized neonates in the wound
healing study will have lidocaine injected at the incisional site. Ambulatory ECG: Mice
will be given appropriate analgesia (SOP 355) prior to the implantation of the transmitter.
Mice will be monitored during the week following the surgery according to the post
surgical monitoring sheet, to assess both surgical recovery and tolerance of the implanted
device. SOP 321 will be followed as indicated . Mice injected ip with tamoxifen will be
monitored to determine if there are any health effects related to the induction of the
mutation in adult mice. SOPs to be followed for the behavioural testing include proper
monitoring and precautions to avoid distress and physical harm to mice in these studies.
The CCAC and OMAFRA require that all AUPs include:
•
•

a 'Monitoring Plan' to minimize animal pain, distress, or discomfort, and
a plan for 'Early Euthanasia' for the purpose of emergency intervention in advance
of the experimental endpoint.

As per UCAC's Animal Care and Use Records Policy, http://uwo.ca/animalresearch/doc/ACU_Records.pdf Animal Records, e.g. scoring sheets, procedure logs,
anaesthetic and surgery records (except those involved in Field Studies) must be kept
with the animals at all times.
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Has a monitoring sheet used for determining interventions and early euthanasia endpoints
been developed for this species, e.g. scoring sheets, anaesthetic record, surgery record.
If YES, please attach the monitoring sheet(s) below.
If NO, please complete the following checklist
Yes

No

Weight -When checked, this indicates that weights will be recorded

Food/Water Intake

Behaviour

Fecal/Urine Output

Body Condition Score

Appearance

Other Monitoring

Please Specify Other Monitoring Type.
For every individual monitoring element checked above:
Describe the frequency, Specify the intervention points including criteria for early
euthanasia, Provide other relevant detail. If attached monitoring sheets capture this
information, then indicate this here.
See monitoring sheets
Please attach your monitoring sheets.
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Endpoint Method Information
Endpoint Method
* Carbon Dioxide Overdose
* Decapitation-no Anesthesia
Cervical Dislocation Under Anesthesia
Drug-Agent Overdose
Endpoint Method
* Carbon Dioxide Overdose
CCAC Classification
Conditionally Acceptable
This method is conditionally acceptable. Please provide sufficient justification for using
this method. Please note that conditionally acceptable methods may require additional
training prior to use.
This euthanasia method is very minimally stressful to the mice as we do it normally in the
home cage under very controlled flow rates. Tissues from the mice are not contaminated
with molecules that would interefere with sensitive assays. Only a few mice for
cardiovascular studies will not be euthanized in this manner.
Provide Additional experimental endpoint detail, as required
Provide endpoint detail for animals not euthanized
For endpoint methods selected above that use drugs, please list them below, and include
the dosage.
Drug Dosage
Endpoint Method
* Decapitation-no Anesthesia
CCAC Classification
Conditionally Acceptable
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This method is conditionally acceptable. Please provide sufficient justification for using
this method. Please note that conditionally acceptable methods may require additional
training prior to use.
For pup E13-16 days following CO2 euthanasia of female Also for P1 pups
Provide Additional experimental endpoint detail, as required
Provide endpoint detail for animals not euthanized
For endpoint methods selected above that use drugs, please list them below, and include
the dosage.
Drug Dosage
Endpoint Method
Cervical Dislocation Under Anesthesia
CCAC Classification
Acceptable
This method is conditionally acceptable. Please provide sufficient justification for using
this method. Please note that conditionally acceptable methods may require additional
training prior to use.
Provide Additional experimental endpoint detail, as required
Provide endpoint detail for animals not euthanized
For endpoint methods selected above that use drugs, please list them below, and include
the dosage.
Drug

Dosage

Isoflurane
Endpoint Method
Drug-Agent Overdose
CCAC Classification
Acceptable
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This method is conditionally acceptable. Please provide sufficient justification for using
this method. Please note that conditionally acceptable methods may require additional
training prior to use.
Provide Additional experimental endpoint detail, as required
Provide endpoint detail for animals not euthanized
For endpoint methods selected above that use drugs, please list them below, and include
the dosage.
Drug

Dosage

Pentobarbital Sodium
Animal Numbers Requested
With a view to the animal numbers disclosed on the Groups and Timelines web page,
please provide your requested total four- and first-year animal numbers by Category of
Invasiveness as well as justification for these numbers.
Please consider the activities selected for this species in the list below with a view to their
combined impact upon an animal.

Species Type Description
Please select the top Category of Invasiveness for this species and, for AUPs containing
breeding colonies, please separate these numbers into the 'Z' category.
Categories of Invasiveness – Levels assigned to AUPs in accordance with CCAC
policy. Experiments involving:
•
•
•
•
•

B - Little or no discomfort or stress
C - Minor stress or pain of short duration
D - Moderate to severe distress or discomfort
E - Procedures causing severe pain at or above the pain tolerance threshold of
unanaesthetized conscious animals
Z - Animals used for breeding purposes (internal letter designation to separate out
breeding from research numbers - a CCAC requirement)

For more detail go to the CCAC Website:
http://www.ccac.ca/en_/standards/policies/policy-categories_of_invasiveness
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CCAC Category 4 YR # 1st YR #
B

0

0

C

0

0

D

7,899

0

E

0

0

Z

1

0

Justification for Number of Animals Requested
We have established a consultation agreement with a statistician so that, where possible,
we can reduce the animal number to a minimal while still retaining sufficient statistical
power. In some cases, pilot studies will be performed with low animal numbers to obtain
information as to whether a further larger study is justified.
Personnel List
Complete the table below to include all individuals directly associated with animal-based
science activities for this AUP. In this section personnel must be associated with the
specific animal activities they will be involved with.
For Personnel Already Listed Below - Please highlight the table row containing each
name, and then select the 'Edit Personnel' button to complete or update information.

Name

Role

Phone

Primary Email

HANDS
ON?

Barr, Kevin J

Researcher Staff
86925
Members

kevin.barr@schulich.uwo.ca

Calder,
Michele D

PI Staff

86925

michele.calder@schulich.uwo.ca Yes

Shao, Qing
(Cindy)

PI Staff

661-2111
cindy.shao@shulich.uwo.ca
86829

Yes

868-27

No

Laird, Dale W Principal

dale.laird@schulich.uwo.ca
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Yes

Name

Role

Phone

Primary Email

HANDS
ON?

Investigator
Novielli,
Nicole

Researcher Staff
86821
Members

nnoviel@uwo.ca

Yes

Abitbol, Julia PI Student

86821

jabitbo@uwo.ca

Yes

Willmore,
Katherine

Co-Investigator

88079

kwillmo2@uwo.ca

Yes

Jarvis,
Sommer

PI Student

88079

sjarvi@uwo.ca

Yes

Press, Eric

Researcher Staff
Members

epress2@uwo.ca

Yes

Beach,
Rianne

Researcher Staff
86821
Members

rbeach4@uwo.ca

Yes

Jewlal,
Elizabeth

Researcher Staff
86821
Members

ejewlal@uwo.ca

Yes

Moore,
Alyssa

Researcher Staff
88057
Members

amoor66@uwo.ca

Yes

Name
Barr, Kevin J
Role
Researcher Staff Members
Organization Department
Schulich School Of Medicine & Dentistry Anatomy & Cell Biology
Weekday Phone #
86925
Emergency Contact #
519-472- 5782
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UWO or Lawson Email
kevin.barr@schulich.uwo.ca
Other Email
Copy this Individual on all Emails

CCAC-Mandated Training Requirements – As per MAPP 7.10, each person working
with live animals requires training that aligns with his/her hands-on animal activity.
At minimum, all individuals listed within this AUP must complete the Basic Care and
Use online ‘animal ethics’ course.
The requirement for additional online training, hands-on workshops or competency
assessments will be determined by the species and animal procedures associated with
each individual as well as his/her previous Canadian training and experience.
For further information, please contact training@uwo.ca.
Will person be handling animal species?
Yes

No

Species Name

Type

Procedure Description

Mouse

Procedures 04. Injections - Sq

Mouse

Procedures 06. Injections - Ip

Mouse

Procedures 13. Cervical Dislocation - Without Anaesthesia

Mouse

Procedures 15. Decapitation - Without Anesthesia

Mouse

Procedures 16. Anesthesia - Gas

Mouse

Procedures 17. Anesthetics - Injectable

Mouse

Procedures 19. Surgery - Recovery

Mouse

Procedures 22. Skin Incisions - No Closure

Mouse

Procedures I. Behavioral Testing
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Based upon elements selected in the previous 'Personnel Activities' tab for this individual,
below is a list of all required training activities - online OWL modules and/or hands-on
workshops. Training activities listed below with dates indicates completion of that
specific training element.
Please contact training@uwo.ca for further details.
Degrees
Experience and Qualifications
Training Event

Description

Aseptic Principals Aseptic principals of
of Surgery surgery for mouse
Mouse
species.
Assessment,
Monitoring and
Intervention

Type

Date
Certified

Training ID

Demonstration 11/09/2009 APSMSE

Behavioural responses of
research animals in pain; Internet-based
how to assess; monitoring Course
procedures

AMI

ethics, regulations, 3 Rs,
Basic Animal
SOPs, safety. Species
Internet-based
Care & Use Ethics
01/01/2007 BACUEC
specific animal care,
Course
Course
housing, EE, etc.
Cervical
Dislocation Without
Anesthesia Mouse

Cervical Dislocation of
Demonstration
mice without anaesthesia.

CDMSE

Decapitation Adult - Mouse

Decapitation of adult
mice.

DECAPAMSE

Decapitation
Without
Anesthesia Mouse

Decapitation without the
use of anesthesia for the Demonstration
mouse

Demonstration

DecapitationDecapitation of neonatal
Demonstration
Neonates - Mouse mice.
Gas Anesthesia - Principals of Gas

DECWAMSE

DECAPNMSE

Demonstration 07/12/2012 GASAMSE
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Training Event
Mouse

Description

Type

Date
Certified

Training ID

Anesthesia in Mice
including set-up,
monitoring, record
keeping and recovery.

covers behaviour, moving
mice, sexing, euthanasia
and some scruffing.
Handling & Care - Students complete
Demonstration
Mouse
webcts: basic handling of
rodents, and assessment,
intervention and
monitoring

HCMSE

Injectable
Anesthesia Mouse

Anesthesia principals,
including set-up,
monitoring, record
keeping, control drug
records and recovery.

Demonstration

INANMSE

Intraperitoneal
and Subcutaneous
Injection
Techniques Mouse

IP and SQ sterile
Injection techniques
demonstrated and
practiced in Mice.

Demonstration

IPSCITMSE

Sterile Injection
Techniques

mandatory workshop
involving injection
techniques.

Demonstration

STINTECH

Name
Calder, Michele D
Role
PI Staff
Organization Department
Schulich School Of Medicine & Dentistry Obstetrics & Gynaecology
Weekday Phone #
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86925
Emergency Contact #
473-4261
UWO or Lawson Email
michele.calder@schulich.uwo.ca
Other Email
MCALDER@UWO.CA
Copy this Individual on all Emails

CCAC-Mandated Training Requirements – As per MAPP 7.10, each person working
with live animals requires training that aligns with his/her hands-on animal activity.
At minimum, all individuals listed within this AUP must complete the Basic Care and
Use online ‘animal ethics’ course.
The requirement for additional online training, hands-on workshops or competency
assessments will be determined by the species and animal procedures associated with
each individual as well as his/her previous Canadian training and experience.
For further information, please contact training@uwo.ca.
Will person be handling animal species?
Yes

No

Species Name Type Procedure Description
Mouse

Agents Corn Oil

Based upon elements selected in the previous 'Personnel Activities' tab for this individual,
below is a list of all required training activities - online OWL modules and/or hands-on
workshops. Training activities listed below with dates indicates completion of that
specific training element.
Please contact training@uwo.ca for further details.
Degrees
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Experience and Qualifications
Training
Event

Description

Type

Behavioural responses of
Assessment,
research animals in pain;
Monitoring and
how to assess; monitoring
Intervention
procedures

Date
Training ID
Certified

Internet-based
01/01/2009 AMI
Course

Decapitation
Without
Anesthesia Mouse

Decapitation without the use
Demonstration
of anesthesia for the mouse

DECWAMSE

Handling &
Care - Mouse

covers behaviour, moving
mice, sexing, euthanasia and
some scruffing. Students
complete webcts: basic
Demonstration
handling of rodents, and
assessment, intervention and
monitoring

HCMSE

Oral Gavage Mouse

Demonstration 10/30/2012 GAV-MSE

CCAC-Mandated Training Requirements – As per MAPP 7.10, each person working
with live animals requires training that aligns with his/her hands-on animal activity.
At minimum, all individuals listed within this AUP must complete the Basic Care and
Use online ‘animal ethics’ course.
The requirement for additional online training, hands-on workshops or competency
assessments will be determined by the species and animal procedures associated with
each individual as well as his/her previous Canadian training and experience.
For further information, please contact training@uwo.ca.
Will person be handling animal species?
Yes

No

Species Name
Mouse

Type
Agents

Procedure Description
Bromodeoxyuridine (5-bromo-2&#8242;-deoxyuridine Brdu)
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Species Name

Type

Procedure Description

Mouse

Agents

Carbon Dioxide

Mouse

Euthanasia * Carbon Dioxide Overdose

Based upon elements selected in the previous 'Personnel Activities' tab for this individual,
below is a list of all required training activities - online OWL modules and/or hands-on
workshops. Training activities listed below with dates indicates completion of that
specific training element.
Please contact training@uwo.ca for further details.
Degrees
Experience and Qualifications
Training
Event

Description

Type

Behavioural responses of
Assessment,
research animals in pain;
Monitoring and
how to assess; monitoring
Intervention
procedures

Date
Training ID
Certified

Internet-based
01/31/2006 AMI
Course

Decapitation
Without
Anesthesia Mouse

Decapitation without the use
Demonstration
of anesthesia for the mouse

Handling &
Care - Mouse

covers behaviour, moving
mice, sexing, euthanasia and
some scruffing. Students
complete webcts: basic
Demonstration 09/26/2006 HCMSE
handling of rodents, and
assessment, intervention and
monitoring

Name
Laird, Dale W
Role
Principal Investigator
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DECWAMSE

Organization Department
Schulich School Of Medicine & Dentistry Anatomy & Cell Biology
Weekday Phone #
868-27
Emergency Contact #
673-3343
UWO or Lawson Email
dale.laird@schulich.uwo.ca
Other Email
Copy this Individual on all Emails

CCAC-Mandated Training Requirements – As per MAPP 7.10, each person working
with live animals requires training that aligns with his/her hands-on animal activity.
At minimum, all individuals listed within this AUP must complete the Basic Care and
Use online ‘animal ethics’ course.
The requirement for additional online training, hands-on workshops or competency
assessments will be determined by the species and animal procedures associated with
each individual as well as his/her previous Canadian training and experience.
For further information, please contact training@uwo.ca.
Will person be handling animal species?
Yes

No

Species Name Type Procedure Description
Based upon elements selected in the previous 'Personnel Activities' tab for this individual,
below is a list of all required training activities - online OWL modules and/or hands-on
workshops. Training activities listed below with dates indicates completion of that
specific training element.
Please contact training@uwo.ca for further details.
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Degrees
Experience and Qualifications
Training Event
Basic Animal
Care & Use
Ethics Course

Description

Type

ethics, regulations, 3 Rs, SOPs,
safety. Species specific animal
care, housing, EE, etc.

Internetbased
Course

Date
Certified

Training
ID

01/02/2006 BACUEC

Name
Novielli, Nicole
Role
Researcher Staff Members
Organization Department
Schulich School Of Medicine & Dentistry Anatomy & Cell Biology
Weekday Phone #
86821
Emergency Contact #
UWO or Lawson Email
nnoviel@uwo.ca
Other Email
Copy this Individual on all Emails

CCAC-Mandated Training Requirements – As per MAPP 7.10, each person working
with live animals requires training that aligns with his/her hands-on animal activity.
At minimum, all individuals listed within this AUP must complete the Basic Care and
Use online ‘animal ethics’ course.
The requirement for additional online training, hands-on workshops or competency
assessments will be determined by the species and animal procedures associated with
each individual as well as his/her previous Canadian training and experience.
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For further information, please contact training@uwo.ca.
Will person be handling animal species?
Yes

No

Species Name

Type

Procedure Description

Mouse

Procedures 20. Surgery - Non-recovery

Mouse

Procedures I. Behavioral Testing

Based upon elements selected in the previous 'Personnel Activities' tab for this individual,
below is a list of all required training activities - online OWL modules and/or hands-on
workshops. Training activities listed below with dates indicates completion of that
specific training element.
Please contact training@uwo.ca for further details.
Degrees
Experience and Qualifications
Should be on file.
Training
Event

Description

Type

Date
Training ID
Certified

Behavioural responses of
Assessment,
research animals in pain; how Internet-based
Monitoring and
//
to assess; monitoring
Course
Intervention
procedures

AMI

Basic Animal
Care & Use
Ethics Course

ethics, regulations, 3 Rs,
Internet-based
SOPs, safety. Species specific
//
Course
animal care, housing, EE, etc.

BACUEC

Decapitation
Without
Anesthesia Mouse

Decapitation without the use
of anesthesia for the mouse

Demonstration

DECWAMSE

Handling &
Care - Mouse

covers behaviour, moving
mice, sexing, euthanasia and
some scruffing. Students

Demonstration

HCMSE
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Training
Event

Description

Type

Date
Training ID
Certified

complete webcts: basic
handling of rodents, and
assessment, intervention and
monitoring
Name
Abitbol, Julia
Role
PI Student
Organization Department
Schulich School Of Medicine & Dentistry Anatomy & Cell Biology
Weekday Phone #
86821
Emergency Contact #
UWO or Lawson Email
jabitbo@uwo.ca
Other Email
Copy this Individual on all Emails

CCAC-Mandated Training Requirements – As per MAPP 7.10, each person working
with live animals requires training that aligns with his/her hands-on animal activity.
At minimum, all individuals listed within this AUP must complete the Basic Care and
Use online ‘animal ethics’ course.
The requirement for additional online training, hands-on workshops or competency
assessments will be determined by the species and animal procedures associated with
each individual as well as his/her previous Canadian training and experience.
For further information, please contact training@uwo.ca.
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Will person be handling animal species?
Yes

No

Species Name

Type

Procedure Description

Mouse

Agents

Atipamezole

Mouse

Agents

Carbon Dioxide

Mouse

Agents

Ketamine-xylazine

Mouse

Euthanasia * Carbon Dioxide Overdose

Mouse

Procedures 04. Injections - Sq

Mouse

Procedures 06. Injections - Ip

Mouse

Procedures 17. Anesthetics - Injectable

Based upon elements selected in the previous 'Personnel Activities' tab for this individual,
below is a list of all required training activities - online OWL modules and/or hands-on
workshops. Training activities listed below with dates indicates completion of that
specific training element.
Please contact training@uwo.ca for further details.
Degrees
Experience and Qualifications
Training Event

Description

Type

Date
Training ID
Certified

Assessment,
Monitoring and
Intervention

Behavioural responses of
research animals in pain; Internet-based
how to assess; monitoring Course
procedures

AMI

Decapitation
Without
Anesthesia Mouse

Decapitation without the
use of anesthesia for the
mouse

DECWAMSE

Demonstration

Handling & Care - covers behaviour, moving Demonstration 10/09/2014 HCMSE
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Training Event
Mouse

Injectable
Anesthesia Mouse

Description

Type

Date
Training ID
Certified

mice, sexing, euthanasia
and some scruffing.
Students complete webcts:
basic handling of rodents,
and assessment,
intervention and
monitoring
Anesthesia principals,
including set-up,
monitoring, record
keeping, control drug
records and recovery.

Demonstration

Intraperitoneal and
Subcutaneous
IP and SQ sterile Injection
Injection
techniques demonstrated Demonstration
Techniques and practiced in Mice.
Mouse
Sterile Injection
Techniques

mandatory workshop
involving injection
techniques.

Demonstration

Name
Willmore, Katherine
Role
Co-Investigator
Organization Department
Schulich School Of Medicine & Dentistry Anatomy & Cell Biology
Weekday Phone #
88079
Emergency Contact #
UWO or Lawson Email

187

INANMSE

IPSCITMSE

STINTECH

kwillmo2@uwo.ca
Other Email
Copy this Individual on all Emails

CCAC-Mandated Training Requirements – As per MAPP 7.10, each person working
with live animals requires training that aligns with his/her hands-on animal activity.
At minimum, all individuals listed within this AUP must complete the Basic Care and
Use online ‘animal ethics’ course.
The requirement for additional online training, hands-on workshops or competency
assessments will be determined by the species and animal procedures associated with
each individual as well as his/her previous Canadian training and experience.
For further information, please contact training@uwo.ca.
Will person be handling animal species?
Yes

No

Species Name
Mouse

Type

Procedure Description

Euthanasia * Carbon Dioxide Overdose

Based upon elements selected in the previous 'Personnel Activities' tab for this individual,
below is a list of all required training activities - online OWL modules and/or hands-on
workshops. Training activities listed below with dates indicates completion of that
specific training element.
Please contact training@uwo.ca for further details.
Degrees
Experience and Qualifications
Training
Event

Description

Type

Behavioural responses of
Assessment,
research animals in pain;
Monitoring and
how to assess; monitoring
Intervention
procedures

Internet-based
Course
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Date
Training ID
Certified

AMI

Training
Event

Description

Type

Date
Training ID
Certified

Decapitation
Without
Anesthesia Mouse

Decapitation without the use
Demonstration
of anesthesia for the mouse

Handling &
Care - Mouse

covers behaviour, moving
mice, sexing, euthanasia and
some scruffing. Students
complete webcts: basic
Demonstration 10/09/2014 HCMSE
handling of rodents, and
assessment, intervention and
monitoring

DECWAMSE

Name
Jarvis, Sommer
Role
PI Student
Organization Department
Schulich School Of Medicine & Dentistry Anatomy & Cell Biology
Weekday Phone #
88079
Emergency Contact #
UWO or Lawson Email
sjarvi@uwo.ca
Other Email
Copy this Individual on all Emails

CCAC-Mandated Training Requirements – As per MAPP 7.10, each person working
with live animals requires training that aligns with his/her hands-on animal activity.
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At minimum, all individuals listed within this AUP must complete the Basic Care and
Use online ‘animal ethics’ course.
The requirement for additional online training, hands-on workshops or competency
assessments will be determined by the species and animal procedures associated with
each individual as well as his/her previous Canadian training and experience.
For further information, please contact training@uwo.ca.
Will person be handling animal species?
Yes

No

Species Name

Type

Procedure Description

Mouse

Agents

Pentobarbital Sodium

Mouse

Euthanasia Drug-Agent Overdose

Mouse

Procedures 06. Injections - Ip

Based upon elements selected in the previous 'Personnel Activities' tab for this individual,
below is a list of all required training activities - online OWL modules and/or hands-on
workshops. Training activities listed below with dates indicates completion of that
specific training element.
Please contact training@uwo.ca for further details.
Degrees
Experience and Qualifications
Training Event

Description

Type

Date
Training ID
Certified

Assessment,
Monitoring and
Intervention

Behavioural responses of
research animals in pain; Internet-based
how to assess; monitoring Course
procedures

AMI

Decapitation
Without
Anesthesia Mouse

Decapitation without the
use of anesthesia for the
mouse

DECWAMSE
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Demonstration

Training Event

Description

Type

Date
Training ID
Certified

covers behaviour, moving
mice, sexing, euthanasia
and some scruffing.
Handling & Care - Students complete webcts:
Demonstration
Mouse
basic handling of rodents,
and assessment,
intervention and
monitoring

HCMSE

Intraperitoneal and
Subcutaneous
IP and SQ sterile Injection
Injection
techniques demonstrated Demonstration 10/04/2016 IPSCITMSE
Techniques and practiced in Mice.
Mouse
Sterile Injection
Techniques

mandatory workshop
involving injection
techniques.

Demonstration

Name
Press, Eric
Role
Researcher Staff Members
Organization Department
Schulich School Of Medicine & Dentistry Physiology & Pharmacology
Weekday Phone #
Emergency Contact #
UWO or Lawson Email
epress2@uwo.ca
Other Email
Copy this Individual on all Emails
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STINTECH

CCAC-Mandated Training Requirements – As per MAPP 7.10, each person working
with live animals requires training that aligns with his/her hands-on animal activity.
At minimum, all individuals listed within this AUP must complete the Basic Care and
Use online ‘animal ethics’ course.
The requirement for additional online training, hands-on workshops or competency
assessments will be determined by the species and animal procedures associated with
each individual as well as his/her previous Canadian training and experience.
For further information, please contact training@uwo.ca.
Will person be handling animal species?
Yes

No

Species Name

Type

Procedure Description

Mouse

Procedures 04. Injections - Sq

Mouse

Procedures 06. Injections - Ip

Mouse

Procedures 16. Anesthesia - Gas

Mouse

Procedures 19. Surgery - Recovery

Mouse

Procedures 22. Skin Incisions - No Closure

Mouse

Procedures I. Behavioral Testing

Based upon elements selected in the previous 'Personnel Activities' tab for this individual,
below is a list of all required training activities - online OWL modules and/or hands-on
workshops. Training activities listed below with dates indicates completion of that
specific training element.
Please contact training@uwo.ca for further details.
Degrees
Experience and Qualifications
Training Event

Description

Type
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Date
Training ID
Certified

Training Event

Description

Type

Date
Training ID
Certified

Aseptic Principals
Aseptic principals of
of Surgery Demonstration 05/26/2015 APSMSE
surgery for mouse species.
Mouse
Assessment,
Monitoring and
Intervention

Behavioural responses of
research animals in pain; Internet-based
how to assess; monitoring Course
procedures

AMI

ethics, regulations, 3 Rs,
Basic Animal
SOPs, safety. Species
Care & Use Ethics
specific animal care,
Course
housing, EE, etc.

Internet-based
01/01/2014 BACUEC
Course

Decapitation
Without
Anesthesia Mouse

Decapitation without the
use of anesthesia for the
mouse

Demonstration

DECWAMSE

Gas Anesthesia Mouse

Principals of Gas
Anesthesia in Mice
including set-up,
monitoring, record
keeping and recovery.

Demonstration

GASAMSE

covers behaviour, moving
mice, sexing, euthanasia
and some scruffing.
Handling & Care - Students complete webcts:
Demonstration 10/09/2014 HCMSE
Mouse
basic handling of rodents,
and assessment,
intervention and
monitoring
Intraperitoneal and
Subcutaneous
IP and SQ sterile Injection
Injection
techniques demonstrated Demonstration 10/28/2014 IPSCITMSE
Techniques and practiced in Mice.
Mouse
Sterile Injection

mandatory workshop

Demonstration
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STINTECH

Training Event
Techniques

Description

Type

Date
Training ID
Certified

involving injection
techniques.

Name
Beach, Rianne
Role
Researcher Staff Members
Organization Department
Schulich School Of Medicine & Dentistry Physiology & Pharmacology
Weekday Phone #
86821
Emergency Contact #
UWO or Lawson Email
rbeach4@uwo.ca
Other Email
Copy this Individual on all Emails

CCAC-Mandated Training Requirements – As per MAPP 7.10, each person working
with live animals requires training that aligns with his/her hands-on animal activity.
At minimum, all individuals listed within this AUP must complete the Basic Care and
Use online ‘animal ethics’ course.
The requirement for additional online training, hands-on workshops or competency
assessments will be determined by the species and animal procedures associated with
each individual as well as his/her previous Canadian training and experience.
For further information, please contact training@uwo.ca.
Will person be handling animal species?
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Yes

No

Species Name

Type

Procedure Description

Mouse

Procedures 04. Injections - Sq

Mouse

Procedures 06. Injections - Ip

Mouse

Procedures 16. Anesthesia - Gas

Mouse

Procedures 17. Anesthetics - Injectable

Based upon elements selected in the previous 'Personnel Activities' tab for this individual,
below is a list of all required training activities - online OWL modules and/or hands-on
workshops. Training activities listed below with dates indicates completion of that
specific training element.
Please contact training@uwo.ca for further details.
Degrees
Experience and Qualifications
Training Event

Assessment,
Monitoring and
Intervention

Description

Type

Behavioural responses of
research animals in pain; Internet-based
how to assess; monitoring Course
procedures

Date
Training ID
Certified

AMI

ethics, regulations, 3 Rs,
Basic Animal
SOPs, safety. Species
Care & Use Ethics
specific animal care,
Course
housing, EE, etc.

Internet-based
10/01/2017 BACUEC
Course

Decapitation
Without
Anesthesia Mouse

Decapitation without the
use of anesthesia for the
mouse

Demonstration

Gas Anesthesia Mouse

Principals of Gas
Anesthesia in Mice
including set-up,
monitoring, record

Demonstration 06/25/2018 GASAMSE

195

DECWAMSE

Training Event

Description

Type

Date
Training ID
Certified

keeping and recovery.
covers behaviour, moving
mice, sexing, euthanasia
and some scruffing.
Handling & Care - Students complete webcts:
Demonstration 10/05/2017 HCMSE
Mouse
basic handling of rodents,
and assessment,
intervention and
monitoring

Injectable
Anesthesia Mouse

Anesthesia principals,
including set-up,
monitoring, record
keeping, control drug
records and recovery.

Demonstration 08/15/2018 INANMSE

Intraperitoneal and
Subcutaneous
IP and SQ sterile Injection
Injection
techniques demonstrated Demonstration 06/07/2018 IPSCITMSE
Techniques and practiced in Mice.
Mouse
Sterile Injection
Techniques

mandatory workshop
involving injection
techniques.

Demonstration

Name
Jewlal, Elizabeth
Role
Researcher Staff Members
Organization Department
Schulich School Of Medicine & Dentistry Anatomy & Cell Biology
Weekday Phone #
86821
Emergency Contact #

196

STINTECH

UWO or Lawson Email
ejewlal@uwo.ca
Other Email
Copy this Individual on all Emails

CCAC-Mandated Training Requirements – As per MAPP 7.10, each person working
with live animals requires training that aligns with his/her hands-on animal activity.
At minimum, all individuals listed within this AUP must complete the Basic Care and
Use online ‘animal ethics’ course.
The requirement for additional online training, hands-on workshops or competency
assessments will be determined by the species and animal procedures associated with
each individual as well as his/her previous Canadian training and experience.
For further information, please contact training@uwo.ca.
Will person be handling animal species?
Yes

No

Species Name

Type

Procedure Description

Mouse

Procedures 04. Injections - Sq

Mouse

Procedures 06. Injections - Ip

Mouse

Procedures 17. Anesthetics - Injectable

Based upon elements selected in the previous 'Personnel Activities' tab for this individual,
below is a list of all required training activities - online OWL modules and/or hands-on
workshops. Training activities listed below with dates indicates completion of that
specific training element.
Please contact training@uwo.ca for further details.
Degrees
Experience and Qualifications
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Training Event

Assessment,
Monitoring and
Intervention

Description

Type

Behavioural responses of
research animals in pain; Internet-based
how to assess; monitoring Course
procedures

Date
Training ID
Certified

AMI

ethics, regulations, 3 Rs,
Basic Animal
SOPs, safety. Species
Care & Use Ethics
specific animal care,
Course
housing, EE, etc.

Internet-based
09/01/2017 BACUEC
Course

Decapitation
Without
Anesthesia Mouse

Demonstration

Decapitation without the
use of anesthesia for the
mouse

covers behaviour, moving
mice, sexing, euthanasia
and some scruffing.
Handling & Care - Students complete webcts:
Demonstration
Mouse
basic handling of rodents,
and assessment,
intervention and
monitoring

Injectable
Anesthesia Mouse

Anesthesia principals,
including set-up,
monitoring, record
keeping, control drug
records and recovery.

DECWAMSE

HCMSE

Demonstration 10/12/2017 INANMSE

Intraperitoneal and
Subcutaneous
IP and SQ sterile Injection
Injection
techniques demonstrated Demonstration 09/19/2017 IPSCITMSE
Techniques and practiced in Mice.
Mouse
Sterile Injection
Techniques

mandatory workshop
involving injection
techniques.

Demonstration

Name
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STINTECH

Moore, Alyssa
Role
Researcher Staff Members
Organization Department
Schulich School Of Medicine & Dentistry Anatomy & Cell Biology
Weekday Phone #
88057
Emergency Contact #
UWO or Lawson Email
amoor66@uwo.ca
Other Email
Copy this Individual on all Emails

CCAC-Mandated Training Requirements – As per MAPP 7.10, each person working
with live animals requires training that aligns with his/her hands-on animal activity.
At minimum, all individuals listed within this AUP must complete the Basic Care and
Use online ‘animal ethics’ course.
The requirement for additional online training, hands-on workshops or competency
assessments will be determined by the species and animal procedures associated with
each individual as well as his/her previous Canadian training and experience.
For further information, please contact training@uwo.ca.
Will person be handling animal species?
Yes

No

Species Name Type Procedure Description
Based upon elements selected in the previous 'Personnel Activities' tab for this individual,
below is a list of all required training activities - online OWL modules and/or hands-on
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workshops. Training activities listed below with dates indicates completion of that
specific training element.
Please contact training@uwo.ca for further details.
Degrees
Experience and Qualifications
Training Event
Basic Animal
Care & Use
Ethics Course

Description
ethics, regulations, 3 Rs, SOPs,
safety. Species specific animal
care, housing, EE, etc.

Type

Date
Training
Certified
ID

Internetbased
Course

BACUEC

Protocol Attachments
The following is a list of all attachments listed on this Protocol
Descrip
tion

File Name

Original File Name

2015-030_3_MSC_0001_Monitor sheet.xlsx

Monitor sheet.xlsx

2015-030_3_MSC_1018_0001_imaging-laserquestions.doc

imaging-laser-questions.doc

2015-030_3_MSC_160_0001_tamoxifen
SDS.pdf

tamoxifen SDS.pdf

2015-030_3_MSC_160_0001_chem-pharmquestions Tamoxifen.doc

chem-pharm-questions
Tamoxifen.doc

2015-030_3_MSC_29_0001_2006-10110_9_MSC_29_0001_brdu msds.pdf

2006-10110_9_MSC_29_0001_brdu
msds.pdf

2015-030_3_MSC_29_0001_2006-10110_9_MSC_29_0001_BRDU.doc

2006-10110_9_MSC_29_0001_BRDU.
doc

2015-030_3_MSC_313_0001_2006-10110_9_MSC_313_0001_isoflurane msds.pdf

2006-10110_9_MSC_313_0001_isoflur
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Descrip
tion

File Name

Original File Name
ane msds.pdf

2015-030_3_MSC_313_0001_2006-10110_9_MSC_313_0001_isoflurane.doc

2006-10110_9_MSC_313_0001_isoflur
ane.doc

2015030_3_MSC_347_0001_NAIR_PRETTY_DEPI
LATORY_CREAM msds.pdf

NAIR_PRETTY_DEPILATO
RY_CREAM msds.pdf

2015-030_3_MSC_347_0001_Nair Safety Form
Laird Lab.doc

Nair Safety Form Laird
Lab.doc

2015-030_3_MSC_421_0001_propranolol
msds-2.pdf

propranolol msds-2.pdf

2015-030_3_MSC_526_0001_atropine
msds.pdf

atropine msds.pdf

2015-030_3_MSC_627_0001_Pentobarbital
Sodium Solution.pdf

Pentobarbital Sodium
Solution.pdf

2015-030_5_0001_2015-030_2_0001_Laird
new 2015 rev[2].pdf

2015-030_2_0001_Laird new
2015 rev[2].pdf

2015-030_6_0001_RNC-003 Tail-suspension
test for use in mice SOP.pdf

RNC-003 Tail-suspension test
for use in mice SOP.pdf

2015-030_6_0001_RNC-004 EPM behavioural
testing SOP.pdf

RNC-004 EPM behavioural
testing SOP.pdf

2015-030_6_0001_RNC-005 Locomotor
Activity Test - SOP.pdf

RNC-005 Locomotor Activity
Test - SOP.pdf

2015-030_6_0001_RNC-006 Morris Water
Maze Procedure SOP.pdf

RNC-006 Morris Water Maze
Procedure SOP.pdf
Behavio
ural
Behavioural testing
testing timeline.pdf
timeline

2015-030_6_0001_Behavioural testing
timeline.pdf
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Descrip
tion

File Name
2015-030_6_0001_Laird 2015 030 mod Nov
2017.pdf

Original File Name
Laird 2015 030 mod Nov
2017.pdf

Behavio
ural
Behavioural testing
testing timeline.pdf
timeline

2015-030_6_0001_Behavioural testing
timeline.pdf

Amendment Reason
Protocol Number
2015-030
Protocol Version
11
Protocol Title
The Role of Gap Junction in Diseases
Approve Date
05/19/2015
Expiration Date
05/01/2019
Full Name
Laird, Dale W
Reason for Change
Personnel updates
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Curriculum Vitae
Name:

Sommer Jarvis

Post-secondary

University of Guelph
Bachelor of Science (Bio-Medical Sciences)
Guelph, Ontario, Canada
2012 - 2016 .

Education and
Degrees:

The University of Western Ontario
Master of Science (Developmental Biology)
London, Ontario, Canada
2016 - present
Honours and
Awards:

Western Graduate Research Scholarship
2016 – present
Canada Federation of University Women Scholarship
2012
Simcoe East District of Women’s Institute Award
2012

Related Work
Experience

Research Assistant
Madan Lab
Ontario Veterinary College
University of Guelph
2014
Field Research Volunteer
Flockhart Lab
Ontario Veterinary College
University of Guelph
2014

Teaching
Experience
2016-2017

Teaching Assistant
Organismal Physiology, Biology 2601
Teaching Assistant
First Year Biology labs, Biology 1002B, 1202B
2017-2018
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